Injectable biodegradable carriers for the delivery of therapeutic agents and tissue engineering by Levato, Riccardo
  
 
 
ADVERTIMENT. La consulta d’aquesta tesi queda condicionada a l’acceptació de les següents 
condicions d'ús: La difusió d’aquesta tesi per mitjà del servei TDX (www.tesisenxarxa.net) ha 
estat autoritzada pels titulars dels drets de propietat intel·lectual únicament per a usos privats 
emmarcats en activitats d’investigació i docència. No s’autoritza la seva reproducció amb finalitats 
de lucre ni la seva difusió i posada a disposició des d’un lloc aliè al servei TDX. No s’autoritza la 
presentació del seu contingut en una finestra o marc aliè a TDX (framing). Aquesta reserva de 
drets afecta tant al resum de presentació de la tesi com als seus continguts. En la utilització o cita 
de parts de la tesi és obligat indicar el nom de la persona autora. 
 
 
ADVERTENCIA. La consulta de esta tesis queda condicionada a la aceptación de las siguientes 
condiciones de uso: La difusión de esta tesis por medio del servicio TDR (www.tesisenred.net) ha 
sido autorizada por los titulares de los derechos de propiedad intelectual únicamente para usos 
privados enmarcados en actividades de investigación y docencia. No se autoriza su reproducción 
con finalidades de lucro ni su difusión y puesta a disposición desde un sitio ajeno al servicio TDR. 
No se autoriza la presentación de su contenido en una ventana o marco ajeno a TDR (framing). 
Esta reserva de derechos afecta tanto al resumen de presentación de la tesis como a sus 
contenidos. En la utilización o cita de partes de la tesis es obligado indicar el nombre de la 
persona autora. 
 
 
WARNING. On having consulted this thesis you’re accepting the following use conditions:  
Spreading this thesis by the TDX (www.tesisenxarxa.net) service has been authorized by the 
titular of the intellectual property rights only for private uses placed in investigation and teaching 
activities. Reproduction with lucrative aims is not authorized neither its spreading and availability 
from a site foreign to the TDX service. Introducing its content in a window or frame foreign to the 
TDX service is not authorized (framing). This rights affect to the presentation summary of the 
thesis as well as to its contents. In the using or citation of parts of the thesis it’s obliged to indicate 
the name of the author 
i 
 
 
Injectable biodegradable carriers for the delivery of 
therapeutic agents and tissue engineering 
 
 
Author: Riccardo Levato 
Universitat Politècnica de Catalunya, Barcelona, España 
Director: Dr. Miguel Ángel Mateos-Timoneda 
UPC tutor: Dr. Elisabeth Engel 
 
 
Programa de Doctorat en Enginyeria Biomédica 
 
 
Departament de Enginyeria Biomédica 
 
Universitat Politècnica de Catalunya 
 
Barcelona, 2014 
 
 
Tesis presentada per obtenir el títol de Doctor per la Universitat Politècnica de Catalunya 
 
 
 
 
 
 
 
 
Vol. I 
ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Riccardo Levato, 2014 
All rights are reserved 
 
 
iii 
 
A mio padre e mia madre, Domenico e Maria Carla 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iv 
 
Until you attain the truth, you will not be able to amend it.  
But if you do not amend it, you will not attain it. 
 In the meanwhile, do not give up.  
 
(José Saramago, Book of Advices, in “History of the Siege of Lisbon”) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
v 
 
INDEX 
 
Abstract (English and Spanish)  ...................................................................................................................... 1 
List of Figures  .................................................................................................................................................. 5 
List of Tables  .................................................................................................................................................... 8 
List of Abbreviations  ....................................................................................................................................... 9 
 
Chapter 1 -  General Introduction ................................................................................................................ 11 
1.1 General introduction, motivation and aim of the Thesis...................................................................... 12 
1.2 Outline of the Thesis ............................................................................................................................ 13 
1.3 References ........................................................................................................................................... 15 
 
Chapter 2 – Introduction and state of the art .............................................................................................. 16 
2.1 Introduction to Biomaterials ................................................................................................................ 17 
2.2 Biomaterials in Regenerative Medicine  .............................................................................................. 19 
2.2.1 Tissue Engineering  ................................................................................................................ 19 
2.2.1.2 Cells in Tissue Engineering  ...................................................................................... 23 
2.2.1.3 Scaffolds .................................................................................................................... 25 
2.2.1.4 In vitro culture, bioreactors and environmental stimulation  ..................................... 28 
2.2.1.5 General remarks on tissue engineering and its current state ...................................... 29 
2.2.2 Cell Therapy  .......................................................................................................................... 30 
2.3 Biomaterials and advanced drug release  ............................................................................................. 33 
2.4  Polymeric biomaterials for scaffolds and delivery devices  ................................................................ 36 
2.5  Injectable biomaterial systems  ........................................................................................................... 41 
2.5.1  In situ forming polymeric matrices and hydrogels  ................................................................ 41
 2.5.2  Bioprinting and injectable biomaterials  ................................................................................. 47 
2.6  Microcarriers and Nanocarriers  .......................................................................................................... 50 
 2.6.1  Micro and Nanocarriers in biomedical technology  ................................................................ 50 
2.6.2 Fabrication Methods  .............................................................................................................. 52 
2.6.2.1 Emulsion-based techniques  ....................................................................................... 53 
2.6.2.2 Nozzle- or injection based methods  .......................................................................... 54 
2.6.2.3 Nanoprecipitation  ...................................................................................................... 57 
2.6.3 Drug delivery with functionalized active carriers  ...................................................................... 58 
2.6.4  Microcarrier culture technology  ............................................................................................ 60 
2.6.5  MC properties to control cell adhesion, proliferation and fate  .............................................. 63 
2.6.6  MCs for cell therapy  .............................................................................................................. 64 
vi 
 
2.6.7  MCs in Tissue Engineering  .................................................................................................... 67 
2.6.8  MCs in bottom-up TE and biofabrication   ............................................................................. 71 
2.7  References  .......................................................................................................................................... 73 
 
Chapter 3 – Green-inspired fabrication of polylactic acid MCs with controlled size  ............................. 88 
3.1 Introduction  ........................................................................................................................................ 89 
3.2 Materials and Methods  ....................................................................................................................... 90 
3.2.1  Materials  ................................................................................................................................ 90 
3.2.2  Differential scanning calorimetry ........................................................................................... 90 
3.2.3  Viscosity of EtLac-PLA solution   .......................................................................................... 90 
3.2.4  MCs preparation ..................................................................................................................... 91 
3.2.5  MCs size distribution determination ....................................................................................... 91 
3.2.6  MCs morphology .................................................................................................................... 91 
3.2.7  Encapsulation of rhodamine ................................................................................................... 92 
3.3 Results   ............................................................................................................................................... 92 
3.3.1  PLA-EtLac solution characterization  ..................................................................................... 92 
3.3.2  MCs preparation and size determination ................................................................................ 93 
3.3.3  MCs morphology, inner porosity and Janus wrinkle pattern   ................................................ 95 
3.3.4  Drug encapsulation ................................................................................................................. 97 
3.4 Discussion  ........................................................................................................................................... 98 
3.5 Conclusions  ...................................................................................................................................... 102 
3.4 References  ........................................................................................................................................ 103 
 
Chapter 4 – Preparation of PLGA nanoparticles functionalized with DNase I to target biofilm 
extracellular matrix  for advanced antibiotic delivery   ............................................................................ 106 
4.1 Introduction  ...................................................................................................................................... 107 
4.2 Materials and Methods  ..................................................................................................................... 108 
4.2.1  Preparation of nanoparticles  ................................................................................................ 108 
4.2.2  Nanoparticles characterization  ............................................................................................. 109 
4.2.3  Drug encapsulation and in vitro release   .............................................................................. 109 
4.2.4 Quantification of DNase I activity containing NP   .............................................................. 110 
4.2.5  Bacterial Strain and growth conditions  ................................................................................ 110 
4.2.6  Minimal inhibitory concentration (MIC) assays  .................................................................. 110 
4.2.7  NPs activity against P. aeruginosa biofilm  ......................................................................... 110 
4.2.8  NPs cytotoxicity  ................................................................................................................... 111 
4.2.9  Statistical Analysis  ............................................................................................................... 112 
vii 
 
4.3 Results  .............................................................................................................................................. 112 
4.3.1  Preparation of nanoparticles and drug encapsulation    ........................................................ 112 
4.3.2  In vitro release of ciprofloxacin  ........................................................................................... 112 
4.3.3  Minimum inhibitory concentrations (MICs)  ........................................................................ 114 
4.3.4  Antibiofilm activity of CPX loaded NP   .............................................................................. 114 
4.3.5  Cytotoxicity  ......................................................................................................................... 115 
4.4 Discussion  ......................................................................................................................................... 117 
4.5 Conclusions and future perspectives ................................................................................................. 119 
4.6 References  ........................................................................................................................................ 119 
 
Chapter 5 – Cell delivery from functionalized polylactic acid microcarriers tuning MSCs migratory 
behavior in response to chemokine stimulation   ....................................................................................... 123 
5.1 Introduction  ...................................................................................................................................... 124 
5.2 Materials and Methods  ..................................................................................................................... 125 
5.2.1  Materials  .............................................................................................................................. 125 
5.2.2  MCs fabrication  ................................................................................................................... 125 
5.2.3  MCs functionalization   ......................................................................................................... 125 
5.2.4  Isolation of mesenchymal stromal cells   .............................................................................. 126 
5.2.5  Cell culture assays  ............................................................................................................... 127 
5.2.5.1 MSCs adhesion assay ................................................................................................ 127 
5.2.5.2 MSCs proliferation assay  ......................................................................................... 127 
5.2.6 CXCR4 expression analysis  ................................................................................................. 128 
5.2.6.1 Immunofluorescence ................................................................................................. 128 
5.2.6.2 Flow cytometry  ........................................................................................................ 128 
5.2.7  Migratory response of MSC to SDF-1α  ............................................................................... 128 
5.2.8  Statistical Analysis  ............................................................................................................... 129 
5.3 Results  .............................................................................................................................................. 129 
5.3.1  MCs characterization and surface coating   .......................................................................... 129 
5.3.2 Cell response in terms of adhesion and proliferation  ........................................................... 129 
5.3.3 Evaluation of migratory potential in response to SDF-1α  ....................................................... 132 
5.3.3.1 CXCR4 expression.................................................................................................... 132 
5.3.3.2 Migratory response of MSC to SDF-1α  ................................................................... 135 
5.4 Discussion  ......................................................................................................................................... 136 
5.5 Conclusions  ...................................................................................................................................... 139 
5.6 References  ........................................................................................................................................ 139 
 
viii 
 
Chapter 6 – Cell-laden microcarriers as building elements for tissue constructs via 3D bioprinting   143 
6.1 Introduction  ...................................................................................................................................... 144 
6.2 Materials and Methods  ..................................................................................................................... 145 
6.2.1  Materials  .............................................................................................................................. 145 
6.2.2  Microcarrier surface modification  ....................................................................................... 145 
6.2.3  Cells and culture conditions   ................................................................................................ 146 
6.2.4 Microcarrier culture   ............................................................................................................ 146 
6.2.5  Cell viability in MC-laden bioinks  ...................................................................................... 146 
6.2.6  Mechanical properties of MC-laden bioink  ......................................................................... 147 
6.2.7  Osteogenic differentiation  .................................................................................................... 147 
6.2.8  Bioprinting of MC-laden GelMA  ........................................................................................ 148 
6.2.9  Fabrication of bilayered osteochondral models .................................................................... 148 
6.2.10  Statistical analysis  ................................................................................................................ 149 
6.3 Results  .............................................................................................................................................. 149 
6.3.1  Cell viability in MC-laden bioinks    .................................................................................... 149 
6.3.2  Mechanical properties of MC-laden GelMA  ....................................................................... 150 
6.3.3  Osteogenic differentiation of MSCs  .................................................................................... 151 
6.3.5    Bioprinting of MC-MSC constructs  ..................................................................................... 152 
6.3.6  Printing of osteochondral models  ........................................................................................ 154 
6.4 Discussion  ......................................................................................................................................... 155 
6.5 Conclusions and future perspectives ................................................................................................. 158 
6.6 References  ........................................................................................................................................ 159 
 
Chapter 7 – Conclusions and future perspectives ..................................................................................... 163 
7.1  Conclusions  ...................................................................................................................................... 164 
7.1.1  Chapter 3 – MCs fabrication  ................................................................................................ 164 
7.1.2  Chapter 4 – Antimicrobial NPs  ............................................................................................ 164 
7.1.3  Chapter 5 – Cell delivery and migration from MCs   ........................................................... 165 
7.1.4  Chapter 6 – Cell-laden MCs bioprinting   ............................................................................. 166 
7.2  Future perspectives  ........................................................................................................................... 167 
7.3  References  ........................................................................................................................................ 168 
 
Appendix A – List of publications  .............................................................................................................. 169 
Appendix B – List of contribution to congresses and conferences  .......................................................... 170 
Acknowledgments  ........................................................................................................................................ 171 
1 
 
ABSTRACT 
The design of smart biomaterial devices plays a key role to improve the way conventional therapies are being 
administered, as well as to promote the development of new approaches for advanced therapies, such as 
regenerative medicine and targeted drug release. Injectable biodegradable materials, such as those consisting 
of suspensions of polymeric particles, are highly versatile devices that can be delivered through minimally-
invasive injections. The physic-chemical properties of the particles can be engineered to obtain smart 
scaffolds for tissue engineering, carriers for drug release and cell culture and therapy. The aim of this Thesis 
is to develop a novel class of biodegradable and injectable particulate carriers based on polylactic acid 
(PLA), that are capable to trigger and guide specific responses from the cells and the biological milieu. First, 
a novel route to fabricate PLA-based microcarriers (MCs) is set and characterized. This production method 
involves green, non-harmful chemicals and it is easy to scale-up. Such technique allows controlling key MC 
parameters, such as size and size distribution, which can be tuned in the range suitable for drug and cell 
delivery applications. The favorable regulatory status of the materials and reagents used to fabricate the 
MCs, may also be beneficial for the translation of the produced particles from bench to bedside. The 
principles guiding this fabrication procedure can inspire also techniques to generate nanocarriers for 
controlled drug delivery. Recent studies point out the importance of drug-loaded and submicron-sized 
biomaterials in the treatment of severe clinical conditions, such as persistent biofilm infections. These 
nanoparticles (NPs) can also be endowed with smart functionalities to enhance drug delivery through the 
biofilm matrix. In this way, NPs encapsulating the antibiotic ciprofloxacin have been produced and 
functionalized with DNase I. These carriers target and degrade directly the biofilm matrix, thus improving 
antimicrobial activity of the encapsulated drug and promoting established biofilm eradication. On the other 
hand, larger particles such as MC, display a suitable surface area for cell expansion. MCs can also be used to 
deliver cells with therapeutic potential as “living drugs”, ideally in a spatio-temporal controlled fashion. This 
is especially important, as cell injection in standard cell therapies, often renders the treatment ineffective, as 
it is accompanied by massive cell mortality. PLA MCs modified with different functionalization approaches 
and suitable to support homing and survival of Mesenchymal Stromal Cells (MSCs) have been produced. 
The physic-chemical properties of the MCs and biofunctionalized coatings play an important role on cell 
adhesion, proliferation and migratory potential in response to chemokines that are fundamental in controlling 
MSC tissue localization, like SDF-1α. The results highlight the importance of carriers design to control cell 
release and delivery, and provide important considerations to instruct a new generation of efficient cell 
carriers. Another exciting application of injectable MCs is to use cell-laden particles as building blocks to 
fabricate living tissues in vitro. Combination of MC technology with 3D bioprinting is an appealing strategy 
to generate grafts of multimaterial tissues with controlled architectures. The suspension of injectable PLA 
cell-laden MCs within hydrogel-forming, gelatin-based materials generated an extrudable, composite bioink. 
MCs can be used as mechanical reinforcement for soft hydrogels and as means for cell expansion (for 
instance in a spinner flask bioreactor) to encapsulate high cell payload. MSCs on surface functionalized PLA 
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MCs were shown to form MC-MSCs aggregates, with enhanced cell-to-cell contact, and were shown to 
differentiate towards the osteogenic lineage. This result suggests potential applications of MC-MSCs laden 
bioinks for bone tissue engineering, and the composite material is proposed as component to build 3D 
printed osteochondral graft models. Taken together, the injectable devices developed in the Thesis constitute 
a promising biomaterial platform for biomedical applications with high versatility, which can be employed in 
a wide array of tissue engineering, and cell and drug delivery strategies. 
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RESUMEN 
El diseño de dispositivos  basados en biomateriales inteligentes, juega un papel fundamental a la hora de 
mejorar las terapias convencionales, así como en el desarrollo de nuevas estrategias para la medicina 
regenerativa y la liberación controlada de fármacos. Materiales inyectables biodegradables, tales como las 
suspensiones de partículas poliméricas, constituyen dispositivos versátiles, que se pueden suministrar por 
medio de inyecciones mínimamente invasivas.  Las propiedades físico-químicas de las partículas pueden ser 
modificadas para obtener andamios inteligentes para la ingeniería de tejidos, transportadores para liberación 
de fármacos y cultivo y terapia celular. El objetivo de esta Tesis es el desarrollo de una nueva clase de 
partículas transportadoras inyectables y biodegradables, basadas en ácido poliláctico (PLA), que sean 
capaces de desencadenar y guiar respuestas específicas por parte de las células y del entorno biológico. 
Primero, se ha creado y caracterizado una nueva ruta para fabricar microstransportadores (MCs) basados en 
PLA. Este método de producción utiliza reactivos verdes y no-tóxicos, y es sencillo de adaptar para la 
fabricación a gran escala. Esta técnica permite controlar parámetros fundamentales en las MCs, tales como 
su tamaño y dispersión, que pueden ser controlados dentro de los rangos adecuados para aplicaciones  de 
liberación de fármacos y células. El hecho que los materiales y reactivos utilizados están bien aceptados por 
las agencias reguladoras, puede favorecer el traslado de las partículas fabricadas desde la investigación hasta 
la práctica clínica. Los principios de este método pueden adaptarse a otras técnicas de fabricación para 
generar nanotransportadores (nanopartículas, NPs) de fármacos. Estudio recientes subrayan la importancia de 
biomateriales submicrométricos cargados con compuestos bioactivos en el tratamiento de enfermedades, tal 
como las infecciones provocadas por biofilms. Estas NPs pueden ser modificadas con funcionalidades 
inteligentes, para mejorar la distribución del fármaco en la matriz del biofilm. De esta manera, se han 
producido NPs que encapsulan el antibiótico ciprofloxacino, modificadas superficialmente con DNasa I. 
Estos transportadores tienen como diana la matriz que compone el biofilm y pueden degradarla, 
incrementando la actividad antibacteriana del ciprofloxacino y promoviendo la erradicación de los biofilms. 
Por otra banda, las partículas más grandes, como las MCs, poseen una superficie adecuada para la expansión 
celular. Las MCs se pueden usar para transportar “drogas vivas”, es decir células con potencial terapéutico, 
posiblemente controlando su distribución espacial y su cinética de liberación. Esto es de particular 
importancia, porque la ineficiencia de muchas terapias celulares actuales se debe a la gran cantidad de 
células que no sobreviven una vez inyectadas in vivo. Se han producido MCs de PLA modificadas por 
diferentes estrategias de funcionalización y aptas para suportar en su superficie células madres 
mesenquimales (MSCs). La biofuncionalización y las propiedades físico-químicas de las MCs juegan un 
papel  fundamental en la adhesión y proliferación célular, así como la capacidad de las MSCs de migrar en 
respuesta a estímulos quimiotácticos, que regulan su localización en los tejidos, tal como el SDF-1α. Los 
resultados subrayan la importancia del diseño de las MCs para controlar la liberación de las células, y a la 
vez aportan información para desarrollar una nueva y más eficiente generación de transportadores de células. 
Otra aplicación prometedora de las MCs inyectables es su uso como bloques de construcción para fabricar 
4 
 
tejidos vivos in vitro. La combinación de la tecnología de las MCs con la bioimpresión 3D constituye una 
estrategia atractiva para obtener injertos de tejidos multimateriales con arquitectura controlada. Se han 
obtenido biotintas compuestas y capaces de ser extruidas mezclando materiales basados en hidrogeles de 
gelatina con las MCs de PLA cargadas con células. Las MCs actúan de refuerzo mecánico para el hidrogel y 
como vehículo para la expansión celular (por ejemplo, en un bioreactor “spinner flask”) para encapsular 
elevadas cantidades de células. Las MSCs forman agregados células-particulas, una vez sembradas en las 
superficies de las MCs, y estos complejos, ricos en contactos célula-célula, se demostraron capaces de 
suportar la diferenciación osteogénica de las MSCs. Este resultado sugiere potenciales aplicaciones de las 
biotintas cargadas de agregados de MCs y MSCs para la ingeniería del tejido óseo. Esta biotinta ha sido 
también utilizada como componiente para generar un modelo de injerto osteocondral, por medio de una 
técnica de impresión 3D.  El conjunto de dispositivos inyectables desarrollados en esta Tesis constituyen una 
plataforma muy versátil y prometedora para aplicaciones biomédicas,  en particular en estrategias de 
ingeniería de tejidos, y liberación de células y fármacos. 
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1.1 General introduction, motivation and aim of the Thesis 
 
The latest years have been characterized by significant progresses in biology, pharmacology and medicine. 
Significant advances in the knowledge of biological systems, their pathologies and regenerative processes, 
go along with the understanding of cell and tissue behavior, as well as the development of novel 
pharmaceutical compounds.  This progress are paving the way for new paradigms in medicine, centered on 
personalized, regenerative therapies and routes for specific and controlled delivery of therapeutic compounds 
[1]. A great push in this direction comes from the field of biomedical engineering, which applies the 
principles of engineering to biological systems to obtain predictive models for cells, tissues and organs, and 
to design technological solutions to diagnose the status –health/disease- of such systems and restore, 
maintain or improve their functionality. As this definition suggests, biomedical engineering covers a wide 
variety of applications and is intrinsically multidisciplinary. In this field, the tools and the scientific lore of 
“classical” engineering (structural, mechanical, electronic and chemical, to mention some), are used to 
understand, model and solve problems related to a highly complex and yet not fully understood system: the 
human body. This challenge certainly makes biomedical engineering an extremely fascinating field of 
research: the possibility to apply its knowledge to prevent or cure pathologies and to improve life conditions 
of patients is a driving force for scientific research. Moreover, the potential to design and implement devices 
capable to translate this knowledge into clinical practice provides strong motivation for this investigation.  
A multitude of technologies - pacemakers, devices for dialysis and extracorporeal circulation, medical 
imaging techniques, substitute heart valves, hip prosthesis, to name a few- have been solidly implemented in 
medicine in the past century, and are nowadays part of common clinical practice. Research in bioengineering 
is strongly oriented to provide new answers to health issues. Personalized therapies, computational predictive 
models, advanced drug delivery and regenerative medicine are a few keywords indicating the current 
directions of scientific research that promise to describe the medical practice of the next future. 
The field of Biomaterials plays an important role in this direction. Biomaterials are required whenever there 
is a need for a physical component of a device that enters in contact with a biological system, may it be 
inside the body such as prosthesis or outside (i.e. components of a heart-lung machine in contact with the 
blood, sensors in equipments to analyze biological fluids). 
There is a continuous crosstalk between novel therapies and developments in biomaterials, and the need of 
new approaches to biomaterials sciences and engineering goes together with the need of healthcare for 
society; which is increasing, due the aging of the population in the developed countries [2].   
Biomaterials need to be designed as smart devices, capable i) to improve the way conventional therapies are 
being administered, ii) to trigger specific responses once in contact with the biological milieu, iii) as well as 
to promote the development of new approaches for advanced therapies, such as tissue engineering and cell 
delivery [3]. Following these guidelines, for instance, biomaterials can be used as drug delivery devices, 
carriers for cell therapy, scaffolds for tissue engineering and platforms to build 3D tissue models for in vitro 
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drug screening. Furthermore, biomaterials meant to be administered into the body should be biodegradable, 
in order to be safely removed or metabolized by the organism, once their function is fulfilled [4].   
Furthermore, biomaterials devices should be easy to apply, possibly with minimally invasive injections and 
no need for surgical intervention. This specification is greatly appealing, as it improves the compliance of 
patients to the treatment and facilitates the translation of the biomaterial device to the clinical practice [5]. 
Among the various classes of injectable materials, this Thesis focuses on the development of injectable 
and biodegradable polymeric micro- and nanoparticles. Versatility is a key advantage of micro- and 
nanocarriers, which can address a wide range of applications, alone or in combination with other 
materials, such as the delivery of therapeutic agents, to act as culture supports and as cell-instructive 
components in regenerative medicine strategies. The aim of this work is to study novel approaches to 
generate and design such carriers, as well as how to control and choose the material properties in 
order to generate effects on specific biological targets. In this way, antibacterial as well as cell-fate 
guiding materials can be obtained. Moreover, these injectable materials are studied as components to 
build living tissues in vitro by means of biofabrication and tissue engineering strategies. 
 
 
1.2 Outline of the Thesis 
The outline of the Thesis is schematized in Figure 1.1. 
 
 
Figure 1.1: Outline of the Thesis 
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In Chapter 2 a general introduction to the most important topics developed in the Thesis is provided. A 
review about biomaterials, with a special focus on biodegradable polymers and their chemical modification 
to tune their biological activity is provided, together with a description of classes of injectable polymers, and 
their application in controlled drug delivery, cell therapy and tissue engineering. The main concepts 
belonging to such areas of biomedical research and clinics are also described and summarized. Moreover, 
Chapter 2 provides an overview of the state-of-the-art concerning biodegradable injectable micro- and 
nanocarriers. The review covers topics ranging from the fabrication of such devices, their interaction with the 
biological environment and application in bioengineering. Furthermore the main research trends and open 
perspectives in the area of polymeric particulate carriers are discussed. 
In Chapter 3 a novel method to produce microparticles (MPs) made of polylactic acid (PLA) is described. 
This technique, based on the generation and break-up into droplets of a polymer solution jet by means of 
hydro- and aerodynamic forces, was set using no toxic chemicals. The most important engineering 
parameters involved in polymer processing and MPs fabrication are analyzed, in order to set a straight-
forward, clean, scalable technique to generate MPs with controlled size. The method was also designed to 
allow the possibility to encapsulate bioactive compounds into the fabricated MPs. Morphology of the MPs is 
extensively studied, and potential biomedical applications of the particles generated with this method are 
discussed.  
Chapter 4 presents a modification of the method described in Chapter 3 to fabricate Nanoparticles (NPs). 
NPs were characterized as controlled drug delivery devices, and used to encapsulate ciprofloxacin, a broad-
spectrum antibiotic. The results of NPs in vitro application to treat bacterial infection, with particular 
attention to their ability to eradicate biofilm infections, are also presented. The issue of surface modification 
of NPs is also introduced and studied. NPs were endowed with specific functionalities to interact actively 
with their target, the biofilm extracellular matrix, using different coatings. 
In Chapter 5 the MPs obtained with the technology introduced in Chapter 3, were evaluated as delivery 
vehicles for cell therapy applications. In particular, the potential of these MPs to act as microcarriers (MCs) 
for the controlled release of Mesenchymal Stromal Cells (MSCs) is assessed. These MCs were submitted to 
two different surface treatments and modified with recombinant collagen and RGD peptide coatings, and the 
role of such functionalization techniques on MSCs behavior in terms of homing, adhesion, proliferation and 
migratory potential is described through in vitro assays. Particularly, the specific migratory response 
triggered by SDF-1α, a key chemokine in stem cells recruitment in vivo is studied. Injectability of MSC-
laden MCs is also discussed. The results collected with this research can offer guidelines for the choice and 
design of more efficient cell carriers, capable to guide MSCs therapeutic activity. 
In Chapter 6 MCs selected based on the results obtained in Chapter 5 are tested as elements to build living 
tissue grafts using a biofabrication technique, for innovative applications in Tissue Engineering. MCs are 
used to generate MC-MSCs complexes, via static and dynamic culture in a spinner flask. MSC-laden MCs 
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are suspended into a gelatin(methacrylamide)/gellan gum hydrogel to generate an injectable composite 
material. The potential of the MCs to improve the gel mechanical properties, as well as to act as a homing 
material to guide MSCs fate and promote osteogenic differentiation are analyzed. Using MSC-laden MCs, 
the hydrogel-MCs composite is employed as a bioink, and through a bioprinting technique, 3D constructs are 
built. Clinically-relevant size models of an osteochondral graft are also generated with such technology. The 
implications of MCs culture combination with bioprinting are also discussed. 
Finally, Chapter 7 summarizes the overall conclusions to the topics described in the experimental work, and 
provides future perspectives for the continuation and application of the research developed in this Thesis. 
 
The research presented in this Thesis was developed at the Biomaterials for Regenerative Therapies group of 
the Institute for Bioengineering of Catalonia (IBEC), under the supervision of Dr. Miguel Angel Mateos-
Timoneda, and the direction of Prof. Josep Planell and Prof. Elisabeth Engel. The author gratefully 
acknowledges the Spanish Ministry of Education, Culture and Sport (MECD) for the financial support 
through the FPU program (Formación de Profesorado Universitario - University Lecturer Training, grant 
reference AP2010-4827). The work reported in Chapter 6 was performed at the Department of Orthopedics 
of the University Medical Center Utrecht (UMC, Utrecht, Netherlands), in collaboration with Dr. Jos Malda, 
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2.1 Introduction to Biomaterials 
Since the beginning of the use of materials as implants or devices in contact with the human body, a long 
road has already been walked down. Materials such as metals, glass and ceramics have been sporadically 
used as tissue grafts through history, and since the first decades of the 20th
It was not until the second half of the 20
 century pioneering physicians 
started to use plastics as well. However, most of these experiments were doomed to fail, due to the lack of 
understanding in matters of toxicology and foreign body reaction [1]. After 1960, a so-called first generation 
of biomaterials was developed for use as medical devices. They were mostly based on bioinert metals, 
ceramics and polymers, and aimed to minimize adverse host response after implantation and thus be 
tolerated by the human body. Despite of the development of these successful implants, such as artificial 
joints, heart valves, stents and ocular lenses, the understanding of biological repair and regeneration 
mechanisms, as well as of the interaction between materials and tissues was limited. Thus, the design of 
these devices was still mostly due to the choice of commodity products the surgeons could easily find, rather 
than being driven by biocompatibility issues [2].  
th
To date, biomaterials to improve human life have become key elements in medicine, and are growing more 
and more important. With the aging of population, the need for replacement and repair of degenerated or 
 century that biomaterials science and engineering became an 
important and recognized field of study, and from 1980s, the focus of the field moved towards the need of 
improving integration between (artificial) materials and living tissues. A second generation of bioactive 
materials, capable of promoting tissue ingrowth and device-tissue interlocking were produced. In this period, 
studying of phenomena at the biomaterial-tissue interface became fundamental, and lead to an increase in 
implants lifetimes [3]. In such context, biodegradable and bioresorbable materials acquired more and more 
importance, as they break into non-toxic compound, capable of being eliminated gradually from the body 
once their in vivo function is completed [4]. This scientific and cultural context is reflected in the by then 
accepted definition of the term “biomaterials” as “nonviable [materials] used in a medical device, intended to 
interact with biological systems” [5]. In the following years and up to recently, the increasing crosstalk 
between the fields of materials science and cellular, molecular and developmental biology has, instead, lead 
to expand and analyze in detail what that “interact with biological systems” implied, leading to a third 
generation of devices, that aimed to guide and promote the body regenerative/repairing processes, interacting 
directly with cells and providing physic-chemical signals to trigger the activation of genes implicated in 
ECM synthesis and tissue repair, for instance [6]. The wide spectrum of “interactions” that a biomaterial may 
establish with the biological milieu, together with the fact that several devices are nowadays composed by a 
combination of supporting materials and living cells at the same time, lead to the affirmation of more 
comprehensive definitions. Current biomaterials can be generally defined as “substances that have been 
engineered to take a form which, alone or as part of a complex system, is used to direct, by control of 
interactions with components of living systems, the course of any therapeutic or diagnostic procedure, in 
human or veterinary medicine” [7]. 
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diseased tissue and organ is also increasing. The consequences of this need for society are reflected by the 
size of the biomaterials industry, estimated around 28 billion US dollars, and by its growing market, which is 
expected to worth 58.1 billion US dollars by the present year [8].These impressive data and previsions go 
along with the increment in clinical demand and patient expectations.  
Holding its footstep on this foreground, biomaterials science is moving forward from the research directions 
followed in the past decade, and aims to fabricate smart and biomimetic materials. Biological materials show 
an intimate relationship between shape and microstructure, as they both originate during the growth of the 
tissue and development of the organism [9]. This implies that form and structure are created in the same, 
self-assembly process, and such structures are able to remodel themselves and dynamically adapt to the 
different stimuli provided by the surrounding environment. Unlike engineered materials, the final result is 
not an a priori design, but rather the result of a dynamic evolution, and thus biological materials and tissues 
display high functional flexibility and adaptability. The concept of biomimicry in materials engineering 
follows the idea that matrices can be fabricated, which reproduce nature hierarchical structures and its simple 
and elegant mechanisms conserved through genera and species [8]. A summary of the different properties of 
biological, engineered and smart materials is presented in Table 2.1. However, since we are still long way 
from recreating exactly natural tissues and their full functionality, a key challenge in biomaterials design is to 
determine how and to which degree artificial devices should recreate the complexity of native tissues (i.ei, in 
terms of structure, morphology, biochemistry). Common strategies to generate smart materials include, for 
instance: modification of surface properties [11], design of advanced 3D architectures [12], pH/temperature 
responsiveness [13]. In general, such properties should provoke instructive effects over cells and tissues. 
However, the required degrees of complexity, the type of response the biomaterial needs to trigger, and the 
method to endow the device with smart functionalities, depend, of course, on the type of application that the 
material is designed for, as well as on the type of material. The generation of smart materials, is necessary 
for most regenerative therapies strategies -which include tissue engineering, cell therapy and gene therapy- 
since biomaterials can be actuators in directing cell and tissue behavior rather than passive spectators. 
Analogously, smart functionalities are keys to improve drug delivery devices, for example, by permitting 
triggered drug release under certain stimuli, creating drug carriers capable of targeting certain cells/tissue or 
mimicking some enzyme activity. Biodegradable polymers are the preferred choice for these applications, 
which require devices that are gradually removed during the timescale of the healing process [14]. 
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Table 2.1 Filling the gap. Biomimicry can help to design engineered materials that can reduce the 
difference between biological, living, materials, imitating their properties (adapted from [10]) 
Biological Materials Engineered Materials Smart Materials 
Growth by biological controlled 
self-assembly 
Fabrication (exact design) 
Fabrication (exact design). 
Self-assembly techniques can 
be implemented 
Hyerarchical structuring, from the 
nano- to the macroscale 
Forming of the part, and after that, 
microstructuring of the material 
Bottom-up assembly of units, 
or self-assembly strategies to 
induce a degree of hyerachical 
structure 
Adaptation of form and structure to 
the application 
Selection of the material(s) 
according to the function 
Selection of the material(s) 
according to the function 
Healing and Remodeling according 
to signal received from the 
environment 
Secure design 
Stimuli-responsive 
Cell-instructive 
 
 
 
 
2.2 Biomaterials in Regenerative Medicine 
2.2.1  Tissue Engineering 
One of the most promising fields of medicine is the substitution of damaged or diseased tissues, and the 
necessity of adequate tissue replacements is increasing as the population ages. Many current clinical 
strategies to treat tissue defects rely on autologous, heterologous or even xenogenic transplantation. 
However, such approaches are far from optimal. Autotransplantation is only possible for limited tissues, and 
implicates donor site morbidity. On the other hand, the difficulty in finding compatible donors, lack of a 
complete recover of tissue functionality and immunogenicity are the main drawbacks of heterologous 
transplantation. Furthermore, also xenogenic tissues and organ have important donor-host compatibility 
issues and expose the recipient to the risk of cross-species transmission of pathologies. Donor compatibility, 
in particular, often requires the patient to undergo pharmacological treatments (e.g. immunosuppression) that 
may have important side consequences, so that while the damaged tissue is restored, other physiological 
functions may be significantly hampered. Another well established possibility is the implantation of inert 
biomaterials specifically processed to possess properties similar to those of the natural tissue. The field of 
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biomaterials in medicine is lively and brought to the realization of widely used artificial prosthesis, as 
reviewed in the previous paragraph. Despite of the success of these devices in accomplishing the anatomical 
and structural role of the original tissue/organ, artificial devices, usually fail to recreate all the complex 
physiological functionalities of biological materials. In fact, biological materials, that are the main 
constituents of living organisms and build up tissues, cover a variety of roles and functions, such as structural 
support, protection, insulation, metabolites and ions storage, signals generation and transmission, and 
production and conversion of energy, among others [10]. Therefore, it is evident the need for the evolution of 
such an approach towards the full restoration of all the biological functionality of native tissues.  
This need constituted a turning point in the development of biomaterials with bioactive properties and 
capable of positively interact with the host organism and therefore guide cell activity. Strategies that aim at 
this objective belong to the field of regenerative medicine, which includes all the therapies directed towards 
the regeneration of tissue or organs affected by damages or diseases.  
In this area are included Tissue Engineering (TE), Cell Therapy and Gene Therapy. Tissue Engineering can 
be defined as proposed during the 2005 Satellite Consensus Conference of the European Society of 
Biomaterials (ESB): 
“Tissue Engineering is the creation of new tissues for therapeutic reconstruction of the human body through 
the controlled stimulation of properly chosen cells with a combination of molecular and mechanical signals 
[15]” 
It is evident how tissue engineering is a highly interdisciplinary field and a crossover of knowledge from 
engineering, biology, materials science and medicine. In its paradigm, tissue engineering includes the 
utilization of adequate cells seeded on a biodegradable structure (the scaffold), which acts as a temporary 
artificial extracellular matrix (ECM). The cell-biomaterial construct is induced to maturate under specific 
environmental conditions, providing biochemical (growth factors or chemical cues given by the same 
scaffold) or physical signals (dynamic culture condition, mechanics of the scaffold) whose nature depends on 
the type of tissue that has to be recreated (fig. 2.1).  
  
 
Figure 2.1: Schematic representation of the paradigm of tissue engineering 
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Cell culture conditions can be regulated through the use of a bioreactor, a system capable of maintaining the 
environmental parameters under control, while providing several stimuli (e.g. mechanical and electric) to 
induce tissue formation. The classical TE approach is given in Figure 2.2. 
 
 
Figure 2.2: Formation of a regenerated tissue from autologous cells. 
 
A sample of autologous tissue is taken from the patient to isolate the needed cells (usually pluripotent or 
progenitor cells, such as mesenchimal stem cells) that are afterwards cultured to increase their number. Cells 
are then seeded onto a scaffold (either 3D or 2D, according to the application) to be further cultured in an 
appropriate environment (static or dynamic) and the construct is afterwards implanted into the patient. The 
result is the gradual formation of newborn fully functional tissue together with the degradation and 
bioresorption of the scaffold [16]. More generally, it is possible to classify tissue engineering strategies as 
histoconductive, if the scaffold promotes the formation of the tissue through previously seeded cells, or 
histoinductive if the implanted construct promotes neovascularization and tissue regeneration is driven by 
cells recruited from the surrounding tissues [17]. The first strategy usually allows the production of limited 
volumes of tissue-like structures, while in the latter may be unsuccessful if the cells recruited in vivo are 
damaged by the tissue defect [18]. Histoconductive strategies may be also roughly classified between top-
down and bottom-up (Figure 2.3) approaches [19]. In the first case, cells are required to home on a 
prefabricated scaffold, and from that to create the engineered tissue and its microarchitecture. In bottom-up 
techniques, instead, a modular, “tissue unit” is generated, and a multitude of these units is used to build a 3D 
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structure either by biological self assembly or by imposing a certain spatial distribution to the unit using 
microfabrication or rapid prototyping techniques. Such modules can be composed by cells alone or cells and 
biomaterials, such as gels and particles. 
 
 
Figure 2.3: Graphical representation of top-down and bottom-up Tissue Engineering. 
 
While the final aim of engineered tissue is to obtain devices that can recapitulate the complexity and the 
functionality of living tissues (and organs), such objective can be achieved by trying to replicate tissues ex 
vivo, already during the scaffold-cells construct design, or rather to develop devices that, thanks to their 
smart functionalities and physic-chemical properties, are able to replicate complex biological effects using 
“simplified” signals that can “establish key interactions with cells in ways that unlock the body’s innate 
powers of organization and self repair” [20]. 
Additionally, tissue engineering provides a set of tools that can be used for regenerative medicine, but whose 
potential application goes beyond the only scope of tissue replacement, healing or enhancement, and can 
benefit other fields of biomedical research. Tissue engineering constructs, in fact, can also be used as in vitro 
models of living tissue, with potential applications as disease models, developmental biology studies and 
drug testing 3D platforms [21]. Nowadays, most of biological research is conducted on 2D cell culture on 
Petri dishes, an oversimplified model, uncapable of fully recapitulate cell behavior in vivo, and on animal 
models, which demand expensive facilities and have non-negligible ethical implications [22]. Tissue 
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engineering constructs can help to bridge the huge gap between 2D cell culture and animal models, and thus 
reducing the cost of animal experimentation, introducing a new class of in vitro models, one step closer to 
living tissues, 3D cell-to-cell communication.  
Given this overview of the TE approach, four critical elements that are the backbone of the design and 
implementation of TE strategies can be identified: 
a) A cell source is required. The choice of the type of cell (stem cells, differentiated cells) and their origin 
(i.e. autologous/heterologous), poses some limitation on cell availability, and how to expand those cells to a 
sufficient number to achieve tissue regeneration. In the case of histoconductive strategies, it should be clear 
which type of cells need to be recruited in vivo. 
b) A scaffold, capable of supporting the regenerative process, home cells and/or recruit cells from the patient 
and act as an active matrix to guide cells fate. Several design aspects such as type of material, desired 
structure, inclusion of bioactive/smart cues, and method of application of implantation of device have to be 
taken into account. 
c) 3D, in vitro, tissue culture on the scaffold. To generate a construct composed by cells cultured on the 
biomaterial. The culture can be done under static or dynamic conditions, in devices known as bioreactors. 
d) A stimulation, to guide cell behavior and tissue deposition and maturation. This can be provided by the 
chemical composition of the culture medium (i.e. growth factors), by the scaffold (drug release, mechanical, 
physical and chemical properties) and bioreactors as well (i.e., mechanical and electrical stimulation, 
improved diffusion of nutrients). 
 
2.2.1.2 Cells in Tissue Engineering 
Cells are the main actors in tissue organization and functionality. They build up the ECM and direct its 
architecture, produce factors and signals that regulate tissue activity. Cells are also in charge for inducing 
tissue healing and remodeling, thus being the principal responsible of living materials homeostasis, adaptive 
behavior and responsiveness to environmental stresses [22]. It is no wonder that a huge effort in regenerative 
medicine and tissue engineering is directed towards the choice, isolation and purification of cells capable of 
inducing tissue regeneration, as well as developing strategies to control their biological activity [23]. 
Generally speaking, cells used in tissue engineering need to i) proliferate to and adequate amount, in order to 
colonize scaffolds and ii) being able to produce ECM and pro-regenerative factors (chemokines and other 
instructive molecules) adequate to the target tissue. Other mechanisms involving cell migration, sensing of 
the environment and communication are also fundamental in determining tissue regeneration. Considering 
the two necessary requirements mentioned above, two types of cells sources can be identified and used: 
already differentiated cells from the target tissue (e.g. osteoblasts for bone, chondrocytes for cartilage, 
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cardiomiocytes for the heart, and so on), or cells retaining the potential to differentiate towards the desired 
phenotype, such as progenitor cells [24]. The second approach has several advantages, especially when stem 
cells are considered. Stem cells are defined by their capability of self-renewal and multilineage 
differentiation. Self-renewal implies that these cells can proliferate without losing their phenotype, and thus 
continuously preserve their pool, while the differentiation potential consists in that stem cells, given the 
appropriate physic-chemical signals, can commit towards certain fully mature and tissue-specific cell types 
[25]. Stem cells can be classified into toti-, pluri- and multipotent, based on the different possible lineages 
that they can give rise to. Totipotent cells are able to differentiate into any cell type of the organism (such as 
a zygote and the cells following its very first divisions), while pluripotent cells are found in the inner cell 
mass of the blastocyst, and are defined as embryonic stem cells [26]. Although these cells hold great promise 
in tissue engineering, as they can differentiate in a wide spectrum of lineages, their usage raises several 
ethical and safety concerns [27]. On the other hand, several adult tissues, such as bone marrow, skin and 
adipose tissue, have been demonstrated to home a niche of multipotent stem cells, more limited in their 
differentiation potential, but also easier to retrieve and use in clinics and research, without sharing the same 
limitations of embryonic cells. It has also been inferred that every tissue may host a pool of stem and 
progenitor cells, which take part in healing and regeneration processes [28], and may be sometimes 
implicated also in cancerous diseases [29]. 
One of the most investigated and promising cell type in regenerative medicine are Mesenchymal Stem Cells 
(MSCs), that can be retrieved, for instance, from the bone marrow and the adipose tissue, and are known to 
be able to differentiate towards osteogenic, chondrogenic and adipogenic lineages [30]. For most of MSCs 
that are currently under investigation, although their multipotency is confirmed, their actual stemness and 
characterization is controversial [31]. For this reason, these cells are more correctly defined as Mesenchymal 
Stromal Cells (also abbreviated as MSCs), even though it should be noted that in the literature both 
terminologies can be found, and are often interchangeable [32]. In this Thesis, this second nomenclature to 
indicate MSCs will be used.  MSCs are adherent-dependent cells, displaying a fibroblast-like morphology, 
once plated on tissue culture plastic. They are characterized by the in vitro expression of CD105, CD73 and 
CD90, and are negative for CD45, C34, CD14 or CD11b, CD79α or CD19 and HLA-DR surface molecules, 
and their in vitro adipogenic, chondrogenic and osteogenic differentiation ability [32]. Moreover, there have 
been reports of induction of MSCs differentiation towards additional phenotyopes, including myogenic [33] 
and neuronal lineages [34], which considerably expand the potential of MSCs for regenerative therapies. A 
scheme of MSCs differentiation potential is represented in Figure 2.4.  
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Figure 2.4: Multilineage commitment of MSCs, adapted from [35]. 
MSCs can be retrieved from different tissues (including umbilical cord blood and placenta), although the 
most common (and easier to access) sources are the bone marrow and the adipose tissue. In bone marrow 
biopsies about the 0.002% of the cellular fraction is composed by MSCs [36], while lipoaspirates can have 
up to a 2% of MSCs [37]. Once these cells are isolated and purified from the tissue sample, they need to be 
expanded to relevant numbers to be used in clinical settings, and, at the same time, cells have to preserve 
their “stem” phenotype, before being induced to differentiate towards the required cell type. Additionally, 
cell expansion and culture should be performed in rapid ways, compatible with the clinical needs of the 
patient. Knowledge of the biological mechanisms underlying these processes is fundamental in any 
regenerative therapy strategy and establishing and providing cues capable of guiding them can be provided 
by soluble factors, dynamic culture and by an accurate design of biomaterial scaffolds.   
In the recent years, the discovery that adult, differentiated cells can be reprogrammed to dedifferentiate into 
an embryonic-like state, and from this state be expanded and differentiated again into a new cell phenotype, 
has risen a lot of attention. These cells, called induced-Pluripotent Stem cells (iPSC), possess the potential of 
tissue regeneration of embryonic cells, without sharing the ethical drawback and difficulties in retrieval [38]. 
Although it is foreseeable that these cells will play a key role in the next future of regenerative medicine and 
open new therapeutic perspectives, to date the lack of knowledge on their biological response and the risk of 
teratogenesis that they carry, limits their application as constituents for in vitro disease models [39].  
2.2.1.3 Scaffolds 
The ECM, together with the cells that produce it, makes up the 3D composition of a tissue, providing 
structural integrity and support. Far from being only a mechanical component, the ECM is a complex and 
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hierarchically organized source of signals, capable of determining cell fate.  ECM macromolecules bear 
chemical functionalities that cells can recognize, are anchoring points for growth factors, can be pulled and 
stretched by cells to transmit mechanical signals and can be degraded to allow tissue remodeling and cell 
migration [40]. In addition that cells growth and tissue organisation are strictly dependent on mechanical, 
physical and biochemical signaling provided by the complex background in which those structures are 
involved: biological response to these pathways can determine the success or the failure of the wound 
healing process. Considering these cell-ECM interactions, it is evident that scaffolds for tissue engineering 
should be fabricated to act as a temporary ECM substitute, able to replicate its functions. Moreover, 
scaffolding materials are usually implanted at sites of tissue defects incapable to heal themselves, or in 
tissues with poor regenerative capabilities (such as cartilage and neuronal tissue). Advanced scaffolds must 
provide the molecular and physical information coded within the extracellular milieu, in order to establish 
specific interaction with cells, and thus unlocking their potential for tissue regeneration and organisation. For 
this reason, they have to be able to trigger specific cellular responses and regenerative processes, which the 
damaged organism may not be able to put into action. Of course, as the term scaffold itself suggests, they 
have to sustain mechanically the neo-tissue growth. Some of the most important specifications to design 
scaffolds can be summarized as follows [41]: 
• Biocompatibility of the materials used to fabricate the device, meaning that the material does not 
exert a toxic effect on its environment, nor provoke any uncontrolled immunological or foreign body 
reaction; 
• Bioresoption: the materials must possess a degradation kinetics paired with the rate of tissue 
regeneration. Degradation products must satisfy the specification of biocompatibility; 
• Highly interconnected porosity. Pore dimensions should be adequate to allow cell colonization of the 
scaffold, tissue growth and mass transport (biological fluids, metabolic and catabolic substances); 
• Surface properties favorable to cell adhesion and targeted to provide stimuli, also through the release 
or the exposure of bioactive molecules (e.g. growth factors). It is generally acknowledged that biomaterial-
cells interactions are mediated by phenomena occurring on material surfaces, especially dynamic protein 
adsorption, and that engineering surface properties is a powerful tool to guide protein-biomaterials 
interactions, and cell reaction to biomaterials [42]. 
• Mechanical properties compatible to those of the tissue to regenerate. Scaffold should resist 
physiological loads typical of the native tissue and, during degradation, and gradually transfer them to the 
forming tissue; 
• Promote vascularization (when necessary). Every living cell needs access to a nutrient and oxygen 
supply, for this reason, generation of functional vascular networks is fundamental for tissue survival. In 
absence of such mass transfer system, tissue engineered construct size is limited by oxygen diffusion 
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distance, which is too low to allow the fabrication of grafts with clinically relevant dimensions [43]. Certain 
tissues, such as cartilage, are naturally avascular, therefore nutrients should be provided through other means 
(for instance, using hydrogel scaffolds allowing proper diffusional rates) [44]. 
• Inclusion and release of bioactive molecules, to act as chemical signals to guide cell response; 
• Sterilizability. A scaffold to be used in the biological milieu must be sterile, and the sterilization 
procedure should pose no relevant harm to the device (i.e. should not induce degradation of the material and 
its properties); 
• Ease of handling and suitability to be implanted with common surgical practice, possibly even with 
minimally invasive procedures; 
• Adequate shelf-life; 
• The fabrication and the processing procedures should be respectful of the specifications cited above.  
In order to address these specifications, scaffold design and tuning of the properties of the device is 
fundamental. Furthermore, cells can respond in specific manners even to certain morphological feature, 
scaffolds geometry and shape, biomolecules coating, and chemical composition [45]. Following this step, the 
device must undergo a rigorous characterization in order to be validated (Figure 2.5). 
 
Figure 2.5: Example of a workflow of scaffold design and device validation. Although only few 
materials are reaching applications in humans, each step in the development of such devices can 
provide new insight and information to improve scaffolds in regenerative medicine.  
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2.2.1.4 In vitro culture, bioreactors and environmental stimulation 
While the scaffold can provide a regeneration-promoting 3D microenvironment, another key necessity for 
tissue engineering is how to recapitulate the dynamic environment of cells. In vivo, cells receive stimulation 
from each other, from the extracellular milieu, but also from other tissues and organs, as well as from 
biomechanical and biochemical actors, both in space in time. This is especially important when considering 
the in vitro culture step on 3D scaffolds. Standard culture techniques are mostly oriented to expand cells in 
the bidimensional surface of a plastic well, and rely on simple diffusion of metabolites from the medium to a 
film of cells directly exposed to it. Although they can be used also to generate cell-laden scaffolds, this 
approach is far from being efficient. When moving from a 2D to a 3D environment it is necessary to: i) 
guarantee homogenous distribution of cells and neo-deposited tissue through the scaffold volume, ii) permit 
efficient mass exchange in the construct, allowing removal of catabolites, provision of oxygen, nutrients and 
bioactive compounds and iii) recapitulate the effect of external stimuli to induce maturation of the construct 
(i.e. mechanical stresses, electric signals). A technical solution to this need is the implementation of 
bioreactors, devices where biochemical processes can develop under closely monitored and controlled 
conditions [46]. Several types of bioreactors exist, and many of them are custom-made in order to meet the 
type of mechanical/electrical stress that the target tissue requires. Figure 2.6 reports a few examples of 
possible bioreactors. 
 
 
Figure 2.6: Examples of bioreactors. A) spinner flask, B) perfusion bioreactor, C) rotating system [47], 
D) system to exert a mechanical tensile loading on the construct [48]. 
 
Systems that are able to generate culture medium flows, such as spinner flasks, roller bottles and perfusion 
bioreactors, respond to the need generated by the point i) and ii) of the specifications described above. 
Additionally, perfusion systems, can apply beneficial shear stresses onto cells, which are also profitable to 
guide seeded cells fate and differentiation [49]. Flow systems combined with porous scaffolds, have also 
been demonstrated to enhance cell proliferation and ECM production, in comparison to static culture [50]. 
Furthermore, application of physical stimulations, such as cyclic mechanical loading has been shown to 
A) B) C) D)
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participate in cell maturation and improvement of the quality of the neo-tissue formation. For instance, 
smooth muscle cell-laden constructs exposed to time-controlled series of tensile stresses were proven to 
increase their expression of myosin heavy chain, a marker for myogenic phenotype, and subsequent muscle 
matrix synthesis [48]. Devices combining sets of different stimuli can be also be designed; for instance, 
Tandon et al. have proposed a bioreactor allowing for construct perfusion and electrical stimulation to 
engineer cardiac tissue [51].  
Indeed, bioreactor systems are key components in tissue engineering, as they produce a controlled 
environment, profitable to induce cells to generate efficient matrices. At the same time, development of 
bioreactor technology that can reduce risks of culture contamination and generation of more reproducible 
outcomes, also provides an automatization of the cell culture procedure, which is fundamental to permit 
scaling-up of the graft generation and thus its clinical application [52].  
 
2.2.1.5 General remarks on tissue engineering and its current state 
Nowadays, tissue engineering is considered a discipline in its maturity. TE products are already used in 
clinical settings, mostly in the area of skin (i.e. TransCyte, Apligraft, Oasis Wound Matrix), bone (INFUSE 
is a clear example of a successful TE product) and cartilage (i.e. Hyalograft C, Bioseed C, MACI), with few 
devices having obtained a regulatory green-light for other applications such as blood vessels, nerves, heart 
valves and bladder, among the others. These commercially available products have been summarized in the 
literature [20]. Despite of the central role of skin and orthopedic devices, current estimations foresee that 
cardiac TE products will become increasingly more central, due to the fact that cardiovascular diseases are 
the principal cause of death in the industrialized countries [8]. Additionally, to date, there are 41 clinical 
trials registered in the USA, as obtained by searching the words “Tissue Engineering” in the 
clinicaltrials.gov database. Despite of this, still too many tissue engineering strategies that showed promising 
results in preclinical studies, fail to reach the clinical practice. The problem of generating large grafts with 
functional vasculature and guarantees their survival, has been one of the main topics of the past and present 
decade, and still remains a fundamental bottleneck for many TE devices [53]. In the last years, many 
successful cell-free TE products, which rely on supporting the body’s ability to self-heal, have reached the 
market and the clinics, especially for bone, cartilage and skin repair. Regulatory approval of cell-based 
products (in Europe falling under the regulation of the Advanced Therapies Medicinal Products, EC 
regulation No 1394/2007) is also a long and challenging route, and there is a crescent push for the applied 
research area to design and study TE grafts with such legislation in mind [54]. Additionally, to date, among 
the most important examples of engineered tissues, cell-seeded, tissue cultured in vitro,  successfully 
implanted in humans and with higher-impact in the generalistic media two notable cases can be cited: the 
bladder constructs developed by Atala et al. (2006) [55] and the engineered airway, from a donor trachea 
decellularized, implanted by Macchiarini and coworkers (2008) [47]. These devices, as well as many others 
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designed according similar guidelines, still remain of limited application and with them other products as 
well, since they mostly respond to the need of a patient-specific/on demand implant, and can be better 
applied in hospitals or clinics that have available a Good Manufacturing Practice (GMP) facility for the 
treatment of cell culture constructs. Although such approaches are very appealing, they do not easily match 
the requirement of a conversion of the device fabrication from a bench-scale to a clinical and industrial scale, 
providing at the same time GMP, at affordable costs.  
The design of new, smart biomaterials, devices with improved functionalities and cell-instructive properties 
also goes in the direction of facing and overcoming some limitations. Furthermore, as an additional 
requirement, these biomedical devices should be as easily as possible implantable with standard surgical 
practice, in order to improve their acceptance by most of the clinicians that will have to handle them. For 
these reasons, making TE strategies more effective and at the same time easier to translate towards the 
biomedical industry and the medical practice is a great challenge, whose reward will be a benefit for health 
and society.  
 
2.2.2 Cell Therapy 
Unlike tissue engineering approaches, which imply the de novo generation of the damaged tissue on a 
scaffolding support, cell therapy focuses on the in vivo delivery of cells as “living drugs”, for disease 
treatment and tissue regeneration. Such therapeutic activity can be exerted via progenitor cell differentiation, 
ECM deposition and regeneration of a new tissue or by secretion of biomolecules that act as drug or as 
promoters to enhance healing and physiological processes in the host. Depending on the type of cell chosen 
and their potential biological activity, cell therapy has been proposed to tackle a wide variety of tissues and 
pathologies, such as tumors, heart dysfunctions and degenerative diseases. To do so, as for tissue 
engineering, the choice of adequate cell and their expansion technique are key issues, and will determine the 
type of therapy to be performed. Both stem and differentiated cells as autografts or allografts are potential 
candidates as therapeutic agents, and both cell types are already in use in the clinical practice.  
According to a recently published survey on cellular therapies, only in 2011, 1759 treatments were applied 
on patients, for the treatment of cardiovascular, musculoskeletal, neurological, and gastrointestinal diseases, 
and tumors, skin and cornea defects and diabetes, among others. Among those procedures, the majority 
involved the transplantation of MSCs (autologous in 659 cases and allogenic in other 320), Haematopoietic 
Stem Cells (HSC, autologous in 397 cases, allogenic in 14) and chondrocytes (214 autografts) [56]. 
Two notable examples of cell therapy in clinics are HSCs transplants for the treatment of leukemia or 
myeloma and Autologous Chondrocytes Implantation (ACI), a treatment to repair articular cartilage damage. 
The first case is probably one of the clearest examples of the use of stem cells and their proliferation and 
differentiation ability to regenerate a tissue. HSCs, which reside in the bone marrow, are transplanted, 
usually in patients whose compromised cancerous bone marrow or blood cells have been treated with radio- 
31 
 
and chemotherapy, and they proliferate and give rise to a new, donor-derived healthy bone marrow and cells. 
Such procedure is able to replace the host cells with (compatible) donor cells (i.e. leukocytes). Additionally, 
in case of allogenic white blood cells may be prone to attack and eliminate residual cancer cells that the host 
immune system was not able to target. Despite potential side effect of this approach, including graft-vs.-host 
disease, the procedure is well established, leading to high survival rates especially in young patients [57]. On 
the other hand, ACI (Figure 2.7) is the golden standard of knee cartilage transplant procedures.  
 
 
Figure 2.7: Example of an ACI procedure, adapted from [58]. 
 
Chondrocytes from a healthy site are harvested, can be expanded in vitro to achieve a sufficient quantity, and 
injected in the site of the cartilage defect. Such approach, which relies on the ability of differentiated 
chondrocytes to synthesize neo-cartilage ECM, has however some limitiations: it is an expensive and time-
consuming procedure, due to the cell culture steps; moreover, chondrocytes are often prone to 
dedifferentiation during the expansion, and this generally leads to the repair of the cartilage defect with 
fibrocartilage, having lower quality, compared to native cartilagineous tissue [59]. 
For tissue engineering applications, adult stem cells and especially MSCs are a very promising therapeutic 
vector in cell therapy [56]. Indeed, the fast proliferative nature of MSCs, ease of harvesting and their 
multilineage differentiation, already discussed earlier in this chapter, are the reasons for the high expectation 
raised by these cells. While the interest around these cells has been for long time mostly focused on 
multipotency and tissue engineering, comparatively little is understood regarding the anatomical localization 
of these cells and their natural role in tissue homeostasis [60]. However MSCs display a wide spectrum of 
biological functions that open the way for their application in many pathology treatments, and a deeper 
comprehension of the elusive nature of MSCs, may help improving cell therapy. Most of the experiments 
using transplantation of cultured MSCs into animals, led to the observation that MSCs therapeutic effects 
could not be explained by differentiation into tissue specific cells alone. For instance MSCs injected to the 
infarcted myocardium successfully reduced fibrosis, contractile strain alterations, and cardiomyocyte 
apoptosis, while improving angiogenesis [61]. These effects are mostly due to the so-called “bystander” or 
paracrine effects”. MSCs are known to secrete trophic factors, with angiogenic and antiapoptotic properties, 
as well as cytokines to support the cells of the damaged tissue and push them to work more efficiently, 
improving their biological activity. This role goes along with the secretion of immunomodulatory and anti-
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inflammatory factors, which can reduce the environmental stress imposed by an overinflammated 
sorrounding on the native cells of the tissue. Such activity is exerted both via cell-to-cell contacts with 
immune cells, such as T-lynfocytes  and dendritic cells, and production of soluble biomolecules (i.e. IL-10, 
interferon-γ)[62].    
MSCs have also been proven to support haematopoiesis, as well as HSCs and Endothelial Progenitor Cells 
(EPCs) recruitment (secreting VEGF and SDF-1α, for instance) [63].  Additionally, MSCs appear to 
contribute to the stabilization and maturation of neo-blood vessels, localizing themselves around the vessel 
and acting as pericyte-like cells [64]. Indeed, there is increasing evidence that perivasculature may be an in 
vivo niche for MSCs and that perycyte may be among the biological progenitors of MSCs [65].   
Another important ability of MSCs that can be beneficial to devise cell therapy strategy is MSCs high and 
selective migratory capability. In vivo MSCs where found to be mobilized from their niches in response to 
certain tissue injuries, such as tumor development and myocardial infarction, this migration and increased 
tissue localization seem to be mediated by the secretion from tumoral cells and cells resident in ischemic 
tissues of potent chemoattractors like SDF-1α, VEGF, MCP-1, among others [66]. MSCs, following 
gradients of these molecules are able to home into the diseased tissue, migrate through it and specifically 
localize at the site of the injury [67].  
Using this potential, MSCs are even recruited by tumoral cells that are secreting such factors, possibly to 
stabilize their vascular network. MSCs injected in glioma where found to be localized inside the main 
tumoral mass, at the site of injection, but also to be able to track satellite cells in process of migration that 
were evading from the main tumoral mass, and to establish cell-to-cell contacts with them [68]. Such specific 
migration makes MSCs interesting candidates as controlled delivery vehicles for antitumoral agents. This is 
particularly appealing when thinking of applying MSCs therapy to tissues whose surgical treatment is too 
difficult, such as to the brain. Alieva et al., for instance, have engineered MSCs to express Herpes Simplex 
Tyrosine Kinase, deliver it to aggressive gliomas, and then trigger tumor cells death with the systemic 
administration of the drug ganciclovir. This enzyme/pro-drug therapy, coupled with delivery using MSCs, 
has been proven successful in strongly reducing glioma mass in mices [69].  
The extent of this MSC versatility, depends on the subsets of cells used (i.e. STRO-1 positive MSCs display 
higher support to HSCs activity and higher colony-forming tendency than other subsets [70]), and the tissue 
from which the cells are harvested. However, more research is needed to correctly purify extracted MSCs 
and define the nature to fully understand these functional differences between these cells and their actual role 
in vitro [71]. Current knowledge seems to indicate that MSCs are prone to lose or have altered expression of 
certain membrane receptors and several of these trophic factors, once plated in vitro [72]. Therefore, the 
definition of alternative culture protocols to preserve optimal MSCs functions are subjects of great interest in 
the field of cell therapy. Furthermore, it should be taken into account, that under the current regulatory 
framework, the approval of new cell therapeutic products, especially those derived from cells cultured in 
vitro and altered by mean of cell engineering (such as gene therapy) must undergo stringent safety trials [73]. 
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As such, straightforward strategies to control MSCs phenotype and receptors/cytokines expression should be 
sought.  
The most important limitation of cell therapy (independently of the cell type to be delivered) is poor cell 
grafting and efficiency of transplantation. Injected cells are usually required to home in a highly 
inflammated, sometimes necrotic or scar tissues. Massive cell death, as well as cell dispersion by biological 
fluids, occurs within a few days post-implantation, so that only less that 1% of the injected cells survives and 
is localized at the desired site [74].  
Biomaterials are still important actors in cell therapy, but as delivery vehicles, rather than structures were 
cells have to deposit the newly synthesized tissue, as it is for tissue engineering. With the advances in 
biomedical sciences, the borders between cell therapy, tissue engineering and gene therapy have become 
blurred, and often regenerative approaches, apart from being performed using a combination of the three, are 
not that easy to distinguish. Indeed, cell therapy has adopted many principles from scaffold-based TE, as 
well as concepts from the field of controlled drug delivery.  Biomaterials carriers can be designed with 
appropriate topography, shape and smart functionality to improve cell homing, and have been demonstrated 
to dramatically increase cell survival after grafting in the host [75]. These carriers can be either in the form 
of macroscale delivery devices (hydrogels or porous scaffolds) or as suspension of particles, called 
microcarriers. The role, advantages and limitations of these types of biomaterials devices in cell delivery will 
be expanded later on in this Chapter. In any case, cell survival alone may not be enough for the required 
therapy. As discussed about MSCs, cells can lose much of their healing/trophic potential before reaching the 
damaged tissues, for example during the expansion steps or the delivery itself. Novel, successful therapies 
should take into account the multiple mechanisms that cells have to put into action, and be designed to 
enhance or at least preserve them (i.e. selective migratory capability, paracrine factor secretion and 
immunomoldulation, for MSCs). Similarly to what discussed about scaffolds for TE, biomedical engineers 
need to fabricate instructive materials that can, with their properties and simplified signals, guide cell 
functionality towards this goal.     
  
2.3 Biomaterials and advanced drug release 
Another field of medicine where biomaterials technology is a key component is the delivery of therapeutic 
agents. As seen in the previous paragraph, since cells can be considered a living drug, the term therapeutic 
agents can be used to group together both cells and drugs. Regarding non-living drugs, there are plenty of 
bioactive compounds that are researched, marketed and make part of the current pharmacological treatment 
of diseases. They range from classical synthetic drugs, to vaccines, proteins and growth factors. However, 
classical ways to deliver these compounds -such as oral, intravenous or intramuscular injections- are 
inherently inefficient, as they do not allow control of the spatial and temporal distribution of the free drug. 
This fact has four notable consequences: i) the drug has to be taken multiple times in order to maintain its 
34 
 
concentration in the therapeutic window, meaning the range of concentration at which it has the desired 
biological effect, ii) doses must be relatively high, since most of the compound will not be able to reach only 
the target tissue, but instead will be also unnecessarily distributed in other parts of the body, iii) side effect of 
the compound (especially systemic ones), are more likely to be experienced by the patient, and iv) labile 
drugs can quickly undergo degradation or inactivation, compromising their therapeutic potential [76]. This 
last point should be especially taken into account when dealing with harmful compounds, such as 
chemotherapeutic agents. In order to overcome these limitations, strategies for controlled drug delivery have 
been devised (as depicted in Figure 2.8). As for temporal control, biomedical devices that can be loaded with 
a drug and then permit a constant, nearly zero-order release to the organism have been developed since 
1960s, when it was demonstrated that the diffusion rate from a drug reservoir, could be tuned using a silicon 
rubber membrane [77]. 
 
 
Figure 2.8: A) Standard delivery of therapeutic compounds vs. B) Controlled release, with an initial 
burst and then a zero-order release profile. 
 
Biodegradable materials, especially polymers, soon became fundamental in this area, since they are able to 
release loaded compound both by means of passive diffusion through the polymer matrix and gradually, as 
the material degrades and is reabsorbed by the organism: tuning the degradation kinetics adds a degree of 
control over the liberation of the drug. Polylactic acid and its copolymers are among the most notable 
examples of polymers for drug delivery responding to these characteristics, as demonstrated by their use in 
devices used in medicine, such as Zoladex (PLA-PLGA device releasing anticancer treatment) and Absorb 
(PDLA coronary stent medicated to prevent re-stenosis). Degradation-mediated release can be controlled, 
choosing a polymer that undergoes surface erosion (such as certain polyanhydrides [78]) or bulk degradation.  
Besides using passive mechanisms, smart and stimuli-responsive materials have been used to control 
temporal release, in order to achieve an “on-demand delivery”, most often in response to physiological 
conditions such as pH, temperature and ionic concentrations [79] (see also Figure 2.9 and 2.10). The 
crosslinks that prevent the delivery device to release the drug are based on reversible interactions such as 
ionic bonds, hydrogen bond, hydrophobic and van der Waals interactions. For instance, pH-responsive 
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materials, including hydrogels, can be used to improve the oral availability of drugs, or to protect labile 
compounds that have to be released in the intestine, such as proteins, once they enter the acidic environment 
of the stomach.  
 
Figure 2.9: Passive drug release vs. active stimuli-triggered release, from a carrier biomaterial.  
 
Figure 2.10: Mathematical modeling of different methods of controlled drug release, adapted from 
[79] 
As an example, alginate-based polymers are known to display reduced solubility and shrinkage at low pH, 
forming a skin of alginic acid that can protect compounds encapsulated in it, while they become freely 
soluble in the slightly alkaline intestine, allowing the release and absorption to the blood stream of the 
carried drug [80]. Also polymers usually regarded as “non-smart” can display a specific, triggered release 
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behavior, if used for carefully chosen applications. For instance, PLGA microspheres were used to target 
intracellularly macrophages and deliver nucleic acids for gene therapy. The release of the compound is 
triggered by the polymer degradation by the acidic phagosomal environment after internalization of the 
carrier [81].  
The type of biological target addressed by the drug-carrier complex also depends on the size of the 
biomaterial device, which can range from a few nanometers to several centimeters. Controlled delivery 
devices can be roughly classified into macroscale devices or particulate devices, the latter including micro- 
and nano-sized carriers [76]. Size clearly affects not only the target tissue/cell but also the route of delivery 
of the device, with nanosized carriers being suitable for parenteral injection and most macroscale product 
needing surgical implantation. Of course, drug-loaded devices can be successfully implemented also in tissue 
engineering and cell delivery strategies, for instance, macroscale devices can also be loaded with cells and be 
easily thought as medicated scaffolds for tissue engineering [79]. 
Besides the need to control when a drug is released, advanced carriers should be able to target where the 
delivery has to occur. Furthermore, smart carriers can be endowed with functionalities able to recognize or 
specifically interact with their target in order to enhance specifically bind to it, or to enhance the biological 
activity of the drug. This is especially important for the production of drug carriers able to overcome 
biological barriers, which are usually impermeable to many drugs (such as the skin, blood-brain barrier, 
cancer cell membranes, and intestinal capillaries). This objective can be achieved taking advantage of the 
properties of the same materials used to fabricate the device, such as surface chemistry and charge, or by 
modifying it with active molecules able to conceal the material to the immune system (such as PEG chains), 
to perform specific biological activities (such as enzymes), to bind ligands in the target (i.e. lectins or 
antibodies), or to be accepted by cancer cells, for instance covering the material carrier surface with 
transferrin or folic acid, metabolic compounds highly required by tumors [82].   
 
2.4 Polymeric biomaterials for scaffolds and delivery devices 
Several methods to fabricate 3D scaffolds and therapeutic agent carriers exist, and differ according to the 
nature of the chosen material. As mentioned in the previous paragraph, material choice is the first step in 
biomaterial-based devices design. In this field, polymeric materials are among the most promising due to 
their huge versatility, since they can be easily processed into virtually any shape and into a variety of 
physical forms such as sponges, fibers meshes, hydrogels and particles. Polymers can also be prepared from 
a wide assortment of natural or synthetic origin materials, and, according to their composition, can display 
very diverse mechanical and physic-chemical properties. Synthetic polymers are easily obtained in highly 
reproducible way, allowing accurate control over their purity, degree of crystallinity and molecular weight. 
This advantage makes that the final product can be well defined and its exact composition is well known, 
which makes easier the generation of medical-grade materials and their eventual approval by regulatory 
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sources. Additionally, biocompatible synthetic polymers may not induce uncontrolled immunological 
reactions once implanted in the body. These features signed the success of several classes of polymers that 
are currently well-accepted in the medical practice and in biomaterials research, such as poly(α-
hydroxyesters), polyurethanes, polyanhydrides, and polyphosphazenes [14]. Poly(α-hydroxyesters) are 
thermoplastic polymers with hydrolytically labile aliphatic ester linkages in their backbone. They can be 
obtained from a variety of monomers via ring opening polymerization (ROP), and a few examples are 
polyglycolide (PGA), polylactide (PLA), polydioxanone, polycaprolactone (PCL), poly(trimethylene 
carbonate) (PTMC). Additionaly, some of these polymers, such as polyhydroxybutyrate (PHB) can be 
generated by certain bacterial bio-process synthetic routes. Among these polymers, the most extensively 
investigated materials are poly(α-hydroxy acids), that include PLA, PGA, and their copolymers (PLGA), 
which are FDA-approved in several biomedical devices [83]. An example of the PLA synthesis is depicted in 
Figure 2.11, while Figure 2.12 shows some bioresorbable medical products made of this polymer. The 
monomers that build these macromolecules are lactic acid and glycolic acid, two compounds that can be 
obtained by natural sources like corn starch, and are common metabolic compounds in the cell cycle. Lactic 
acid has one chiral carbon, and therefore can be either in the form of L-lactic acid or D-lactic acid. Polymers 
composed only by one stereoisomer (either D or L) tend to be partially crystalline, as the polymeric chains 
can reorganize without excessive steric hindrance, whereas copolymers or mixtures of the D and L isomers 
tend to be amorphous. Thermal and mechanical properties of these polymers are listed in Table 2.2.   
 
 
 
Figure 2.11 Example of a possible ROP synthetic route for PLA. 
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Figure 2.12: Biodegradable orthopedics fixation devices made of PLA, (A) screw and (B) plates. 
Table 2.2: Properties of bulk PLA and PGA, adapted from [14]. 
Polymer Crystallinity 
Young modulus 
[GPa] 
Glass transition 
[°C] 
Melting point 
[°C] 
Degradation 
time [months] 
PLLA 37% 4.8 60-65 175 48-96 
PDLLA - 1.9 55-60 170 12-16 
PGA 45.55% 7.1 35-40 >200 6-12 
PLGA 
(50-50) 
- 2.0 44-55 180 1-2 
 
The degradation of these polymers occurs by bulk hydrolytic erosion, and the degradation kinetics can be 
easily tuned by copolymerizing PLA and PGA, adjusting the molecular weight of the polymers and the 
lactic-to-glycolic acid ratio.  
While PLA has a long history in medicine, it also posseses some drawbacks that may limit its application for 
advanced therapies and regenerative medicine. A versatile and common way to process polymers is working 
from dissolution into solvents. However, PLA is only soluble in toxic organic compounds, such as 
chloroform, which has to be carefully removed in order to ensure the biocompatibility of the final device and 
its regulatory approval. Furthermore, PLA is a hydrophobic material lacking of chemical function that can be 
instructive for cell-behavior, and the only usable groups for chemical modifications are the pending OH and 
COOH at the end of the chain. As PLA per se has no smart or cell-instructive capability, the development of 
strategies to functionalize the polymer or to exploit the physical properties that can be introduced during the 
fabrication and shaping of the device in order to stimulate specific biological targets, is a necessary step. This 
can be done by a combination of mechanical, physical and biochemical signals introduced on the final, PLA-
based device. In this perspective, it could be said that PLA is an old, well-known polymer that can be used as 
a platform to fabricated biomedical devices with new and advanced functionalities, able to interact with the 
biological milieu in ways that enhance regenerative therapies and controlled release approaches. Therefore, 
successful PLA engineering and modification would allow to produce novel, biologically active devices that 
can benefit from the favorable regulatory status of this polymer. 
A B
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Besides synthetic materials, natural-origin polymers are attracting increasing interest for their potential 
biomedical applications. These polymers are usually extracted or derived from animal, fungi or plant tissues 
or bio-processes, and often consist in polysaccharides and proteins. They display several advantages as they 
are obtained from biological sources (often wastes of the food industry), and they resemble structural 
components of native ECM (proteins, glycosaminoglycans and proteoglycans) that can be easily recognized 
by cells and used for chemical modification as well [84]. Additionally, most of these materials are very 
hydrophilic, and can be obtained to generate hydrogels, structures that swell, but do not dissolve in water, 
that can simulate well the highly hydrated environment of living tissues. However, these materials also carry 
several limitations. The purification of the polymer retrieved from natural sources is difficult, and undesired 
impurities may remain in the material, bringing risk of contamination. Additionally, large batch-to-batch 
variations are experienced (in terms of composition and molecular weight distribution), due to the intrinsic 
inter-individual variability. A solution to this drawback can be the fabrication of these macromolecules by 
means of recombinant nucleic acid technology [85]. The similarity of such polymers to ECM components 
also means that they may provoke undesired immune responses. High water contents usually mean low 
mechanical properties, unsuitable to match those of load-bearing tissues; moreover, they often need to 
undergo crosslinking to improve their stability to degradation [84]. A non-exhaustive list of natural origin 
polymers is reported in Table 2.3. 
 
Table 2.3: List of some natural origin polymers having biomedical applications. 
Polymer Type Natural source 
Collagen Protein 
Animal connective tissues 
(bovine, porcine, fish origin) 
Elastin Protein Animal connective tissues 
Fibrinogen Protein Blood 
Gelatin Protein Denaturated collagen 
Silk fibroin Protein 
Coocon of bombyx mori / 
produced by spiders 
Chitosan and Chitin Polysaccharide Crustacean exoskeleton 
Alginate Polysaccharide Brown algae 
Gellan Gum Polysaccharide Bacterial synthesis 
Dextran Polysaccharide Bacterial synthesis 
 
Among the large number of biopolymers that belong to this category, in this work we provide further details 
of a protein and a carbohydrate polymer, gelatin and gellan gum (Figure 2.13), that were used in the 
experimental part of the Thesis. 
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Figure 2.13: Chemical formula of A) a section of a gelatin chain, and B) gellan gum repetitive unit. 
 
Gelatin is a protein obtained from the denaturation of collagen (usually from bovine or porcine skin), that 
have a wide range of application as scaffolds and carrier devices. Similarly to its progenitor protein, it 
preserves in its primary structure a large amount of glycine, proline and hydroxyproline residues. Being a 
product of alkaline or acidic hydrolysis, gelatin chains are generally shorter than collagen ones, characterized 
by a wide molecular weight distribution and mantaines a left-handed proline helix conformation, although 
the native triple helical organization, typical of collagen I, is preserved only in certain regions of the chain; 
this phenomenon generates a material with poorer mechanical properties [86]. However, due to the 
degradation treatment gelatin has relatively low antigenicity, and according to the alkaline or acidic-
processing can display an isolectric point of about 9.0 or 5.0. The possibility to generate gelatin with 
different charges, permits flexibility to enable the formation of biomaterials devices via polyelectrolytes 
complexation of gelatin chains with oppositely charged macromolecules (i.e. via layer-by-layer deposition, 
LBL) [87]. Moreover, like its parent protein, gelatin is rich in binding domains for chemokines and cell-
recognition sites, such as the RGD (arginine-glycine-aspartic acid) peptide, a sequence well known to 
mediate integrin-binding and cell adhesion [87]. Gelatin is also a water-soluble macromolecule that forms 
hydrogels at low temperatures, but displays a poor stability at 37 °C, for this reason chemical modification 
and/or crosslinking reaction are necessary to guarantee its stability in the body. These modification can also 
be used to obtain gelatin-derivatives with stimuli-responsive behavior or capable of crosslinking only when 
exposed to certain stimulations such as UV radiation [88]. 
Gellan gum is a high molecular weight microbial exopolysaccharide, synthesized by certain bacteria strains. 
It is a linear anionic polysaccharide composed of the tetrasaccharide (1→4)-L-rhamnose-α(1→3)-D-glucose-
β(1→4)-D-glucuronic acid-β(1→4)-D-glucose as a repeating unit [89]. Soluble in water at high temperatures 
(>50°C) It can form heat- and acid-resistant hydrogels, that are soft, elastic, flexible and transparent even at 
polymer concentrations as low as 1% w/v. Thermal gelation appears on cooling due to a conformational 
change of the polymer in solution, where randomly distruibuted chains, reorganize into pairs of 
A
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macromolecules in the form of double helices. Single chains can be involved in the formation of more than 
one helix, provoking inter-molecular junctions that stabilize the gel. The gelation also occurs in presence of 
mono- and divalent cations in solution. Known for its use in food industry and thanks to its biocompatibility 
and good mechanical properties, gellan gum raised interest for the fabrication drug delivery devices, and 
tissue engineering and cell encapsulation matrices [89]. 
 
 
 
2.5 Injectable biomaterial systems 
Advanced biomedical devices face the continuous challenge for the translation from the research to the 
clinical use. Many common strategies involve the implantation of preformed devices into the patient through 
an invasive surgical procedure, with open problematics related to possible complications, to patient 
compliance, to the handling of the material, and its colonization from seeded or recruited cells (if applicable). 
Furthermore, if the material has to fill a tissue defect, as it happens in the case of scaffolds for tissue 
engineering, it should be ideally custom-made to perfectly match the geometry of the defect, or better able to 
fit defects not-having standardized shapes [90].  
Injectable biomaterial devices are a class of materials that hold the promise to solve most of the 
aforementioned problems. They can be administrated topically as a low viscosity solution or suspensions and 
can easily fill defects with irregular geometries. Moreover, they can encapsulate cells and bioactive 
molecules, that will be distributed homoegenously in the device matrix, thus sensibly reducing the 
problematics due to the low efficiency of cell seeding on preformed scaffolds, as well as lowering systemic 
side effects of loaded drugs [91].  
The concept of injectability, adopted from pharmaceutical sciences, is a key-product performance parameter 
of any parenteral dosage form. The expression refers to the performance of the material formulation during 
injection, in terms pressure or force required for the delivery, evenness of the flow, and freedom from 
clogging (i.e., no blockage of the syringe needle) [92]. Injectable biomaterials systems can be either in the 
form of in situ gelating/solidifying materials [93] or suspensions of  micro-  and nanoparticles (MPs and 
NPs). 
 
2.5.1 In situ forming polymeric matrices and hydrogels 
Solidification or gelation of polymeric solution can be achieved with different methods including 
precipitation and chemical or physical crosslinking (Table 2.4). As all these methods require the injection of 
the scaffold in a sol state, a preliminary and restrictive requirement is the use of biocompatible solvents, thus 
imposing limitations also on the type of material. Water and saline solutions are obviously the preferred 
choices, anyway a few solvents, such as tetraglycol (FDA approved for pharmaceutical injectable 
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preparations), may be suitable choices, as they are deemed as safe under a certain ratio over the body weight 
[103]. 
Table 2.4: Examples of in situ forming polymeric scaffolds for tissue engineering. 
Material Physical form Forming Method Type of study Reference 
PLGA Porous 
scaffold 
Injected PLGA solution in 
Tetraglycol with porogens. 
In situ hardening after 
solvent displacement 
In vitro MC3T3-E1 cells 
seeding for bone 
regeneration. In vivo 
injection of the scaffold 
without cells. 
[90] 
PEGdA Hydrogel, with 
laminin 
adhesive 
sequences 
UV photocrosslinking, 
Initiated with Irgacure 184 
Murine preadipocytes 
encapsulation of adipose 
tissue engineering. 
Hydrogels modified with 
peptides and biodegradable 
sequences support cell 
proliferation. 
[94] 
OPF Composite 
with gelatin 
microparticles 
Crosslinking with PEGdA, 
initiated with APS/TEMED 
Injected with chondrocytes. 
Cell proliferation and GAG 
production has been tested. 
[95] 
PPF Composite 
with 
PLGA/PEG 
microparticles 
encapsulating  
an ostegenic 
peptide 
Crosslink with PPFDA, 
initiate by BP and DMT 
Implanted in vivo in rabbit 
radial segmental defect. 
Bone growth related to 
release profile of 
osteogenic peptides. 
[96] 
Peptide 
amphipile 
Nanofibrous 
gels 
Self assembly due to 
hydrophobic interaction 
In vitro differentiation of 
MSC into chondrocytes.  In 
vivo repair of rabbit full-
thickness chondral defect 
[97] 
PLGA-
PEG-PLGA 
Hydrogel Inverse thermogelation In vitro epithelial cells 
encapsulation. In vivo 
bandage of a rabbit corneal 
wound  
[98] 
Hydroxy 
butyl 
Chitosan 
Hydrogel Inverse thermogelation In vitro hMSC suspension 
in the hydrogel. Evaluate 
viability as a potential 
treatment for intervertebral 
disk degeneration  
[99] 
PEG-
Hyaluronic 
acid 
Hydrogel Enzymatic crosslinking In vitro mesenchymal 
progenitors encapsulation 
and cartilage deposition for 
IVD repair. In vivo 
immune response 
evaluation 
[100] 
 
Alginate 
dialdehyde 
-Gelatin 
Hydrogel Aldehyde groups linked by 
borax buffer, then Schiff 
reaction to bind gelatin 
In vitro chondrocytes 
encapsulation. Toxicity and 
GAGs deposition 
evaluation 
[101] 
 
Thiolated 
gellan gum 
Hydrogel Thermal gelation + 
disulfide bond formation 
In vitro cytotoxicty assays, 
injectability 
[102] 
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Using this approach, Krebs and co-workers injected solutions of PLGA and different porogens (ammonium 
bicarbonate, sodium bicarbonate or sucrose) in tetraglycol in an immunodeficient mouse. Porous scaffolds 
were obtained due to precipitation of the polymer after the removal of tetraglycol by effect of biological 
fluids, and the procedure showed no significant cytotoxicity (Figure 2.14) [90].  
 
Figure 2.14: SEM photomicrographs of 50:50 PLGA scaffolds depicting interior and surface 
microarchitecture. (A and B) PLGA only; (C and D) PLGA + sucrose; (E and F) PLGA + sucrose + 
diH2O; (G and H) PLGA + diH2O. (C, E and G) Scaffold inner morphology; (A, B, D, F and H) 
scaffold surface. All scale bars represent 200 μm except in (B), where it represents 1 mm. Adapted 
from [90]. 
Despite this result, water based systems are currently the most common choices in the field of injectable 
biomaterials, which employ water-soluble monomers or macromers that form 3D matrices either via 
chemical or physical crosslinking.  
Chemical crosslinking often needs initiators capable of creating free radicals that react with functional 
groups, often unsaturated bonds, to propagate the crosslinking reaction. Crosslinking enhances certain 
mechanical properties of the scaffold, such as stiffnes, usually at the cost of resilience. A challenge in this 
area is controlling the solidification time, which must be clinically relevant in order to avoid tissue necrosis 
around the injected material. Not only, any exothermic reaction that takes place should not reach 
temperatures capable of causing thermal necrosis of the tissues, a renowned issue with commercially 
available polymeric bone cements [91]. When a source of energy is required to activate the initiator, it can be 
provided by light or temperature, for instance. Photopolymerization has the potential to be triggered by the 
surgeon with, for example, an UV lamp or optical guide, and may be preferred to thermally-induced 
crosslinking for tissues were light transmission is still easily permitted (e.g. derma, subcutaneous adipose 
tissue). Overviews of cytocompatibility of different photoinitiating systems are provided in literature [104]. 
Acrylic derivatives of poly(ethylene glycol) (PEG), like poly(ethylene glycol) diacrylate (PEGdA), are 
extensively studied in tissue engineering and drug release due to their biocompatibility and as they can form 
covalent hydrogels whose mechanical properties can be tuned to resemble those of soft tissues. 
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Patel et al. synthesized PEGdA 6000 Da hydrogels (Figure 2.15) modified with biodegradable and cell 
adhesive peptide sequences (a collagenase-sensitive sequence and a laminin domain) that could form after 5 
minutes of UV treatment. The system was proven to be suitable for preadipocytes proliferation, thus having a 
potential as in situ forming scaffold for adipose tissue engineering [94]. Similarly Witte and Kao studied the 
UV gelation kinetics of an interpenetrated network of PEGdA and gelatin, optimizing the UV time exposure, 
distance from the radiation source and quantity of photoiniziator [105].  
 
 
Figure 2.15: PEGdA 6000 Da hydrogel, scale bar 5 mm (left), PEGdA and Irgacure 184 chemical 
structure (right) [94]. 
 
However, several tissues are not easily reached by external light sources, and thus in many cases thermally-
activated crosslinking agents are preferred. Ammonium persulfate/N,N,N’,N’ –tetramethylethylenediamine 
(APS/TEMED) is  a well known water soluble and cytocompatible thermal radical initiator. Parks and co-
workers recently used this system to obtain solid scaffolds from oligo or poly(propylene fumarate) (OPF or 
PPF) [95]. Solidification at 37 °C was achieved in 10 minutes and the scaffold supported chondrocytes 
delivery and biosynthetic activity. Inner porosity was achieved forming composites with gelatin or PLGA 
drug-loaded microspheres.  PPF is a widely studied polymer for in situ radical polymerization and therefore 
was also studied in combination with other crosslinkers, such as the system benzoyl peroxide (BP) and N,N-
dimethyl-p-toluidine (DMT) [96]. Other biocompatible ways to achieve chemical crosslinking include 
biologically inspired bonds such as biotin-avidin [106] and thrombin-factor XIII coupling [107]. Anyway, 
their application on a large-scale production presents several challenges. 
More recently a great interest around physically crosslinkable systems has been grown. Biomaterials whose 
solidification can be triggered in situ by self-assembly or by environmental cues (pH, temperature, ionic 
concentration) are desiderable as they can be set in mild physiological conditions and avoid the used of 
initiator, whose concentration and choice is strictly limited by cytoxicity issues, as briefly mentioned above. 
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Physical crosslinking is generally driven by reversible interactions that form either strong (e.g. ionic) or 
weak bonds (most commonly hydrophobic interactions). A first group of physical hydrogels utilizes ionic 
crosslinking to trigger gel formation. The most famous polymers exhibiting this gelation are alginates, 
polyanionic saccaridhes derived from certain algae or mushrooms, that can be crosslinked by divalent cations 
such as Ca2+
 
. These cations bind between the guluronic acid that forms alginate chains, forming interchains 
bridges. Alginate hydrogels have been commonly used as extracellular matrix analogues, as they provide the 
advantage of biocompatibility, and recent research has focused on optimizing their gelation kinetics, 
homogeneity, mechanical properties and bioactive behavior [108]. Apart from ionic concentration, body 
temperature is one of the most appealing stimuli to drive sol-gel/solid transitions and in the last years several 
polymers that show a reverse sol-gel transition around 37 °C have been synthesized. They are generally 
amphiphilic polymers that are soluble in water at temperatures below the Low Critical Solution Temperature 
(LCST). Above LCST and in a proper range of concentration, hydrophobic interactions between the 
polymeric chains prevail, causing coacervation, micellization and partial crystallization of the 
macromolecules that induce the precipitation of a hydrogel. For example, PLGA-PEG-PLGA copolymers 
can be designed to exhibit a LCST between 20 and 35°C (Figure 2.16).  
 
Figure 2.16: Mechanism of gelation in a PLGA-PEG-PLGA thermoreversible hydrogel. Adapted from 
[93]. 
 
The forerunners of these types of polymers are Pluronic (BASF) and Poloxamer (ICI), which are not 
biodegradable. A wide variety of synthetic and natural biodegradable polymers with thermally responsive 
characteristic have afterwards been synthesized or identified, so that their sol-gel transition can take place in 
the range of physiological temperatures (fig. 2.17). Several synthetic routes have been explored to obtain 
block or graft copolymers of hydrophobic and hydrophilic chains (Figure 2.18), to chemically modify 
natural-origin biopolymers, or to obtain amphiphilic polypeptides either through solid-phase synthesis or 
recombinant technology [109].  
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Figure 2.17: Chemical formulae of some inverse thermosensitive hydrogels and schematic of their 
gelation process. Adapted from [93]. 
 
 
Figure 2.18: Example of synthesis of PLGA-PEG-PLGA triblock copolymer. 
 
Many of these systems have also been evaluated specifically for applications in tissue engineering, 
elucidating many parameters that affect both their thermosensitive nature and the release kinetics of 
encapsulated drug and cells. For instance, ephitelial cells viability and potential to repair corneal wounds was 
assessed for a PLGA-PEG-PLGA formulation [98], while the mechanical suitability of a thermosensitive 
chitosan derivative to act as a scaffold in intervertebral disk injuries was evaluated, together with the 
cytocompatibility with MSCs [99].  
However, despite of the interesting properties of physical hydrogels, there are several key-points that should 
be taken into account when choosing these systems as injectable biomaterials. Physical crosslinking and self-
assembly often lack the mechanical strength that can be achieved using the conventional methods of 
chemical crosslinking, potentially rendering these systems inappropriate for load bearing tissues such as 
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tendon, bone, cartilage. Not only, the degree of physical crossliking cannot be finely tuned, thus making 
more difficult to control the drug release profile. 
 
2.5.2 Bioprinting and injectable biomaterials 
Injectability, together with the ability of a biomaterial to solidify or maintain a determined shape imposed 
after the injection step, is a very versatile property. The concept of injectability of biomaterials followed by 
shape-retention can be associated with extrudability under conditions and parameters (injection stresses, 
temperature, material and solvent composition) that are compatible with labile, biological matter, including 
cells. In polymer engineering, extrusion is a well-established processing method, and can be followed, for 
instance by molding or fiber spinning. Fibers obtained in this way can be also used as building units for the 
bottom-up production of novel biomaterial devices, for instance, using additive manufacturing techniques. 
This concept is the foundation of Biofabrication, which consist in the replication of complex 3D living 
tissues, via a computer-controlled fabrication process that involved the deposition, patterning and assembly 
of both living and non-living matter with a pre-designed 3D organization [110].  Biofabrication methods 
include 3D printing of bioinks, hydrogel-based materials encapsulating living cells, which can be also called 
bioprinting [111].  
 
 
Figure 2.19: Examples of different bioprinting approaches. Hydrogels fulfiling the extrudability 
requirement can be used in robotic dispensing systems as bioinks. Adapted from [111]. 
 
The bioprinting process starts from a blueprint of the tissue to be fabricated in Computer Aided Design 
(CAD) softwares. This allows designing and generating custom-made devices such as patient-specific 
implants, as the computerized model can also be acquired from tomographic images. Subsequently, a 
Computer Aided Manufacturing (CAM) software instructs the hardware of the bioprinting apparatus. An 
example of different experimental set-ups for bioprinting is depicted in figure 2.19. In the case of robotic 
dispensing of bioink fibers, a dispensing tool head navigates in the x, y, z direction, depositing the gel fibers 
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in a layer-by-layer fashion [112]. Figure 2.20 shows some anatomically-shaped structures produced using a 
bioprinting technology. This relatively new, still under development, area of technology has the great 
potential to revolutionize many fields of bio-based industries. As for biomedical engineernig, biofabricated 
constructs can be obtained combining several materials and cell types, thus allowing to recapitulate complex, 
multilayered or multicomponent tissues, such as articular cartilage [113], or recreate tissue-like grafts with ex 
vivo pre-generated vascular networks [114]. Potential biomedical applications include, but are not limited to, 
fabrication of i) tissue and organs for transplantation and regenerative medicine, ii) living, 3D tissue models 
of human disease, and iii) platforms for drug toxicity and drug discovery research.  
 
 
Figure 2.20: (A, B, C) CAD designs of 3D printed tissue models. (D) Distal femur made with a gelatin-
methacrylamide bioink. (E) and (F) ear and vascular network made with a thermoplastic polymer; the 
structure fabricated via additive manufacturing can be then colonized with cells, allowing also 
“classical” tissue engineering approaches. Adapted from [112]. 
 
Most of the hydrogel systems that can be extruded and quickly set to maintain the geometry imposed during 
the bioprinting process are potential candidates as bioinks. Gelation and long-term shape stabilization can be 
also induced exploiting certain hydrogels physical crosslinking capability as well as crosslinking methods, as 
described in the previous paragraph for injectable gels. Moreover, bioinks must not only be designed in order 
to achieve high printing fidelity, but also to offer a matrix to guide encapsulated cell behavior, allow 
migration and neo-tissue deposition. The implication of bioink design in biofabrication and the delicate 
balance between fabrication and cell culture necessity has been extensively reviewed elsewhere [111], and 
this knowledge has brought to the application of many hydrogel-forming materials for bioprinting, including 
alginate, gelatin and its derivatives, gellan gum, agarose, fibrin, collagen, hyaluronic acid, and PEG [111]. 
Hydrogels tend to be unsuitable to withstand high mechanical stresses, therefore strategies to reinforce the 
printed constructs have to be devised, when aiming to generate load bearing constructs, as for bone or 
cartilage tissue engineering, for instance  [115, 116]. 
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Controlling the 3D distribution of multiple (artificial or natural) ECM components, cell population and 
growth factor, although representing a great innovation, it is still not enough to reproduce ideal grafts for ex 
vivo tissue fabrication or for the generation of implantable device that can fully regenerate native tissues. A 
strong understanding of the biological mechanism underlying tissue homeostasis and regeneration, stem cell 
biology, and the development of biomaterials and molecules inspired by this knowledge that can trigger and 
guide cell bioactivity are essential. For this reason, strategies that can provide the inclusion of cell-
instructive, physic-chemicals cues into the bioink matrix are still sought to achieve ex vivo tissue 
regeneration [117]. Furthermore, as for all cell-based tissue fabrication approaches, techniques that are 
compliant with GMP to obtain high amount of regenerative-competent cells, are also necessary, in order to 
allow scaling-up of the production [118].  
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2.6 Microcarriers and Nanocarriers 
2.6.1 Micro and Nanocarriers in biomedical technology 
In the field of injectable biomaterials, apart from macroscale devices, particulate systems can be used as 
carriers of therapeutic agents. Particles suspension in physiological solutions can share some properties with 
in situ forming devices, namely injectability, capability of filling defects with irregular geometries and 
encapsulate and delivery labile compounds, depending on their dimension and shape. Additionally, particles 
display a great versatility for biomedical applications. They can be either presented in the form of nano- 
(NPs) or microparticles (MPs). It should be noted that, especially in the pharmacology literature, the terms 
nanoparticle is (mis)used for particles ranging from hundreds of nanometers to a few micrometers. For the 
sake of clarity, and to facilitate the distinction between the materials prepared in this experimental work, 
particles sizes up to a few hundreds of nanometers will be termed nanoparticles. Size is the main parameter 
affecting the type of application these biomaterials are designed for, as drug delivery systems, carriers for 
cell therapy, or components for tissue engineering (Figure 2.21). Injectability is mainly dependent on 
particles size and concentration in the suspension; according to these two parameters, the needle gauge for 
the injection should be chosen in order to minimize the strength necessary to administrate the particles and 
therefore the pain for the patient.  
  
Figure 2.21: Example of typical applications of micro- and nanocarriers according to the size. 
 
While NPs are more suitable for drug delivery and intracellular targeted release of bioactive compounds 
(particles whose dimension is less than 5 µm are readily subject to endocytosis by macrophages), MPs can be 
also manufactured with dimensions that are adequate for cell adhesion and spreading, as cell culture and 
expansion platforms, either alone or in combination with 3D scaffolds to form composites [119]. MPs are 
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extensively studied and already in use in pharmaceutical practice for biomolecules encapsulation and 
controlled drug release, thus a broad range of up-to-date studies related to MPs production, modification and 
applications is presented in literature, constituting a valid base for the development of particle-based 
biomaterials.  
MPs are also advantageous regarding in vitro culture of anchorage-dependent cells, as they offer a high 
surface-volume ratio, suitable for cell homing. Other important properties of nano- and microparticles are 
their shape (spherical, cylindrical, laminates, needle-like) and degree of inner porosity (Figure 2.22), which 
determine where in the carrier the therapeutic agent will be located (encapsulated in the matrix, confined in 
inner porous compartment, or even adhering at the particle surface, the latter being more common for living 
cells, rather than drugs). 
 
 
Figure 2.22: Examples of possible inner morphology of particles, with a schematic representation of 
the distribution of bioactive compounds. 
 
Looking into the field of regenerative medicine, MPs can be applied not only as pharmaceutical devices, but 
also as active components in tissue engineering and cell delivery strategies. Tissue regeneration through cell 
therapy with pluripotent or stem cells have recently achieved interesting results even in repairing tissues with 
low self-renewal capability, such as cartilage, or composed by post-mitotic cells, such as neuronal tissue 
[120]. However, free-cell transplantation faces many problems related to cell survival, as only a small 
percentage of the implanted cells survives or remains in the area of the tissue defect. Instead, cell delivery on 
MPs has several biological and practical advantages, if compared with delivery without carriers. In fact, cells 
can easily aggregate on MP surface forming complexes that promote cell-cell interaction, while, once 
injected, the cell-MP complexes are less likely to be dispersed by biological fluids than free cells. Not only, 
during their fabrication process, MPs can be loaded with drugs and growth factors capable to support tissue 
regeneration. MPs diameter for adequate cell adhesion should be at least around 50 µm, as smaller particles 
could be easily eliminate by the organism, or induce undesired inflammatory responses [120].  
Many different materials have been processed to obtain microparticles. Natural polymers such as chitosan, 
alginate, gelatin and pectin are mostly used in combination with cell suspension, in order to achieve cell 
encapsulation [121], even though dextran microparticles, in commercial formulation known as Cytodex®, 
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have been utilized also to carry cells on their surface, together with other materials [122].  Anyway, 
biocompatible and biodegradable synthetic polymers, such as PLA, PGA and their copolymers are the most 
studied and used in pharmaceutical practice as well as in tissue engineering, due to their ease, reproducible 
and standard manufacturing.  
 
2.6.2 Fabrication Methods 
Although it is possible to produce particulate materials in a top-down fashion, starting from a macroscale 
material and reducing it to particles, for instance by grinding, these approaches allow little to no control over 
the particles shape, size, as well as surface and inner morphology. Therefore, the most investigated particles 
fabrication methods require the generation of liquid droplets of polymer solutions and their subsequent 
solidification into particles (Table 2.5). The way the first step is performed is fundamental in determining the 
type of particle produced and its size, from the nano- to the microscale. 
Table 2.5: Overview of particle fabrication methods 
Droplet generation process 
 
Particles 
size 
Polymers Advantages Disadvantages 
Emulsion (turbulent mixing) 10 nm to 
mm scale 
All types Size dependent 
of emulsification 
method. Control 
over porosity. 
High 
polydispersity 
Membrane emulsification 1-100 µm PLA, PGA, 
PLG, PCL, 
PEG-PLA 
High control 
over size and 
porosity. 
Low production 
rate 
Emulsion (microfluidics) 1-300 µm All types Monodisperse 
particles, low 
mechanical 
stresses 
Low production 
rate 
Flow focusing 10-300 
µm 
All types Low stresses, 
monodisperse 
particles 
Only works at 
specific ranges 
of flow ratios 
Electrohydrodynamic jetting 0.1 to 30 
µm 
All types Type of 
electrospray. 
Control over 
particle size and 
shape 
Small diameter 
Ultrasound atomization > 40 µm All types Reproducible, 
scalable, fast 
Polymer 
solution must 
have low 
viscosity 
Spray drying and 
electrospray 
10 nm to 
100 µm 
All types Fast and scalable High 
polydispersity 
Supercritical fluid 
atomization methods 
10 nm to 
100 µm  
PLA, PGA, 
PLG, PCL, 
PEG-PLA 
Limited use of 
toxic chemicals 
High 
polydispersity 
Nanoprecipitation 50-400 
nm 
All types Fast. 
Monodisperse 
particles 
Size depends on 
solvent/non-
solvent pair 
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2.6.2.1 Emulsion-based techniques 
Emulsions rely on the mixing of two (or more) immiscible liquid phases. A general representation of an 
emulsion-based fabrication method is depicted in Figure 2.23.  At least an “oil” phase (which can be 
typically an organic solvent with a polymer dissolved in it) and a water phase are needed, and one as to act as 
a dispersed phase and the other as a continuous phase. The two phases are mixed and droplets of the oil 
phase are formed, whose diameter is highly dependent on the type of emulsion (nature solvent used, 
multiple, double or single emulsion) and on the shear stress applied to the suspension (the higher, the smaller 
the mean dimension but with broader size distribution; therefore use of homogenizer or magnetic stirrers 
strongly affects the result). In this step, if the emulsification is performed using high-speed homogenizers or 
sonication devices, small, nanosized drops can also be produced [123]. The addition of amphiphilic 
surfactants to the water-phase is helpful to stabilize the boundaries between the oil and the water phase, thus 
also controlling shape and diameter of the droplets [124].  
Single emulsions are mainly used for particle production which may be coupled with encapsulation of 
biomolecules that are soluble in the phase used to dissolve the polymer (typically the oil phase), while 
double emulsions are mainly used to encapsulate drugs that are not soluble in the solvent for the polymer 
(e.g. water  soluble proteins encapsulated into PLGA spheres). When organic, volatile solvents are used, 
droplet solidification into particles occurs over time, with solvent evaporation. Nano- and microparticles are 
formed as the solvent is transported out from the initial droplet, diffused into the continuous phase and 
evaporated through the emulsion-air interface [125]. Right after the emulsification, the water is saturated 
with the solvent; once the evaporation initiates, the droplets near by the interface will start to solidify. As the 
polymer precipitates, the remaining solvent inside the droplets is expulsed and the microparticle generates. A 
slow solvent evaporation rate induce particle volumetric shrinkage and thus produces smaller particles (but 
also can eliminate part of the encapsulated drug). Faster evaporation rates avoid shrinkage and may retain 
more drug, but the droplet is soon covered by a thin hard surface layer with a less dense core that may induce 
either the collapse of the sphere or to the formation of hollow capsules, as the polymer accumulates only on 
the surface (in this conformation, burst release of the drug is more intense, as part of the drug is pushed and 
trapped to the polymeric shell). Parameters such as polymer concentration, type of surfactants and water 
flows induced by osmotic imbalance may cause the formation of random porosity on the surface (more 
similar to cracks in the polymeric outer shell of the particle). Addition of porogens as well as the use of 
double emulsion methods can introduce a certain extent of porosity which can be desiderable for cell 
delivery, and must be carefully controlled in drug delivery applications in order to limit the burst diffusion of 
the drug [126]. 
54 
 
 
Figure 2.23: General scheme of an emulsion/solvent evaporation procedure. 
 
Emulsification by turbulent mixing of the oil and water phases, generate a population of droplets with a very 
high dispersion in diameter distribution. Polydispersed particles will display a dishomogenoeus behavior, for 
instance, in terms of degradation patterns (i.e. smaller particles have higher surface area and degrade faster), 
which can be detrimental to accurately control the release profile of encapsulated drugs [127]. In order to 
solve this problem, modifications of the emulsion system have been explored, such as membrane 
emulsification [128] and emulsification in microfluidic systems [129]. Once the emulsion is established, 
apart from solvent evaporation, particles can also be obtained by other phase separation techniques, such as 
non-solvent or thermally induced phase separation [130, 131], or in the case of some hydrogel forming 
materials, by triggering gelation (i.e. immersion in Ca2+
 
 rich solutions for sodium alginate droplets) [132]. 
2.6.2.2 Nozzle- or injection based methods  
Dripping of a liquid medium at an orifice is a common phenomenon that produces drops and can be observed 
in our daily life, for instance, when considering water dripping from a faucet. A liquid coming from an 
orifice, if the flow rate is high enough, can also assume the form of a jet, that can be defined as a stream of 
matter having a more or less columnar shape [133]. Jets with a laminar flow are usually thinner than the 
nozzle they are coming from, and present an inherent fluid dynamic instability (Rayleigh instability) that can 
lead to their eventual break-up, provoking the atomization of the liquid (Figure 2.24) [133]. Addition of 
external stresses such as high injection pressures, mechanical perturbations, electrical fields or coflowing 
fluids can tune a jet diameter, as well as the way a jet breaks and generate droplets of controlled size.   
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Figure 2.24: (A) Liquid jets are experienced every day, for instance, as water flowing from a faucet. 
Fluids at a nozzle tip can generate (B) large drops by dripping or stretch into laminar jets that will 
eventually break-up (C) into a train of similarly-sized droplets. (D) Turbulent flows, for instance those 
generated by high pressures, can break into a spray of polydispersed droplets. Jet stability and break-
up also depend of the flow speed, external stresses and fluid viscosity, with high viscosities acting as a 
protective factor for jet stability - (E) shows a viscous honey jet stretching without breaking -. Adapted 
from [133]. 
These principles are the bases of many droplets-generation techniques, which, tuning the flow parameters 
and the intensity of the external applied stress, can also be used to produce filaments of the polymer, as well 
as particles with complex shapes (discs, needles).  The combination of fluid flows, viscosity and external 
stress determines the final size of the fabricated particles. Flow Focusing technology, for instance exploits 
the interaction between an inner fluid pulled by a coflowing, immiscible fluid. The higher the flow rate of the 
outer fluid, the small the droplets; while the higher the flow rate of the inner fluid, the larger the produced 
droplets. The main advantage of this method is that only mild, hydrodynamic forces are involved in the drop 
generation, allowing to operate the system in conditions suitable for the encapsulation of labile compounds 
(i.e. proteins) or even cells [134]. If the outer fluid is a gas, drops can be either dried before reaching a 
collector plate, or be collected in a liquid bath to be solidified with other methods. Once the drops are formed 
following jet break-up, they can be readily solidified by rapid solvent evaporation, thermal or non-solvent 
induced phase separation, drying or through chemical reaction (i.e. for polymer crosslinking and hydrogel 
formation). Moreover, methods based on laminar jets are extremely useful to obtain highly monodisperse 
particles [135]. Droplets generated in this way can also be dispersed in a continous immiscible liquid phase 
to obtain an emulsion, which can be processed as described in the previous paragraph [136].  
Solution atomization using ultrasound pulses generators, as well as electrical fieldsapplied  to the dispensing 
nozzle, have also been successfully used in cell [137] and drug encapsulation applications [138]. 
Electrohydrodynamic jetting is a technique described by Bashakar and co-workers [139, 140], this method 
exploits a typical electrospinning apparatus, whose parameters have been tuned to obtain spherical particles 
instead of fibers. By tuning polymer concentration, distance of the collector and solvent systems, the authors 
have been able to produce particles with discoid and rod-like conformation, with characteristic dimensions in 
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the order of 3-5 μm. In the range of polymer solution concentration studied (1.3 to 4.3% w/v), the final shape 
of the particles resulted from a combination of the solvent evaporation behavior related to the jet 
conformation imposed by the flow rate and the voltage applied to the system. An interesting feature of this 
work was the possibility of co-jetting 2 or more solutions of different polymers (dissolved with compatible 
or possibly with the same type of solvent) from two spinnerets in order to obtain bicompartimental particles 
with spatially controlled chemical composition. This configuration was applied to selectively functionalize 
only one compartment of the particle, with targeted reactions. The procedure was also used to obtain 
bicompartimental nanofibers. 
 
Atomization of a polymer solution flowing from a nozzle can also be obtained with stresses inducing a 
turbulent break-up, however at the cost of renouncing to the monodispersity of the generated particles. A 
typical example of this approach is the case of spray drying, a solution is injected applying a high pressure 
through a nozzle, and at the nozzle tip it atomizes due to the pressure drop [141]. This process is exploited 
also in many supercritical fluids based technology. Any substance whose pressure and temperature are above 
the critical point is called supercritical fluid (SCF). Supercritical fluids possess the solvent power of liquids 
and the diffusivity of gases, and their properties vary extremely by tuning their density with small changes of 
parameters such as pressure. There are used as solvent systems, reaction media or in the processing of 
materials to obtain foams, fibers and particles. According to the solubility of the material to be processed, 
they may be used either as solvents or antisolvent for precipitation of the polymer. The most studied 
supercritical fluid is carbon dioxide, as it is non-toxic, non-inflammable and has a critical point close to 
environmental conditions (304 K and 7.28 atm). Several biodegradable polymers, including polylactide and 
its copolymers have been processed in the form of micro and nanoparticles (with or without drugs) through 
different methods involving supercritical CO2
- Rapid expansion of supercritical solutions (RESS): the polymer is dissolved in the supercritical fluid and 
the high pressure solution is rapidly depressurized by spraying through a noozle. The pressure induced phase 
separation leads to the formation of the particles. PLLA solutions in supercritical carbon dioxide have been 
obtained by addition of co-solvents such as acetone and ethanol. 
.Among this techniques the most relevant are: 
- Supercritical antisolvent (SAS) and solution enhanced dispersion by supercritical fluids (SEDS) processes: 
A solution of the polymer in an organic solvent is sprayed in a chamber saturated with the supercritical fluid 
that acts as an non-solvent and forces the particles to precipitate (SAS), or the SCF and the polymer solution 
are sprayed together from a coaxial nozzle (SEDS). In the last case, the SCF acts as an antisolvent and a 
dispersion medium at the same time. PLA have been processed in this way after dissolution in methylene 
chloride, using carbon dioxide as an antisolvent. 
The most interesting feature of these methods is the possibility to target the size of the particles and obtain 
even submicron diameters in a relatively easy, fast way, which can be also suitable for scaling up the 
production. Several studies have demonstrated that, even though process parameters may affect the shape of 
the particles, their actual morphology is mainly dependent on the material properties. Semicrystalline 
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polymers (including PLLA) tend to form almost perfectly spherical particles, but as the crystallinity 
increases, polymers are more likely to produce fibrous or spherulite-resembling structures.  
Drug encapsulation in the particles has been proven to be either possible during particle formation (obtaining 
a drug-polymer blend) or by inducing SCF-mediated polymerization in presence of the bioactive molecule 
[124, 142]. 
 
2.6.2.3 Nanoprecipitation 
Nanoprecipitation is best known for being a quick, single-step technique preparation of nanoparticles that 
can encapsulatate high yields of water-insoluble drugs [143]. Due to its ease of application is currently one 
of the most applied methods to produce nanoparticles between 100 and 300 nm for drug encapsulation 
[144].This method consist in the precipitation of the polymer in a semi-diluted solution following the 
displacement of the solvent into a water-based bath, assumed that the organic solvent is miscible with this 
bath (Figure 2.25). A typical system is PLGA dissolved in acetone, dispensed in a water bath.  
 
 
Figure 2.25: Schematic representation of the nanoprecipitation principle with (right) or without (left) 
NPs functionalization by adsorption of molecules dissolved in the coagulation bath. 
 
 
The polymer solution is added dropwise (e.g. syringe pump) into a coagulating bath, while parameters such 
as pH of the water solution, addition of active substances or other polymers to the organic phase and polymer 
concentration affect the drug incorporation efficiency (depending on the properties of the drug an alkaline or 
acid bath may be preferred) and the particle shape. As soon as the (large) polymer droplet enters the bath it is 
broken into a multitude of nanoparticles by the turbulent flows driven by the gradient of surface tension 
between the two liquid (Marangoni effect) [145]. The nanoparticles can then be collected via 
ultracentrifugation, for instance.  Large amounts of toxic solvent may be avoided with this method. This 
method is widely used for manufacturing nanoparticles that are generally smaller than those obtained with 
emulsion methods [146]. The aqueous phase may also be charged with additives that will be partially 
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entrapped on the surface of the polymeric particle (e.g. magnetic compounds, charged macromolecules or 
inorganic ions), and this fact can be exploited to functionalize the device surface. Alternative coagulating 
solvent may be chosen according to the organic solvent employed; studies reported in literature describe, for 
example, the use of ethanol and methanol and their influence on particle size [146]. The lack of a stabilizer in 
the water bath may frequently lead to agglomeration of the particles; therefore the use of small amounts of 
surfactants may still be necessary. Finally, NPs produced as hollow capsules or solid, filled spheres can be 
obtained, using or not template materials (such as oils mixed with the polymer phase), that can be removed at 
the end of the fabrication procedure.  
 
2.6.3 Drug delivery with functionalized active carriers 
Micro- and nanocarriers, especially the latter, are of great interest in the field of drug delivery devices. 
Polyesters like PCL, PLA and PLGA are widespread choices as biocompatible vehicles whose physic-
chemical properties can be tuned selecting the polymer molecular weight and copolymerization degree [147]. 
Indeed, functionalization strategies can be applied in order to endow polyester-based carriers with smart 
behaviors, since they are materials that, per se, are unable to elicit specific responses from, or to interact 
actively with the biological milieu.  Functionalization of nano- (or micro-) particles for drug delivery can 
have multiple purposes, but in general aims to improve the efficiency of drug delivery, either by enhancing 
passive targeting or allowing active interactions with certain ligand presented on cells or tissue components 
(such as ECM molecules) [148]. As seen in paragraph 2.5.2, several methods of preparation, including 
emulsions and nanoprecipitation, allow the modification of the NPs during the same fabrication procedure by 
means of incorporation of active molecules. Moreover, functionalization can be achieved choosing-
synthesizing polymers to produce NPs that are already endowed with particular properties, or by chemical 
modification (i.e. covalent grafting or physisorption of biomolecules) on the already generated NPs.  
Passive targeting of cells or diseased tissues consists in improving the chances of a NPs device to localize 
into a given target, in an unspecific way. For instance, coating NPs with PEO, pluronic or other non-fouling 
molecules, increase the NPs circulation time in the bloodstream, increasing the number of carriers able to 
accumulate in their target without being eliminated by phagocytic cells or by renal clearance [149]. Pluronic 
coatings have also been proven effective in increasing drugs and NPs ability to cross the blood brain barrier, 
underlining the importance of these polymers in improving the efficacy of the drug delivery process [150]. 
Modification of the surface charge (Z-potential) of nanocarriers, for instance grafting anionic or cationic 
polymer (e.g. alginate and chitosan, respectively), is also a method to promote interaction with certain 
tissues, although in an unspecific way [151]. Controlled drug release with functionalized NPs is also a 
fundamental area of research for the treatment of tumors. Nanomedicine strategies to target cancer cells 
involve both active target recognition methods, as well as approaches that could be classified as “in between” 
passive and active delivery. As for active delivery techniques, NPs can be functionalized with antibodies or 
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lectins, that are capable to bind specific ligands on the cell membrane and thus locally release high amounts 
of chemiotherapeutic drugs in the proximity (or even inside) cancerous cells. For instance, PLGA-based NPs 
have been surface grafted with anti HER-2, Anti Fas, and against antigen rich MCF7 cells antibodies, to 
successfully bind ovarian [152], breast and colorectal [153] cancers. While it is possible to graft such 
molecules with high efficacy on NPs, identifying univocal cell surface markers for cancerous cells is a major 
challenge, due to the continuous adaptation and mutation of these cell types. For this reason, NPs for cancer 
therapy is often performed developing smart passive targeting. Cancer cells are known to have higher 
metabolic activity, compared to healthy cells, and thus tend to incorporate more nutrients. Functionalization 
of NPs with metabolic compounds that these cells require in higher amounts, such as folic acid [154] and 
transferrin [155], have been proven as successful methods to deliver nucleic acids for gene therapy and 
chemotherapy compounds  preferentially to cancer cells, in the lung and in the ovary. Furthermore, active 
strategies that aim to overcome the hurdle of drug resistance from cancer cells, have also been devised. P-
glycoprotein inhibitors-modified PLGA NPs, that can disable one of the mechanism of defense of these cells, 
have been successfully experimented in vitro and in vivo, for delivery to adenocarcinoma cells resistant to 
the drug Taxol [156]. As it can be seen by these few examples, there is a wide amount of molecules to guide 
NPs localization and improved their spatial distribution and thus drug delivery. A more detailed description 
of these molecules and their application falls out of the scope of this Thesis. An extensive review of the topic 
can be found in the literature [157]. 
Persistent bacterial infections and established biofilms infections are among the pathologies that may be 
treated using drug loaded-NPs. In biofilms (Figure 2.26), bacteria group together on a surface and start 
producing their own ECM, mostly made of polysaccharides and extracellular DNA [158]. Sessile bacterial 
cells are phenotypically different from their planktonic counterpart, are less metabolically active, which 
make them less susceptible to drugs, and are able to communicate with other cells in the biofilm, develop 
resistance to antibiotics and respond cooperatively to environmental stresses and threats [159]. Biofilms act 
as a biological barrier that can protect the encapsulated bacteria and render most antibiotic treatments 
useless. The degradation of β-lactam antibiotics by β-lactamase, the binding of aminoglycosides antibiotics 
to the matrix in P. aeruginosa biofilms and the inhibition of the activity of tobramycin by lung mucus in 
cystic fibrosis patients are good examples of unwanted interactions of the antimicrobial agent with the 
biofilm or tissues of the patient [160]. Nanomedicine treatments using liposomes and polymeric 
nanoparticles have been proposed to overcome these limitations. Functionalized nanocarriers that are able to 
bring drugs within the biofilm matrix, thus increasing local antibiotic concentration in the proximity of 
bacterial cells, and, at the same time, are able to establish interactions with the bacterial ECM thus 
overcoming its defense, will be discussed more extensively in Chapter 4. 
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Figure 2.26: Stages of biofilm formation and maturation. (1) Planktonic cells adhesion on the surface, 
(2) bacterial ECM synthesis and biofilm growth and (3) dispersion of biofiLm parts or planktonic 
bacteria can cause the propagation of the infection. 
 
2.6.4 Microcarrier culture technology 
MPs with size above 40-50 µm are large enough to home cells growing as monolayers on their surface. 
Larger particles, with diameter above 100-150 µm, can also display an open porous morphology, with pores 
large enough to allow cell ingrowth and colonization of the inside of the particle. These types of MPs are 
usually addressed as microcarriers (MCs). Additionally, large particle made of hydrogel materials (from 150 
µm up to a few millimeters), can also be used as microcapsules, whose core may be made of the same 
hydrogel or be hollow and filled with liquid medium compatible with cells, to enclose cells inside.  
The use of microparticles to culture mammalian cells can be traced back to the early 1950-1960s [161], and 
the first microcarriers were initially derived from spherical chromatographic beads, such as 
diethylaminoethyl (DEAE)-Sephadex, and the growth of anchorage-dependent cells on microcarriers was a 
main breakthrough for the culture of virus-infected cells and mass production of vaccine agents [162]. Since 
then, MC technology has evolved together with the increasing knowledge in cell biology and biomaterials 
science. A wide variety of materials, geometries and chemical compositions have been exploited to produce 
MCs. Furthermore, MC technology has received increasing attention for its implications in mammalian cells 
expansion, especially for cell therapy and tissue engineering purposes. The first, great advantage of MC 
culture is that MCs can display high surface area for reduced volumes, thus allowing the expansion of cells 
to great numbers, without requiring the large amount of materials, disposable and space that standard 2D 
tissue culture techniques would need (Figure 2.27) [163]. Additionally, it is feasible to scale up MCs culture 
under Good Manufacturing Practice (GMP), for instance using stirred tanks bioreactors [164]. This 
advantage made MCs culture a fundamental tool in the past decades for recombinant proteins and vaccine 
fabrication, and has nowadays the potential to allow the production of the high cell amounts need in 
regenerative therapies, and that are otherwise impossible to retrieve by tissue biopsies.  
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Figure 2.27: A visual representation of an advantage of microcarrier culture over standard T-flasks. 
MCs have high specific surface area, so that a minute volume such as that of a pellet of MCs 
fabricated in this Thesis work (A), offers the same surface for cell growth as that of two standard T175 
flasks (B). 
 
MCs culture in stirred tanks bioreactors is also suitable for medium sampling for continuous monitoring of 
the cell culture parameters (pH, oxygen tension) and cell metabolites (glucose) consumption and catabolite 
secretion (lactate and ammonia) which are fundamental for large scale and GMP-compliant processing [165].  
MCs exist in many commercially available formulations (Table 2.6) and are used to culture cell lines, 
primary differentiated cells and stem cell types, including MSCs, ESCs and iPSCs. Most of these cell types 
respond to mechanical forces and mechanical properties of the substrate (mechanosensing), as well as 
morphological, topographical and biochemical cues. For this reason, the design and control of MCs shape, 
surface and material properties and chemical composition plays a fundamental role in modulating cell shape, 
organization, proliferation and phenotype expression. As a consequence, several research groups have 
generated MCs of different materials (PLA, PCL, PLGA, gelatin, chitosan, alginate, pectin among others) as 
cell-instructive biomaterials [166-173]. Moreover, as it can be seen in table 2.5, most of these commercial 
MCs are not biodegradable, thus they are mainly designed for cell culture rather than as injectable devices 
for regenerative therapies.   
 
 
 
 
 
 
 
 
 
A B
62 
 
Table 2.6: List of commercially available microcarriers (adapted from [174]) 
MC type Manufacturer Material Charged Diameter 
[µm] 
Surface 
area 
[cm2
Pore 
size 
/g] 
Coating 
Biosilon Nunc Polystyrene No 160-300 255 Solid None 
Collagen SoloHill Polystyrene No 90-150 480 Solid Collagen 
I 
CultiSpher-S Percell-
Biolytica 
Gelatin No 130-380 7500 20 µm None 
Cytopore 2 GE Health Care DEAE-
Cellulose 
+ 200-280 11000 30 µm None 
Cytodex-3 GE Health Care Dextran-
based 
No 141-211 2700 Solid Gelatin 
Cytodex-1 GE Health Care Dextran-
based 
+ 190 ± 58 4400 Solid None 
DE-53 Whatman Cellulose-
DEAE 
+ 35-40 6800 Solid None 
DE-52 Whatman Cellulose-
DEAE 
+ 35-40 6800 Solid None 
FACT III  SoloHill Polystirene + 90-150 480 Solid Collagen 
I 
Fibra-Cel New Brunswick PET-PP disks n/a 6000 120 Porous None 
Hillex II SoloHill Polystirene-
based 
+ 160-200 515 Solid None 
Glass SoloHill Polystyrene No 125-212 360 Solid Si glass 
MicroHex Nunc Polystyrene n/a 125-212 360 Solid None 
Plastic SoloHill Polystyrene n/a 90-150 480 Solid  None 
Pronectin F-
COATED 
SoloHill Polystyrene + 90-150 480 Solid Protein 
with RGD 
RapidCell MP Biomedical Glass No 150-210 325 Solid None 
Synthemax 
II 
Corning Polystyrene n/a 125-212 360 Solid Vitronecti
n peptide 
Tosoh 65 PR Tosoh 
Bioscience 
OH-
methacrylate 
n/a 65 4200 Solid Protamine 
sulfate 
Tosoh 10 PR Tosoh 
Bioscience 
OH-
methacrylate 
n/a 10 90000 Solid Protamine 
sulfate 
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2.6.5 MC properties to control cell adhesion, proliferation and fate 
The characterization of commercial and custom-, lab-scale made MCs is generally incomplete, as it is also 
the establishment of an exact correlation between MCs biochemical, topographical and mechanical 
properties on cell fate. It is generally acknowledged that surface charge plays a key role in regulating protein 
adsorption, especially ECM molecules (i.e. collagens, fibronetinc, laminin, vitronectin) from biological 
fluids, such as serum. Positively charged MCs are thought to enhance ECM coatings like laminin and 
collagen IV [175], although the cationic Cytodex 1 MCs, have been shown to preferentially bind bovine 
serum albumin (BSA) and only a minor fraction of fibronectin [176]. NH2
Anyhow, ideal MCs should be able to display improved cell adhesion also in absence of ECM molecules in 
the culture media, as serum-free culture is more compliant with GMP requirements for cell production. 
[181]. Functionalization of MCs with pro-adhesive molecules (full proteins and peptides) thus becomes an 
important strategy to tune cell response. Controlling the density of coatings of RGD peptides on MCs was 
shown to improve cell proliferation and its implications will be further deepened in Chapter 5. Biomolecules 
coatings are known to modulate the degree of cell spreading and proliferation mostly via integrin signaling 
[182]. For instance, the density of RGD peptides on MCs surface was positively correlated to an increment in 
MSCs proliferation; furthermore, if the cells were induced to differentiate towards osteoblasts or 
chondrocytes, expression of lineage markers was higher for higher RGD densities [183]. The surface 
topography and MCs overall geometry are other important parameters to be taken into account. For instance, 
while the overall curvature of the MCs has an impact on cell viability, as higher curvature expose  seeded 
cells to higher shear stresses during dynamic culture, microscale curvature of the surface, provided by 
grooved and rough surfaces has been shown to promote osteogenesis over adipogenesis in MSCs [184].  
-rich MCs promoted fibronectin 
and vitronectin adsorption, which resulted in MSCs spreading, and therefore higher tendency to differentiate 
towards osteoblasts [178], whereas on COOH-rich MCs, these cells adopted a rounded morphology and a 
marked commitment towards chondrogenic lineages [179]. Gelatinous carriers like CultiSpher, have high 
affinity for fibronectin [180], but showed limited attachment of other ECM proteins.  
Mechanical properties, such as material stiffness [185] and storage modulus [186] have also an impact on 
cell behavior and differentiation, via modification of cell and cytoskeleton and shape mechanosensing 
pathways. However, their exact role is even more difficult to be discerned on MCs, that, due to their shape 
and size, are hard to be tested via conventional deformation systems, and a more detailed biomechanical 
characterization of MCs is required [174]. A proposed mechanism for multi- and pluripotent cells 
differentiation via cell shape regulation on MCs involves RhoA/ROCK signaling (Figure 2.28), whose 
activation stimulated osteogenesis at the expense of adipogenesis (and its downregulation provoked the 
opposite outcome) [187]. Alteration of cytoskeletal tensions in 3D MC culture was also reported to induce 
spontaneous osteogenesis of MSCs [188]. MCs have also great potential in ESC and iPSC cell expansion, 
however, the clinical application of these cells is still limited. Due to their potential health risk, these cells 
should be induced to differentiate before implantation, and effective protocols to remove undifferentiated 
cells should be carefully set (i.e magnetic sorting or FACS) [189].  
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Figure 2.28: Possible mechanisms by which MCs properties modulate (A,B) MSCs and (C,D) PSCs 
(ESCs and iPSCs) fate. Adapated from [174] 
 
2.6.6 MCs for cell therapy 
After cells have been expanded on MCs, they can potentially be then retrieved and used as injectable living 
drugs with no biomaterial. MCs culture, in fact, can be successfully used to achieve cell proliferation, while 
preserving the culture cell specific, differentiated phenotype or multipotency, increasing their biological 
activity and therapeutic potential, compared to cells cultured in T-flasks. For instance, Malda et al. showed 
that chondrocytes cultured in gelatin CultiSpher G MCs retain their chondrogenic phenotype and, once 
retrieved from the MCs and seeded on a 3D synthetic scaffold had enhanced proteoglycan deposition 
compared to cells cultured in 2D [190]. Analogously, Goh et al. have demonstrated that MSCs after culture 
on MCs have higher potential for calcium deposition and bone formation both in vitro (seeded on polyester 
3D scaffolds) and in vivo, respect to their counterpart expanded with conventional methods [191]. Cell 
retrieval can also be simplified, without involving any enzymatic treatment, if MCs made of thermosensitive 
materials are used [192]. 
More importantly, cells clustered on MCs made of biodegradable and biocompatible materials can be 
injected directly together with their carrier, as long as the size of the cell-MCs complex permits the injection 
and the implantation at the desired site. This type of approach shows considerable advantages, as the MCs 
can provide cell homing, and possibly prevent the massive cell death and dispersion that typically occurs 
after delivery of cells in vivo with no biomaterial support. A variety of applications for cell-laden MCs are 
being considered (Table 2.7).  
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Table 2.7: List of relevant studies involving MCs as cell delivery systems. 
Application Cell type MCs Type of study Reference 
Myocardial 
infarction 
Human 
AFSCs 
PLGA porous 
beads 
246.3 ± 17.7 µm 
Injection of cell-MCs complexes into rat 
heart, improvement of scar remodeling and 
heart functions 
  
[193] 
Myocardial 
infarction 
Rat MSCs Alginate- PLL-
alginate  
10, 200 or 400 
µm 
Injection into rat myocardium of cells 
encapsulated into the MCs. Larger MCs 
improved cell survival. Identification of a cell 
amount threshold to improve heart function. 
 
[194] 
Myocardial 
infarction 
Rat MSCs FN-coated PLGA 
loaded with 
VEGF  
60 µm 
 
In vitro cell survival and proliferation is 
improved under hypoxic conditions.  
[195] 
Parkinson 
disease 
Rat 
MIAMI 
cells 
Laminin-PLGA 
loaded with 
neurothropin 3 
60 µm 
Injection in a dopaminergic-deafferent rat 
striatum. Improvement of injected cell 
survival, secretion of chemokines and 
protection/repair of nigrostriatal pathway  
 
[196] 
Parkinson 
disease 
Rat ACCs Cytodex beads Cells on MCs injected in hemiparkinsonian rat 
striatum. Improved behavioral score up to 12 
months post transplantation. 
 
[197] 
Parkinson 
disease 
Human 
RPE 
Gelatin MCs 
(Spheramine) 
60 µm  
Randomized, double-blind clinical trial, cell-
seeded MCs implanted into human striatum. 
No significant difference vs. sham surgery 
 
[198] 
Degenerative 
retinal and 
macular 
disease 
Human 
RPE  
cell-line 
PLLA-PLGA 
blends 
30-120 µm 
In vitro cell culture. Characterization of cell 
viability, proliferation and phenotype 
retention. Proof-of-concept study of potential 
use of cell-MCs for intraocular delivery 
 
[199] 
Articular 
cartilage 
repair 
Human 
MSCs 
FN-coated PLGA 
TGF-β3 loaded 
60 µm  
Co-release of growth factor and cells. 
Improved in vitro chondrogenic 
differentiation. Injected in SCID mice 
cartilage, formation of neo-cartilage. 
 
[200] 
Diabetes Allogenic 
Langhera
ns islets 
Alginate 
microcapsules 
400 µm 
Clinical trial. Intraperitoneal implantation of 
encapsulated cells in non-immunosuppressed 
patients. No relevant immunological response, 
transient reduction of insulin-dependence  
[201] 
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Since MSCs can be induced to differentiate into cardiomyocites, and have been found in ischemic heart 
[202], this cell type is widely studied for heart cell therapy. While many reports focus on the use of 
hydrogels to implant these cells [203], a few promising works involve MCs as cell delivery devices. PLGA 
porous MCs were used to culture MSCs derived from the amniotic fluid in a spinner flask bioreactor and 
obtain cell-MCs complexes enriched with neo-deposited ECM. These systems sustained MSCs survival, 
homing and bioactivity, while permitting cell migration from the carriers, as tested in vitro, and thus 
allowing in vivo scar tissue remodeling and an interesting recovery of the left ventricle ejection fraction 
[193]. In order to enhance MSCs engraftment into the heart, cells should be able to withstand the mechanical 
stress imposed by the cardiac muscle upon intramyocardial injection. MCs can be used as means to 
mechanically (and biochemically) protect cells, when cells are encapsulated inside hydrogel matrices (i.e. 
alginates) or hidden in the polymer porous network, and the size of microcapsules appears to be a key 
parameter in preserving cell viability [194]. As mentioned earlier in this Thesis, the main therapeutic 
mechanism of action of MSCs upon transplantation is the secretion of trophic factors, rather than direct 
differentiation.   For this reason MCs for cell therapy should enhance -or at least preserve- MSCs paracrine 
secretion,  a result that can be achieved, for instance, thanks to the improved cell-cell and cell-ECM contact 
in MSC-MCs complexes [193]. Such a property is also especially important for therapies targeting the 
central nervous system. In fact, less than 1% of the successfully implanted MSCs into the brain have been 
found to undergo neurogenic commitment, and the almost totality of the positive effect observed in vivo are 
attributed to the synthesis of neurotrophic and immunomodulating molecules, that allow surviving native 
neural cells to compensate the lost, impaired or damaged tissue [204, 205]. This mechanism has been 
observed in cell therapy for Parkinson disease [205], and MSCs beneficial secretory activity can be improved 
transplanting these cells with Pharmacologically Active MCs (PAM). These are microdevices that home 
cells on their surface and are loaded internally with growth factors, which are gradually released. For 
instance, MIAMI cells (a subset of MSCs) cultured on PAM encapsulating neurothropin 3 displayed higher 
bioactive molecules secretion, improving the otherwise impaired dopamine related pathways in a rat animal 
model [196]. Other cell type, such as those from Retinal Pigment Epitelium (RPE), have been shown to exert 
therapeutic and neuroprotective activity, which may be enhanced with MC-based transplantation. However, 
it should be pointed out that Spheramine, which, to date, is the only RPE-MCs device tested in a clinical 
trial, showed no significant therapeutic activity against Parkinson disease in humans,  despite of the 
encouraging pre-clinical results [198].  
The applicability and efficacy of MC-based cell delivery is also strongly affected by MCs diameter in 
relationship with the site of transplantation, as the size of the device may trigger undesired immunological 
responses. PLGA MCs implantation into the brain induced no specific astrocytic reaction, and although 
macrophages and microglia cells were showed to be present after biomaterial injection, they disappeared 
after the first days, indicating only acute inflammation [9]. Inflammation intensity was shown to be 
dependent on MPs size and geometry. Particles with diameter between 1 and 30 µm were correlated with 
higher production of TNFα, IL-6 and IL-10 from macrophages, while larger particles induced mild response 
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and no phagocytosis (in rat striatum). Given this observation and the necessity to reduce needle size to 
deliver the therapy to the brain, particles with size around 60-80µm are usually regarded as appropriate for 
brain cell therapy, while MCs can be generally larger for transplantation in other tissues [120]. 
While most MC-based delivery devices are characterized for their ability to sustain cell viability and 
proliferation, only a limited amount of studies focus on how to achieve control cell release in terms of spatial 
and temporal distribution [74]. The understanding of how cells on biomaterial carriers sense and respond to 
the multitude of signals to which they are subject in vivo (i.e. chemokines that regulate repair/disease 
pathways), is a necessary step in order to prevent cell dispersion or unspecific delivery. Moreover, knowing 
how to control these responses with biomaterials properties will be beneficial to design advanced cell 
therapies.  
Another highly promising application of MCs for cell therapies is related to microencapsulation technology, 
consisting in the fabrication of hydrogel-based MCs that enclose cells in their core. This capsules act as a 
barrier that prevents the penetration of large molecules like immunoglobulins, while allowing secretion of 
chemokines or other small cellular products towards the host organism, and have great potential for allo- or 
even xenogenic cell therapy. The cut-off molecular weight of these membranes depends on the polymer 
molecular weight, concentration and degree of crosslinking. Transplantation of microencapsulated cells has 
been studied, for instance to support or partially replace hepatic [206], renal [207] and pancreatic function 
[208]. Devices for the allotransplantation of microenscapsulated Langherans islets into alginate beads, for 
instance, are already being tested in clinical trials for the treatment of insulin-dependent diabetes, and have 
been demonstrated to induce a degree of improvement in patients, while successfully concealing the donor 
cells from the host immune system [201]. The establishment of effective purification protocols to obtain 
clinical grade devices (in case that natural origin polymers are used as raw materials), as well as the 
development of accurate control over cell/MC ratio, MC size and permeability, identification of optimal 
implantation sites and surgery are among the main open challenges in this field  [209]. 
 
 
 
 
 
2.6.7 MCs in Tissue Engineering 
Cells cultured on MCs, that are retained and proliferate on Mc surface, can be used as components for tissue 
engineering strategies (Table 2.8). In this perspective, MCs can be thought as “discrete” scaffold units, which 
can be injected after being colonized with cells. Injection of these cell-MCs complexes is the most 
straightforward application of MCs, and has been studied for engineering a wide variety of tissues. 
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Table 2.8: MCs and their application in Tissue Engineering strategies 
Target Cell type MCs Type of study Ref. 
Adipose 
tissue 
3T3-L1 
preadipocytes 
Porous PLGA 
50 µm 
Cell culture on MCs, partial MC aggregation and 
injection of cell-MCs complexes in mices. 
Formation of neo-adipose tissue. 
 
[210] 
Adipose 
tissue 
Human  
ASCs 
Decellularized 
adipose tissue  
bead foams 
1-2 mm 
Improved in vitro ASCs differentiation. In vivo 
implantation in Wistar rats showed strong 
angiogenesis and adipose tissue regeneration. 
Complete resorption in 12 weeks. 
 
[211] 
Cartilage Rabbit 
chondrocytes 
Nanofibrous star-
shaped PLLA 
20-70 µm 
 
Porous MCs, with fibrous nanostructure improved 
cartilage repair in vivo. Higher quality tissue 
compared to ACI. 
[212] 
Cartilage Bovine 
articular 
chondrocytes 
Porous PLGA 
175 µm 
Culture in spinner flask on MCs with 
interconnected porosity. NH2
 
-modified MCs 
increase in vitro cell proliferation and COL II and 
GAGs expression  
[213] 
Cartilage Mouse MSCs Fibrin 
microbeads 
105-180 µm 
 
In vitro improved cartilage regeneration [214] 
Bone - β-TCP/PLA 
177.6 ± 33 µm 
In vivo transplantation into rabbit bone defect. 
Enhanced repair compared to MCs without β-TCP 
 
[215] 
Bone Rat MSCs CultiSphere S Enhanced bone regeneration in rat calvaria defect 
 
[216] 
Bone MC3T3-E1 
preosteoblats 
Pectin  
300-500 µm 
 
Microencapsulation. Improved mineralization and 
bone deposition in  vitro 
[217] 
Heart Human 
MSCs 
Alginate-RGD 
100-300 µm 
Microencapsulated cells. In vivo reduction of 
infarcted area an improved left ventricle function 
 
[218] 
Smooth 
muscle 
Porcine 
aortic SMCs  
Porous PLGA 
(TIPS) 
200 ± 50 µm 
In vitro cell colonization of the MCs and matrix 
deposition. Improved cell migration and SMCs 
markers. Preserved viability upon injection in vivo 
 
[219] 
Skin Human 
keratinocytes  
Cytodex 3 In vitro expansion in spinner flasks and in vivo 
transplantation in nude mice. Reconstitution of 
multilayered and keratinized epithelium 
 
[220] 
Skin Bovine 
fibroblasts 
CultiSpher G 
130-380 µm 
In vitro formation of microtissue aggregates of 
cells, MCs and neo-synthesized ECM. In vitro 
assembly into large skin tissue precursors. 
[221] 
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Injectable cell- laden MCs usually tend to cluster into multiparticles aggregates, depending on the culture 
condition (Figure 2.29). In this case, the size of the cell-material unit is increased, at the expense of ease of 
injectability, but at the same time such aggregates can display interesting bioactivity, due to higher cell-cell 
communication and ECM matrix deposition [221], that resulted in improved regenerative potential for 
adipose, cartilagineous, bone and skin tissues [212, 213, 216, 221]. MCs composition is always among the 
most important parameters to promote cell differentiation and tissue regeneration. For instance, MCs made 
of decellularized adipose tissue have been shown to already possess a complex combination of signals 
necessary to push seeded ASCs to sustain in vivo angiogenesis and regeneration of native-like adipose tissue 
[218]. MCs based on synthetic polymers like PLGA, which bear no specific signal to guide cell fate, can 
instead benefit from modification with bioactive compounds, such as ion-release ceramic/glass particles for 
bone tissue engineering [215].  
 
Figure 2.29: Scheme of the procedure for Tissue regeneration using cell-laden MCs and injectable 
devices. Adapted from [210]. 
 
MCs can be designed with open porosity or as solid particles. The main advantage of open porosity consists 
in increasing the surface area available for cell growth and promoting the establishment of cell-cell contacts 
in a limited volume. Also, the structure of the polymer skeleton in the MCs can be controlled during the 
fabrication step to add a degree of control over cell behavior through topographical cues. For instance, Liu et 
al. were able to shape the polymer structure of their MCs into a nanofibrous mesh, to better mimick the 
conformation of the native collagenous ECM of cartilage, an thus improve regeneration in an articular 
cartilage defect [212]. Solid sphere MCs, on the other hand, can be easily used to encapsulate and deliver 
over time drugs that can provide biochemical stimuli to guide cell regeneration [196, 200]. 
70 
 
Due to their high versatility, MCs are often used in combination with other materials. MCs without cells can 
be encapsulated into the matrix of “classical” macroscale scaffolds. Ruhé et al. incorporated fast degrading 
PLGA MCs in order to increase the porosity of cement scaffold for bone TE implanted in vivo [222]. Also, 
Kaplan and co-workers have produced silk sponges incorporating silk microparticles, to increase the elastic 
stiffness of the device, which improved for higher MCs loadings, and, at the same time affected the 
differentiation of MSCs towards osteogenic lineage [223]. MCs can be promisingly incorporated into 
hydrogels to generate composite materials. A typical purpose for including MCs in gel matrix is to improve 
the stiffness of these soft materials, as shown by Hu and coworkers, which generated chitosan gels reinforced 
with stiff PLGA MCs [224]. Additionally, since most hydrogels can be used as injectable devices and can 
gelate under mild cell-friendly conditions, cell-MCs complexes can be encapsulated as well.  In this way, 
MCs can be introduced in a continuous matrix that can solidify upon injection in situ and prevent MCs 
undesired movements [225]. At the same time, MCs can provide cues to modulate cell viability and fate, 
through their surface topography, mechanical and chemical properties as described in Section 2.5.5. This is 
especially important when considering, cells in hydrogels are mostly confined in a rounded morphology 
[226], and such condition is even more evident when using non-functionalized anti-fouling gels (such as 
PEG, PVA, agarose). 
 
 
Figure 2.30: Experimental design of two modes of tissue engineering using cells suspended in a 
hydrogel as free cells or as cell-laden MCs. Adapted from [227]. 
 
For instance, Wang et al. have shown that osteblastic cell viability and bone matrix synthesis upon 
suspension in an agarose matrix can be dramatically increased if cells are encapsulated as complexes on TriG 
(gelatin-grafted-gellan) MCs (Figure 2.30) [227]. 
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2.6.8 MCs in bottom-up TE and biofabrication  
MCs can also be thought as building blocks in bottom-up tissue engineering strategies. Before seeding cells, 
MCs can be assembled together to build-up macroscale porours scaffold, whose porosity is dependent on 
MCs size and due to the hindrance between neighboring particles (Figure 2.31). Recently, using a MCs 
fabrication method derived from the work presented in this Thesis, Salerno et al. have shown how to 
combine a microfluidics system and a sintering approach to produce PLA MCs assembled into large 
scaffolds. The porosity of such systems can be controlled mixing particles of different sizes, and MSC were 
shown to proliferate on these matrices [131]. MCs-assembled scaffolds with controlled geometry and 
porosity at the micro- and macroscale can also be obtained by means of rapid prototyping/sintering technique 
[228]. 
 
       
Figure 2.31: (Left) Scaffold made with a microfluidic-PLA MCs sintering combined approach 
(adapted from [131]). (Right) Rapid prototyping scaffold made of sintered CaP/PHBV MCs. (A) CAD 
design, (B) µCT, (C, D) SEM micrographs [229]. 
 
Thanks the ability of cells to self-assemble, another interesting bottom-up fabrication approach consist in 
exploiting the tendency of cell-MCs complexes to coalesce, and then use these aggregates as living building 
blocks. Palmiero et al. have described a process to culture fibroblasts on gelatin MCs, let them self-assemble 
in a preliminary culture step, producing microtissue precursos rich in cell and ECM proteins, and collect 
these units in a perfusion bioreactor to facilitate their assembly into larger tissue engineered construct. This 
approach was proven advantageous to generate skin grafts whose ECM composition resembles that of the 
native tissue [221]. If hydrogel microcapsules are used for this class of biofabrication approaches, it can be 
possible to generate constructs having multiple compartments to home different cell types. Recently, 
collagen gels were used to host two different cell lines (one encapsulated and the other on the MCs surface), 
and then induce cell-MCs complexes self-assembly in a PDMS mold (Figure 2.32) [230]. Although the 
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researchers used 3T3 and HepG2 cell lines, this approach promises to allow the generation of constructs with 
virtually any desired shape and cell composition.    
 
 
Figure 2.32: (A to E) Procedure of a bottom-up cell-mediated assembly of MCs into a 3D tissue. MCs 
aggregates can be shaped into any desired form, and in this proof-of-concept a doll-like figure is 
generated. Adapted from [230]. 
 
As novel frontiers for MCs based biofabrication, considering the examples reported so far and the possibility 
to form hydrogels-MCs composites, injectable, cell-laden MCs could be used as components in bioinks to 
fabricate novel, bioprinted grafts (as described with more detail in Chapter 6).Similarly to many TE product, 
these devices have great potential applications for regenerative medicine, as in vitro disease models and drug 
testing platforms. 
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Chapter 3 
 
Green-inspired fabrication of polylactic acid MCs with controlled size 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In this chapter, a new method to fabricate polylactic acid microcarriers is described and 
characterized. This method involves no harmful chemicals and is the first report of a processing 
method to obtain PLA devices involving the green solvent ethyl lactate. Particles generation is 
obtained by i) generating a polymer solution jet and its subsequent break-up into droplets by means 
of aero- and hydrodynamic forces, and ii) the solidification of these droplets in a coagulation bath. 
Experimental parameters to control particles size in the range suitable for drug and cell delivery 
applications are also characterized, paying particular attention to particle size, polidispersity and 
morphology. The adaptability of such fabrication method to encapsulate drugs is also assessed in a 
proof-of-concept assay using a model, fluorescent compound.  
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3.1 Introduction  
MCs can be fabricated with different types of biomaterials, each possessing appealing physico-chemical 
properties for specific devices and offering different approaches to drug and cell release applications. For 
instance, several synthetic (e.g. polyethylene glycol derivatives) and natural polymers (alginates, chitosans, 
pectins), can be processed under cell-friendly conditions (such as photocrosslinking and ionotropic gelation) 
to form hydrogel spheres suitable for direct encapsulation of cells into the core of the carrier [1]. On the 
other hand, synthetic biodegradable polyesters, including polylactide (PLA), polyglicolide (PGA) and their 
copolymers (PLGA), are mainly used to produce microcarriers to deliver cells cultured on their surface. 
Besides, these carriers can be easily loaded with bioactive molecules as support for the cell therapy [2]. 
Biodegradable polyesters, especially PLA/PLGA, are widely used as they degrade through hydrolysis, a 
process whose kinetics can be tailored varying the polymer molecular weight, crystallinity and 
lactide/glycolide ratio. These features have led to an increasing number of commercial drug delivery 
matrices based on polylactic acid and its copolymers [3]. However, the use of these polymers for drug 
delivery and cell therapy applications still deals with several challenges. Besides their hydrophobic nature 
and the lack of bioactive functional groups, the processing of polylactide often requires the usage of toxic 
solvents, whose residues must be carefully removed from the final device, for patient safety and regulatory 
approval of the device [4]. This aspect becomes fundamental with particular respect to those PLA-based 
products designed to interact with biological milieu. Thus, a PLA processing route that minimize or 
eliminate hazardous compounds will lead to environmentally and regulatory- safe procedures and products. 
Ethyl lactate (EtLac) is a green, water-miscible, biodegradable solvent and Food and Drug Administration 
(FDA) approved aroma in food industry, which does not show any potential health risks [5]. EtLac is not 
teratogenic and it readily undergoes hydrolysis to ethanol and lactic acid, this last compound being a natural 
metabolite in humans. In addition, its ecotoxocity is very low, it is a non-ozone depleting fluid, it can be 
produced from renewable resources with cost-effective technologies, and it has already been studied in 
pharmaceutical applications [6, 7]. Recently, a description of the liquid-liquid equilibrium of PLA and ethyl 
lactate, which present partial miscibility was reported [8]. Considering these features, it is evident that a new, 
well defined PLA MCs preparation process involving ethyl lactate can offer appealing advantages for many 
biomedical applications in terms of biocompatibility and waste disposal, in contrast to methods based on 
traditional organic solvents.  
Among all the described fabrication methods for PLA-based MCs preparation, the emulsion/solvent 
evaporation method is the most used. This process usually requires the use of toxic chlorinated solvents and 
has limited control over certain important MCs parameters, such as size distribution [9]. Another family of 
methods for the fabrication of MCs relies on the preliminary formation of liquid droplets, such as spray 
drying [10], solution dripping [11], ultrasonic and electrohydrodynamic atomization [12, 13], and flow 
focusing [14]. Among these methods, the last three consist of the generation of a liquid jet from a stable 
meniscus at the dispensing tip due to external applied forces and subsequent rupture of the jet into a 
monodisperse train of droplets.  
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In the present study, an alternative ethyl lactate-based manufacturing technique to obtain PLA MCs with 
potential application as cell and drug carriers has been developed. A simple solution extrusion strategy 
coupled with a coaxial flow of gaseous nitrogen was adopted, providing the necessary conditions to induce 
meniscus formation, stretching and break up into droplets. MCs were fabricated through dissolution of PLA 
in ethyl lactate, atomization of the solution into liquid droplets and their subsequent precipitation in a 
hydroalcoholic coagulation bath. Upon immersion into the bath, ethyl lactate was removed and particles 
were formed due to non-solvent induced phase separation (NIPS). MCs size could be controlled by simply 
tuning the gas and solution flow parameters or varying the solution concentration. A complete 
characterization of the MCs morphology, their inner structure and a preliminary assessment of drug 
encapsulation using a fluorescent model compound are also described. This method constitutes a proof of 
principle for the use of EtLac as a processing agent of PLA. The obtained MCs might be used as cell delivery 
systems with potential applications in the field of tissue engineering and drug delivery.  
 
 
3.2 Materials and Methods 
3.2.1 Materials 
Polylactic acid (Purasorb PLDL 7038, inherent viscosity midpoint 3.8 dl g-1, Mw ≈ 850000 Da) was 
purchased from Purac. (-)Ethyl L-lactate (photoresist grade; purity ≥ 99.0%) was obtained from Fluka and 
used without further purification. Poly(vinyl alcohol) (PVA, 30-70 kDa, 88% hydrolyzed) and  all the other 
reagents were from Sigma-Aldrich. 
 
3.2.2 Differential scanning calorimetry 
A thermal characterization of the material processed from ethyl lactate was performed by Differential 
Scanning Calorimetry (DSC, 2029 TA). PLA films (200 µm thick) were prepared by solvent casting. Two 
solutions of PLA 2.5 % w/v in EtLac and in chloroform were prepared, cast into petri dishes and left to 
evaporate under a fume hood for three days. The films were then collected, rinsed thoroughly with distilled 
water and air dried. For each DSC test, about 5 mg of material were loaded in the furnace of the instrument 
and were heated from room temperature up to 220 °C (1st run, heating rate 10 °C/min), then rapidly cooled 
down to room temperature and heated up to 200 °C again (2nd run, rate 10 °C/min).  
 
3.2.3 Viscosity of EtLac-PLA solution  
PLA was dissolved in EtLac at 50°C under stirring to obtain solutions of different concentrations in the range 
between 1 and 4.5 % w/v.  The viscosity of 10 ml samples from each solution was measured at room 
temperature (25 ± 2 °C) through a vibration viscosimeter (SV-10, A&D Company Ldt, Japan). For solutions 
3.5 and 4.0 % w/v, viscosity measurements were also taken at different temperatures (up to 50°C). 
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3.2.4 MCs preparation 
The polymer solution was loaded into a syringe pump and dispensed at a constant rate through the inner bore 
(30G) of a dual concentric nozzle (NNC-DN-2230, NanoNC, South Korea), while the outer coaxial bore 
(22G) was fed with N2
 
 (feeding pressure P = 0.5 bar). The inner needle protruded from the external conduct 
for 1 mm. The coagulation bath, composed by a hydroalcoholic solution (70% EtOH in water with 0.3% 
PVA) under stirring at 100 rpm, was placed 8 cm below the dispensing tip. The solution concentration and 
dispensing rate were varied between 3.5 and 4.0 % w/v and from 10 to 50 mL h-1, respectively. MCs were 
allowed to harden into the coagulation bath for 1 hour before being collected by centrifugation. Following 
extensively rinsing with deionized water, MCs were flash frozen in liquid nitrogen and lyophilized for 48 
hours. MCs batches were coded as XXDNYY to indicate their preparation parameters, where XX stands for 
the polymer concentration, DN stands for dual nozzle and YY is the dispensing rate expressed in mL h-1. 
Particles 35DN10 were prepared varying also the dispensing tip-bath distance from 8 to 18 cm and lowering 
the bath temperature from 18°C to 9°C. 
3.2.5 MCs size distribution determination 
MPs images were taken with an optical microscope (Leica E600 Upright Microscope) and analyzed with 
ImageJ software to determine particle size [15]. For each MCs batch more than 100 measurements were 
taken and the average diameter, standard deviation, dispersion index and geometric standard deviation were 
calculated. A stereomicroscope (Leica MZ16F Fluorescence Stereomicroscope) was used to qualitatively 
describe the overall geometry and shape of the MCs. 
 
3.2.6 MCs morphology 
Morphological analysis of the MCs surface was carried out using a Scanning Electron Microscope (SEM 
Quanta Q200, FEI Company). Before the analysis, samples were mounted on a sample holder and sputtered 
with gold. Surface wrinkles patterns were analyzed from SEM micrographs. Wrinkle wavelength λ, defined 
as the peak-to-peak distance between two neighboring wrinkles, was measured directly from high 
magnification SEM pictures for several MCs in different diameter ranges, using ImageJ software. The inner 
morphology of 35DN10 MCs prepared under different experimental conditions was investigated. To obtain 
MCs cross sections, the samples were dispersed at room temperature in Cryo M-Bed embedding medium 
(Bright), with 5% v/v EtOH to facilitate solution penetration into the MCs, thus preserving the inner 
microstructure during the slicing procedure. The MCs suspension was subsequently frozen at -21°C and cut 
into slices (20 µm thick) with a cryostat (Leica CM 1900), and collected on glass slides. Once defrosted, the 
embedding compound was removed by gently washing the slides with water. Samples were air dried, prior to 
metallization and SEM analysis.  
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3.2.7 Encapsulation of rhodamine 
Rhodamine B (Sigma-Aldrich, λexcitation = 540 nm, λemission
 
 = 625 nm) was dissolved in the polymeric solution 
at a 1% w/wPLA concentration or added to the coagulation bath (0.2% w/v bath solution). In both cases, 
MCs were prepared setting the polymer concentration and the dispensing rate at 3.5% w/v and 10 mL h-1, 
respectively. Rhodamine-loaded MCs were collected on a glass slide, dispersed with mineral oil, and their 
fluorescence distribution was then analyzed with a confocal laser scanning microscope (CLSM, Leica TCS-
SP1). 
3.3 Results 
3.3.1 PLA-EtLac solution characterization 
Differential Scanning Calorimetry (DSC) analysis showed no difference in the glass transition temperatures 
(Tg
Together with the thermal properties, viscosity is a key parameter in polymer solution processing [16,17]. 
The variation of viscosity of the EtLac-PLA solution as a function of polymer concentration and temperature 
is shown in Figure 3.1.  
) between PLA samples obtained from solution in chloroform and ethyl lactate (Tg of 57.22 and 57.16 °C 
in the first heating run, and 57.63 and 57.41 °C in the second run). The absence of endothermic peaks in the 
thermogram (i.e. the absence of a melting event of crystalline domains) confirmed the amorphous nature of 
the materials in all the tested samples. 
Two linear regions in the viscosity-concentration curve can be identified (Figure 3.1a). The viscosity is 
slightly affected by the increase of PLA concentration up to 3.0%. In contrast, a dramatic rise in viscosity is 
found for higher polymer concentrations. Two PLA solution concentrations in this range, 3.5 and 4.0 % w/v, 
were chosen in this work to produce MCs. The temperature dependent behavior of the solution viscosity at 
these concentrations was analyzed. As shown in Figure 3.1b the viscosity values decreased from 77.1 and 
158 cP at 25 °C, to 29.9 and 75.6 cP at 50 °C, respectively.  
 
 
Figure 3.1. Viscosity of PLA-EtLac solutions as function of (a) polymer concentration and (b) 
temperature. 
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3.3.2 MCs preparation and size determination 
A simple and streamlined apparatus for MCs preparation was set (Figure 3).  
 
 
Figure 3.2. Schematic representation of the MCs preparation set up. 
 
Several water-based and hydroalcoholic solutions were tested as coagulation baths, with or without addition 
of surfactants to lower bath surface tension, as summarized in Table 3.1.  
Surprisingly, not all the bath compositions evaluated in this study were suitable for MCs formation. Upon 
dropping PLA-EtLac solution into water, only formation of aggregates was detected. In the case of water-
only baths provided with surfactants like polyvinyl alcohol (PVA) or Tween (1% w/v), the formation of 
polymer aggregates was observed, whereas the addition of Triton X-100 (1% w/v) allowed for particles 
formation. However, increasing the ratio of ethanol in water above 55% v/v led to the formation of spherical 
particles, regardless of surfactants addition. According to these experimental observations, only those baths 
whose surface tension was lower than that of ethyl lactate showed the formation of spherical MCs, regardless 
of their chemical composition. Eventually, for all the MCs characterized in this study, the bath composition 
was set to 70% EtOH in water with 0.3% w/v PVA.  
 
Table 3.1. Composition of the evaluated coagulation baths. 
 
Solution composition Surfactant γ / dynes cm-1 Spherical 
Particles 
 at 
RT 
Water 1% PVA 52.21 [18a] No 
Water 1% Triton X-100 30.00 [18b] Yes 
Water 1% Tween 20 33.90 [18c] No 
Ethanol - 21.81 [18d] Yes 
Water : EtOH (70 : 30) - 33.53 [18d] No 
Water : EtOH (30 : 70) - 25.01 [18d] Yes 
Water : EtOH (30 : 70) 0.3% PVA -      [18e] Yes 
Water : EtOH (45 : 55) 0.3% PVA -      [18e] Yes 
 
Ethyl Lactate - 31.30 [5] - 
 
N2
PLA - EtLac
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Under these conditions, the highest number of spherical particles was obtained, with an overall particle 
formation yield over 95%. Once the proper coagulation bath was designed, MCs with tailored size could be 
obtained directly from generating spherical drops of PLA-EtLac solution.   
With the experimental set-up used in this study, a wide range of MCs sizes could be achieved by simply 
tuning the polymer concentration and fluid flow parameters at the dispensing stage, as it is shown by optical 
and stereomicroscopy analysis results (Figures 3.3, 3.4 and Table 3.2).  
 
 
Figure 3.3. Stereo microscopy images of 35DN10 (a), 35DN50 (b), 40DN10 (c) and 40DN50 (d) MCs. 
All pictures are taken at the same magnification (white bar = 1 mm). 
 
 
 
 
Figure 3.4. MCs diameter as function of polymer concentration and dispensing rate (a) and size 
distribution of MCs prepared with 3.5% EtLac-PLA solution (b). 
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Table 3.2. MCs size and diameter distribution parameters. 
 
Sample Mean / µm SD DI GSD 
35DN10 59.57 12.14 20.38 1.22 
35DN20 71.68 21.20 29.58 1.33 
35DN30 95.11 26.05 27.39 1.32 
35DN40 114.46 28.88 25.23 1.27 
35DN50 124.53 29.26 23.50 1.29 
40DN10 95.23 23.79 24.98 1.29 
40DN20 108.77 25.41 23.36 1.27 
40DN30 133.95 26.11 19.49 1.32 
40DN40 157.62 37.44 23.75 1.29 
40DN50 163.14 47.54 29.14 1.41 
The particles diameter and geometric standard deviation varied from 60 to 180 µm and 1.22 to 1.41, for 
35DN10 and 40DN50 MCs respectively. MCs size increased with the dispensing rate of the solution, for a 
given polymer concentration, as shown in Figure 3.4. For example, for a 3.5% solution, a particle average 
diameter of ~60 µm was obtained for a dispensing rate of 10 mL h-1, while increasing the dispensing rate to 
50 mL h-1
 
 led to particles with average diameter of ~125 µm.  
3.3.3 MCs morphology, inner porosity and Janus wrinkle pattern 
The MCs morphology was qualitatively analyzed from SEM micrographs, revealing that PLA MCs 
possessed an overall spherical shape (Figure 3.5).  
 
Figure 3.5. SEM images of MCs 35DN10 (a), 35DN50 (b), 40DN10 (c), 40DN50 (d). Scale bar = 1 mm. 
 
The particles surface, showed a Janus topography, with two different hemispheres: one with a smoother 
surface and the other displaying a wrinkled-labyrinthine pattern. This asymmetric morphology is present in 
a b
dc
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all the MCs formulations prepared, regardless of the adopted experimental parameters. In order to provide a 
characterization of the obtained patterns, wrinkle wavelength λ was measured (Figure 3.6).  
 
Figure 3.6. Values of λ, wrinkles wavelength, as calculated for MCs falling in different ranges of size. 
 
Values of λ ranges from 1.5 to 3.5 µm for MCs with diameters from 50 to 200 µm. In batches prepared at 
higher polymer concentration and under faster dispensing flow conditions, such as 40DN50, a limited 
quantity of non-spherical particles, sometimes possessing drop-like morphology, were observed.  
The analysis of the cross-section of 35DN10 samples revealed that the MCs possessed a thin, dense outer 
polymeric shell, enclosing a microporous layer. This interior layer is thicker underneath the smoother surface 
hemisphere of the MCs while is thinner, presenting larger pores, in correspondence to the rougher one 
(Figure 3.7). In the radial direction, towards the center of the sphere, the MCs are characterized by the 
presence of macrovoids or by a single macropore, whose dimension is higher in larger MCs, forming an 
empty core surrounded by the polymer shell. As consequence of this heterogeneity, the MCs inner 
microstructure may appear different according to whether the cross-section is taken closer or farther from the 
equatorial plane of the particle.  
 
Figure 3.7. SEM micrographs of 35DN10 MCs prepared varying needle-to-bath distance and 
coagulation bath temperature. Scale bar = 50 µm. 
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Finally, diameter and morphological analysis from batches of particles prepared cooling the coagulation bath 
from room temperature to 9°C or increasing tip-to-bath distance from 8 to 18 cm were not significantly 
different from those reported above, suggesting no influence of these parameters on the particle size and 
morphology. 
 
3.3.4 Drug encapsulation 
To assess the possibility to encapsulate bioactive molecules and to qualitatively evaluate their distribution 
into the MCs, Rhodamine B was chosen as model fluorescent compound. Rhodamine B is soluble in EtLac, 
water and ethanol, thus suitable to assess designed system both for encapsulating compounds dispersed in the 
polymeric phase as well as for uptaking solutes from the coagulation bath. Confocal Laser Scanning 
Microscopy (CLSM) analysis allowed for visualization of rhodamine encapsulation and distribution inside 
the MCs (Figure 3.8).  
 
 
Figure 3.8. CLSM images of cross-sections of 35DN10 MCs prepared dissolving rhodamine into the 
polymer solution (top) and the coagulation bath (bottom). Each set of images depicts different cross-
sections/MPs in order to underline the variability in the fluorescence distribution profile due to the 
exact position of a given cross-section. Pictures are taken at the same magnification (scale bar = 50 
µm). 
 
 
Fluorescence was clearly detected not only when rhodamine was blended directly into the polymeric solution 
but also when it was dissolved in the coagulation bath. In both cases, the fluorophore appeared to be 
concentrated in the outer shell of the MCs and in the inner ramified polymeric structures. Moving towards 
equatorials cross sections, it was possible to appreciate a reduction of the fluorescent areas, paired to the 
increment of porosity.  
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3.4 Discussion 
In this study, a novel method to prepare microparticles made of PLA, using non-toxic solvents has been set 
and characterized.Before the preparation of the MCs is carried out, it is important to study the effect of the 
dissolution in EtLac on the structure of PLA. For this purpose, the thermal properties of PLA processed from 
EtLac solutions were evaluated and compared to those of the same polymer treated from dissolution in 
chloroform, a chlorinated solvent commonly used in PLA processing. As expected, the polymer processing 
with this green solvent does not modify the bulk thermal properties of the material. 
Viscosimetric characterization shows the transition from a lower to a higher viscosity region, around the 
PLA concentration of 3.0% w/v. The first region may correspond to the condition in which the polymer is 
present as isolated coils in a diluted solution, whereas the second can be related to stronger polymer-polymer 
interactions and the transition to a semi-concentrated solution; the latter being a condition required for nearly 
all technical applications of polymer solutions [17]. This is especially important for the herein proposed 
strategy for MCs preparation, which consisted in two steps. The first step is the generation of liquid droplets 
of a polymer dissolved in a water-ethanol miscible solvent, and the second one is the solidification of these 
droplets in the coagulation bath via solvent displacement. This phenomenon is driven by mixing of the 
solvent and non-solvent phase, due to turbulent liquid flows generated by differences in surface tension. On 
one hand, if the drops are made of a diluted solution, with little polymer chain-to-chain interactions, this 
harsh mixing will simply break the drop into a multitude of submicron particles. Such a procedure is 
exploited to generate polymeric nanoparticles, and is a variant of the nanoprecipitation method, proposed by 
Fessi et al. [19], also described in Chapter 4 of this Thesis. On the other hand, viscous PLA solutions that 
show enough cohesion between the polymeric chains, can allow the preservation of the spherical droplet 
shape, upon immersion in a non-solvent with specific physical characteristics (i.e. surface tension). 
The PLA-EtLac solution was extruded through a 30G needle (internal diameter 150 µm) in a coaxial flow of 
gaseous nitrogen. In the air gap outside the dispensing needle, the perturbation given by the gas flow 
stretches the forming solution meniscus. At the relatively high flow rate set in this study, solution jetting 
mode dispensing occurs, followed by break-up into liquid droplets induced by the same nitrogen flow. These 
drops are eventually collected into a coagulation bath under stirring, and solidified into MCs. 
EtLac is a very low volatile compound, and particles precipitation occurs due to NIPS inside the bath rather 
than solvent evaporation in the air gap. For this reason, the composition of the coagulation bath was 
investigated, in order to identify a suitable formulation for particles formation and hardening. The proposed 
MCs formation technique involves a ternary system (polymer, solvent and non-solvent), and its outcome is 
strictly dependent on their compatibility/incompatibility, therefore, the non-solvent choice is a key design 
issue. Regarding PLA, several solvent/non-solvent systems have been studied, including 
chloroform/methanol, dioxane/methanol, dioxane/water and N-methylpyrrolidone/water, among others 
[20,21]. The EtLac miscibility profile oriented the choice towards a non-solvent (i.e. coagulation bath) based 
on water, ethanol and their binary mixtures. Even though solvent displacement and particle solidification are 
relatively fast processes that do not strictly require surfactant presence to stabilize the hardening drop, a 
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small amount of PVA was added to the precipitation mixture in order to avoid particles aggregation and 
reduce the surface tension of the bath. Only baths formulations whose surface tension was lower than that of 
EtLac were able to generate spherical particles. This effect might be due to an interplay between the ease of 
overcoming a bath surface layer possessing lower tension and the stabilizing effect on the droplet shape 
given by surface tension gradient driven motions [22]. 
Analogously to flow focusing [14], the proposed method is only driven by aero- and hydrodynamic forces, 
thus it is possible to tailor droplets (and MCs) size by simply adjusting the fluid flow velocity. Setting a 
given polymer concentration and outer fluid feeding pressure and tuning the dispensing rate of the polymer 
solution, allowed to control the particle dimension; a relation known and described in several gas-liquid or 
liquid-liquid co-flowing experiments [23]. 
The polydispersity of the particles is not dependent on their size. For all the cases, dispersion index (DI, 
standard deviation over average percent ratio) and the geometric standard deviation (GSD) are in the range 
of 19 to 29%, and 1.22 to 1.41, respectively. These values are determined by the fact that under the flowing 
conditions used (nitrogen feeding pressure of 0.5 bar and solution dispensing rate between 10 and 50 mL h-
1
It should be noticed that methods like emulsion/solvent evaporation and spray drying in their standard 
procedure, intrinsically produce highly polydisperse MCs (23 % < DI < 48%), prior to post-processing 
sieving steps [25,26], The fabrication of MCs with very low size polydispersity has been reported using 
microfluidic devices (DI < 5%) [34], or flow focusing droplet generation methods (DI < 15%) [25]. 
), jet break-up is not axysimmetric due to the geometry and design of the system. GSD values give an 
estimation of extent of polydispersity. Ideally, GSD should be close to 1, and up to 1.3 generally indicate 
monodisperse populations [24]. Apart from batch 40DN50, which clearly exceeds the threshold of 
polydispersity, almost all the MCs formulation are characterized by GSD values ranging between 1.22 and 
1.33, suggesting a moderate diameter distribution dispersion.  
These droplet generation methods could be used in combination with our proposed strategy using EtLac, thus 
allowing further improvement of the MCs dispersity. 
Another parameter affecting MCs size is the initial PLA concentration. A similar trend for the particles size 
with the dispensing rate variation was observed for both solution concentrations tested, with an increment in 
particles size by slightly increasing the polymer concentration from 3.5 to 4.0 %. Besides this limited 
difference in polymer content, the 4.0% formulation corresponds to a sensibly higher value for solution 
viscosity, which appears to affect particle formation step.  
In general, opposite theoretical results are reported in literature for coflowing fluid atomization processes 
characterized by axysimmetric jet break up. In these cases, solution viscosity had no effect on drop size [27]; 
especially regarding Flow Focusing (FF) devices, in which the droplet dimension has been related to flow 
parameters independently from viscosity through the equation: 
   (1) 
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Where d is drop diameter,  solution density,  gas pressure difference at the orifice and Ql
Here, for the non-axysymmetric droplet generation procedure described, the variation of the solution 
concentration and thus the viscosity, allowed to control MCs dimension.  
 fluid flow 
velocity [28, 29]. Nevertheless, FF experiments for the preparation of polystyrene microspheres, reported by  
Martín-Banderas et al. [14]  showed that increasing polymer concentration from 4 to 8% w/v caused an 
increment in the droplets size (10 to 20 µm approximately), despite of the theoretical background.  
While the particles size is mainly affected by the droplet generation conditions, the MCs morphology and 
inner microstructure might be governed by solvent removal rate into the coagulation bath and the mechanism 
of diffusion and interaction between the polymer, solvent and non-solvent. As previously discussed, EtLac is 
miscible in all proportions in both ethanol and water, while PLA is markedly incompatible with these non-
solvents. The MCs configuration displaying a dense, thin toplayer enclosing an open porous structure with 
macrovoids is caused by the kinetic of liquid-liquid demixing and phase separation.  
This peculiar morphology can be explained by the mechanism responsible of the microstructure found in 
NIPS membranes, and proposed by Smolders and co-workers [30]. The groundwork of this theory is the 
kinetics of growth of polymer-lean phases and the exchange rate of solvent/non-solvent [31]. In our case, 
once the polymeric drop enters the coagulation bath, a thin polymeric shell at the drop-non-solvent interface 
rapidly precipitates (Figure 3.9). Under this PLA solid layer, solution composition changes as ethyl lactate is 
being extracted to the external bath while the coagulation mixture diffuses within the droplet. This condition 
provokes instantaneous liquid-liquid demixing inside the drop, forming in the solution a polymer-rich phase 
and nuclei of polymer-lean (solvent rich) phase. In the inner shells of the drop, farther from the bath-drop 
interface, precipitation is locally delayed, giving the possibility to the polymer-poor nuclei to grow and even 
coalesce, towards the center of the droplet.  
Eventually, the increased uptake of non-solvent and loss of solvent will cause precipitation, with the PLA 
rich regions giving rise to an inner polymer solid structure, while polymer-lean areas will leave space to 
pores and macrovoids, as shown in Figure 3.7. The fact that the extent of porosity and surface roughness 
appears to be higher in larger MCs suggests an additional delay of precipitation due to longer non-solvent 
diffusion distances along the sphere radius.  
 
 
Figure 3.9: Scheme of the phase separation process, representing the degree of solution demixing and 
polymer phase separation occurring before the precipitation and solidification of the PLA. 
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A similar behavior with formation of macroporous inner structures was observed in PLA 2D membranes 
obtained from EtLac solutions by NIPS after immersion in the same coagulation bath used for the MCs 
fabrication (observed by SEM micrographs of cross-sections, data not shown), in accordance with the 
proposed mechanism.  
The hemisphere with rough outer surface finally forms during the hardening of the particle, in 
correspondence to the high porous layers underneath. The origin of the more homogeneous porosity on the 
opposite hemisphere, instead, is unclear, but may be related to partial solvent evaporation and precipitation 
in the air gap between the dispensing tip and the bath. 
The Janus morphology is an interesting morphological feature of the formed MCs displaying a smoother 
hemisphere opposed to another presenting labyrinthine wrinkling patterns.  
Janus particles, so named after the Roman God depicted with two heads facing opposites directions, likewise 
possess two sides with distinct compositions or surface structures. Such particles have attracted increasing 
interest because of their unique properties and potential applications in a number of fields including optical 
biosensors and functional surfactants [32].  Not only, several studies have been reported focusing on the 
generation and characterization of wrinkled surfaces [33,34], and wrinkle microparticles [35]. For instance, 
Janus wrinkled topographies were obtained on elastomeric MCs by selective UV irradiation of a single 
hemisphere of already prepared MCs [32]. 
In our case, we report the spontaneous generation of Janus wrinkles in a one step procedure, directly during 
MCs solidification and drying. Wrinkle wavelength shows a tendency to increase in larger particles, and this 
finding is in agreement with previous studies on microparticles with wrinkled surfaces [32, 37]. During the 
lyophilization of the microparticles, as the water trapped into the pores is removed, the part of the polymer 
shell on the top of the macroporous inner layer undergoes partial collapse and wrinkles, while the surface at 
the opposite hemisphere, having an inner, more stable layer, remains smoother. To explain such behavior we 
propose the following scenario. When the polymer drop is solidifying into the coagulation bath, the 
precipitating polymer structure it is found in a swollen, stretched state due to the solvent presence. Gradually, 
EtLac is replaced by the water/EtOH mixture, which, during the washing steps, is replaced by water only. 
The surface dense thin PLA skin is stiffer than the underlying core on which it lays, because of the high 
porosity of the inner layer, rich in macrovoids. Eventually, during water removal by lyophilization the 
prestrain in which the polymer is found may be relieved through the buckling of the stiffer surface shell.  
Instead, when water is removed faster with simple air drying, the MCs present a more marked, irregular 
wrinkle formation (data not shown), with even partial collapsing of the spherical structure, thus suggesting 
that the water extraction condition provokes the buckling and plays a role on the stress applied to the MCs 
layers. This solidification-induced deformation scenario is similar to the buckling of a stiff thin elastic film 
on a compliant soft substrate which has been recently reported to happen also during phase inversion 
preparation of polymeric membranes [38]. At the smoother hemisphere, instead, the presence of a thicker, 
less porous, and more stable layer under the polymeric shell, as depicted in Figure 3.7, can prevent buckling 
and surface wrinkles formation.  
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Finally, the peculiar solidification process and the exchange between solvent and non-solvent described 
above suggest that the proposed manufacturing route could be adequate to load compounds present both in 
the polymer solution and in the coagulation bath into the forming MCs. 
Due to the localization of rhodamine inside precipitated PLA, CLSM allowed for a 3D scan of the inner 
morphology from the poles towards the equatorial plane of the MCs, thus supporting the solidification 
mechanism explained above. Moreover, this finding suggests that the precipitation of the polymer is fast 
enough to trap the fluorophore, and penetration of non-solvent into the drop allows for uptaking of solutes. 
On the other hand, the first procedure may be efficient mainly regarding hydrophobic drugs, since 
hydrophilic molecules may suffer a great leakage towards the hydroalcoholic bath.  
 
3.5 Conclusion 
In the present work, a novel manufacturing method to produce PLA MCs using non toxic chemicals was 
developed. MCs were generated from EtLac solution droplets obtained by break-up of the polymeric solution 
due to coflowing gaseous nitrogen. In such a configuration, tuning solution dispensing rate and polymer 
concentration were found to be effective in modifying and controlling the size of the produced particles. The 
proposed method is versatile enough to be adapted to other droplet generation dispensing methods in order to 
achieve different ranges of particles size and monodispersity. The obtained MCs display a macroporous inner 
structure and a compact surface, due to non-solvent penetration into the drop, liquid-liquid demixing, 
nucleation and growth of the polymer lean phase. By this method, MCs with Janus surface with a smoother 
and wrinkle-patterned hemisphere were obtained. As a consequence of the polymer precipitation mechanism, 
the MCs produced from EtLac solution and NIPS can be suitable for encapsulation of bioactive compounds 
that, according to their solubility, degree of hydrophobicity and solvent compatibility profiles, may be loaded 
from different components of the precipitation strategy. With the proposed method, we were able to obtain 
PLA MCs with potential applications in cell and drug delivery. Finally, this method gives a proof-of-concept 
of the possibility to process PLA with ethyl lactate, which may be of more general interest to manufacture 
the polymer for other types of application, such as membranes for separation technology and films for 
packaging purposes.  
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Chapter 4 
 
Preparation of PLGA nanoparticles functionalized with DNase I to 
target biofilm extracellular matrix  for advanced antibiotic delivery  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In this chapter, nanoparticles made with biodegradable poly(lactic-co-glycolic acid) were 
produced, using a technique derived from the green solvent-based processing approach explored in 
the previous chapter. The nanoparticles were studied as drug delivery devices for the treatment of 
bacterial biofilm infections. For this reason, the antibiotic drug ciprofloxacin was encapsulated, 
and the nanoparticles tested against P. aeruginosa. In order to endow the NPs with advanced 
functionality to enhance their antibiofilm potential, a surface coating with DNase I was applied and 
evaluated. 
  
This work was developed in collaboration with the “Bacterial infections: antimicrobial therapies” 
group (Institute for Bioengineering of Catalonia, Spain) lead by Dr. Eduard Torrents.  
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4.1 Introduction 
Micro- and nanocarriers, such as polymeric particles [1], liposomes [2], and hydrogels [3], including 
polymeric biodegradable nanoparticles (NPs) made of PLGA, have been studied to treat bacterial infections 
due to their potential to encapsulate and deliver therapeutic compounds in a sustained fashion. A wide array 
of methods to fabricate such NPs is available, and most of them are easy to scale-up [4], and allow the 
encapsulation of several compounds having different chemical and physical properties. PLGA has tunable 
degradation profile which allows controlling the release kinetics of loaded drugs [5]. Additionally, PLGA 
has already been FDA approved for several biomedical devices. All these features are especially important, 
in order to make easier the translation of drug-loaded PLGA NPs to the clinical practice, as both regulatory 
and technical limitations at scaling-up are major bottlenecks in the traslation from the bench to the bedside 
[6]. Persistent bacterial infections are becoming a major burden to the healthcarte system. The use of PLGA 
NPs which display a controlled releae of the antimicrobial drug may help to treat these infections. 
P. aeruginosa is the major cause of nosocomial infections in humans and is frequently associated with 
chronic pulmonary infections. It is also one of the main actors in chronic obstructive pulmonary disease 
(COPD) and cystic fibrosis (CF), where it is the principal cause of morbidity and mortality for patients [9]. 
The establishment of chronic Pseudomonas infections correlates with the formation of a biofilm, a structure 
with clusters of cells encapsulated in an extracellular polymeric matrix. In such an environment, bacteria are 
more likely to resist to antibiotic treatments, as most drugs do not freely diffuse into the biofilm and thus do 
not reach optimal therapeutic concentrations [10]. Additionally, bacteria in biofilms display a different 
physiology compared to planktonic cells –such as a diminished metabolic rate, as well as improved cell to 
cell communication-, which makes antibiotics less effective and increases the chance of development of 
resistances [11]. Moreover, the emergence and increasing prevalence of bacterial strains that are resistant to 
available antibiotics demand the discovery of new therapeutic approaches [12]. 
PLGA NPs can be properly designed in terms of size to penetrate airway mucus, avoid steric inhibition by 
the dense mucin fiber meshes, and can hide chemical properties of the encapsulated drug (e.g., charge, 
degree of lipophilicity) in order to reduce its unspecific interactions with the biofilm surrounding the target 
bacteria [13]. Therefore, NPs can provide a temporal control on release kinetics and enhanced efficacy of 
loaded compounds [14]. Although these properties make antibiotic-loaded PLGA NPs suitable devices to 
treat bacterial infections, advanced delivery strategies are necessary to achieve biofilm infections eradication. 
Besides the bacterial cells, the biofilm matrix itself can be an additional target for anti-biofilm treatments. In 
fact, unlike the bacterial cells, the extracellular substance is highly exposed to the environment and often has 
a porous structure [15-17]. Biofilm matrix is mainly composed by proteins, polysaccharides chains, and 
extracellular DNA (eDNA). Recent studies have pointed out how the latter is a key factor in biofilm 
formation, structural stabilization, and pathogenicity, acting as a matrix crosslinker and chelator of cataionic 
antimicrobial agents and participates in the events that can trigger the insurgence of antibiotic resistance 
[17]. These findings lead to the development of treatments of cystic fibrosis patients with lytic enzymes like 
deoxyribonuclease (DNase), in the form of aresols, which have been proven successful at reducing mucus 
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secretion viscoelasticity and thus their clearance [18]. Fabrication of smart drug delivery devices, capable not 
only to control antibiotic release, but also to interact with and harm directly the biofilm extracellular matrix, 
and particularly its DNA component, can constitute a fundamental advance in treating persistent infections 
such as those associated with cystic fibrosis. Co-treatment with antimicrobial agents and DNase, may in fact 
enhance biofilm removal and, at the same time, improve the diffusional rates of antibiotic into biofilm, thus 
increasing the elimination of colonized bacterial cells. 
The aim of this study is to assess the potential of functionalized and drug loaded PLGA NPs in the treatment 
of P. aeruginosa infections. PLGA-NPs were obtained and loaded with the fluorquinone antibiotic 
ciprofloxacin (CPX) through a fabrication method involving non-toxic chemicals. Different surface coatings 
were applied to the NP, to modify the material and to tune the interaction with biofilm matrices. In this way, 
negatively charged NPs and poly-L-lisine coated NPs were produced, in order to study the effect on the 
antimicrobial activity of released ciprofloxacin of their passive (via surface charge) interactions with 
planktonic bacteria and biofilm. Novel NPs functionalized with DNase I were investigated in order to 
combine controlled drug release with an active ability of inducing direct degradation of the biofilm matrix. 
 
4.2 Material and methods 
4.2.1 Preparation of nanoparticles 
Poly(lactic-co-glycolic) acid (Purasorb PDLG 5010, Purac, the Netherlands) nanoparticles were prepared 
using a novel, non-toxic chemicals-based methodology, derived from the nanoprecipitation technique [19]. 
PLGA was dissolved in (–)-Ethyl-L-lactate (photoresist grade; purity = 99.0%; Sigma-Aldrich, Spain), to 
form a 1.5 % w/v solution. The solution was loaded into a syringe, mounted on a syringe pump and 
dispensed dropwise (50 mL h-1) into a water bath, provided with 0.3 % w/v of poly(vinyl alcohol) (80% 
hydrolyzed, Mw
 
 = 9000 – 10000 Da, Sigma-Aldrich, Spain), under moderate stirring. The nanoparticles were 
left to stir for 1h at room temperature, and then recollected by three cycles of ultracentrifugation (11500 rpm, 
15 minutes, 4°C) and resuspension in MilliQ water. Eventually, the nanoparticles suspension was flash 
frozen in liquid nitrogen, freeze-dried and stored at -20°C until used. Several compounds were added to the 
polymer phase and the water phase in order to obtain NPs with different properties, as described in Table 4.1. 
Table 4.1: Composition, encapsulation efficiency and overall properties of drug loaded nanoparticles. 
 Coating 
DNase activity 
[µg DNA/mg 
NPs/1h] 
CPX 
content 
[w/w %] 
Size 
[nm] 
Size 
PDI 
Z-potential 
[mV] 
PLGA-CPX - - 0.26 213.6 0.085 -12.9 ±11.20 
PLGA-PL-CPX PL - 0.24 272.5 0.101 +33.5 ± 5.99 
PLGA-PL-CPX-DNase 
PL  
DNase I 
26.2  0.17 251.9 0.122 +28.9 ± 1.43 
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To load ciprofloxacin (CPX, ciprofloxacin base, Sigma-Aldrich, Spain) into the nanoparticles, 700 µg mL-1 
were added to the polymer phase and the water bath was saturated with 50 µg mL-1 of antibiotic. Poly(L-
lysine) coated nanoparticles were obtained by addition to the water phase of 70 µg mL-1 poly(L-lysine) (PL, 
Mw = 70000 – 150000 Da, Sigma-Aldrich, Spain). Finally, PL-coated nanoparticles, were modified by 
covalently grafting deoxyribonuclease I from bovine pancreas (DNAse I) (Sigma-Aldrich, Spain) to the ε-
aminogroups of the PL adsorbed onto the nanoparticles surface. Immediately after the nanoparticles 
formation, ethyl(dimethylaminopropyl) carbodiimide (Acros Organics, Belgium) and N-hydroxysuccinimide 
(Sigma-Aldrich, Spain) (EDC/NHS) were added to the water bath to obtain a 0.1/0.2 M solution. 
Subsequently, 100 µg mL-1
 
 DNAse I were added to the nanoparticles suspension and were stirred for 30 
minutes. Cycles of ultracentrifugation and washing steps were performed in order to remove the unreacted 
chemicals and water-soluble by products. NPs yield was quantified by measuring the weight of the dry 
particles mass after lyophilization and normalized against the mass of PLGA dissolved into ethyl lactate at 
the beginning of the fabrication process. 
4.2.2 Nanoparticles characterization 
Lyophilized NPs were reconstituted in MilliQ water by sonication and their size and surface charge were 
measured using a ZetaSizer NanoZS (Malvern Instruments, UK). Nanoparticles suspension were loaded in a 
standard quartz cuvette to be analyzed by Dynamic Light Scattering (DLS) for size determination or in a 
flow cell cuvette for Laser Doppler Velocimetry (LDV) assays, used to measure the zeta potential of the 
particles (n=5). A morphological characterization of the nanoparticles was carried out using Field Emission-
Scanning Electron Microscopy (FE-SEM, Hitachi S-4100, Japan). To prepare the sample for the analysis, a 
drop of a concentrated nanoparticles suspension was deposited on clean glass coverslip, mounted on a metal 
stub and water was left evaporate. The dried particles were then coated with carbon. 
 
4.2.3 Drug encapsulation and in vitro release 
To quantify the amount of antibiotic encapsulated, 5 mg of dried ciprofloxacin-loaded nanoparticles were 
fully degraded into 0.5 M NaOH, in order to hydrolyze the PLGA. The resulting solution was analyzed with 
UV-vis spectroscopy to detect ciprofloxacin absorbance peak at 280 nm.  
In vitro release kinetics of ciprofloxacin was assessed using a High Performance Liquid Chromatography 
(HPLC, Waters e2695, USA). A known amount of nanoparticles was suspended in PBS and loaded into a 
Slide-A-Lyzer Dyalisis Cassette, MWCO 2000 Da (Thermo Scientific, Spain). The cassette was immersed in 
30 mL PBS and left at 37°C. 500 µL aliquots of PBS were taken at any given time point, and stored at 4°C 
until HPLC analysis. After every time point, 500 µL of fresh PBS was added to maintain the sinking volume. 
Samples (n=3) were run through a C18 stationary phase (Sunfire C18 5µm column, Ireland), and the mobile 
phase consisted of a mixture of 900 mL 0.5% v/v acetic acid in milliQ water, 50 mL of acetonitrile and 50 
mL of methanol. The elution peak was detected with a photodiode array system (Waters 2998, USA), 
monitoring ciprofloxacin absorbance peak at 280 nm. Antibiotic quantification was then carried out using a 
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proper standard curve and calculating the area below the elution peak, using the Origin 8.0 software 
(OriginLab Corporation, USA). 
 
4.2.4 Quantification of DNase I activity containing NP 
 
50 µg of DNase I-containing NPs were added to a 400 ng DNA plasmid pGEM-T (Promega, Spain) in water. 
A control consisting of DNA alone (400 ng in water) and NPs with no DNase (50 µg in water) were also 
tested. After incubation 30 minutes at 37 °C the mixtures were loaded onto a 0.8 % TAE agarose gel, stained 
in ethidium bromide and visualized under UV light (Gel DocTM XR+, Bio-Rad Laboratories, Spain). DNase 
I activity was calculated by quantification of DNA degradation using Quantity One software package (Bio-
Rad Laboratories).   
4.2.5 Bacterial Strain and growth conditions 
Wild-type Pseudomonas aeruginosa PAO1 strain CECT 4122 (ATCC 15692) was obtained from the Spanish 
Type Culture Collection (CECT). The strain were stored at −80°C as glycerol stocks. To obtain inocula for 
examination, the strain was cultured overnight on LB (Pronadisa, Spain) medium for P. aeruginosa at 37°C. 
Cells were then harvested by centrifugation (8,000 × g for 10 min). Bacterial growth was measured by 
reading absorbance measurements (OD550
 
). 
MICs were determined by a microtiter broth dilution method as described by Cole et al. [
4.2.6 Minimal inhibitory concentration (MIC) assays 
20] and modified by 
Beckloff et al. [21]. In brief, 100 μL of bacteria at a density of 5 × 105 CFU mL-1 in Mueller-Hinton broth 
(BD Biosciences) were inoculated into the wells of 96-well assay plates (tissue culture-treated polystyrene; 
Costar 3595, Corning Inc., Corning, NY). Different concentrations of nanoparticles were added to each well, 
in order to achieve an equivalent amount of encapsulated CPX of 0.0078, 0.0156, 0.03125, 0.0625, 0.125, 
0.25, 0.5, or 1 μg mL-1. The microplates were incubated at 37°C at 150 rpm for 12 h in an Infinite 200 Pro 
microplate reader (Tecan) and every 15 minutes an absorbance measurement at OD550
 
 was performed.  
The minimum biofilm eradication concentration (MBEC) physiology and genetic assay (MBEC BioProducts 
Inc., Edmonton, Alberta, Canada) was previously described by Ceri et al. [
4.2.7 NPs activity against P. aeruginosa biofilm   
22]. In brief, P. aeruginosa 
suspension (200 μL, 5 × 105 CFU mL-1) was inoculated into the wells of an MBEC device, together with 
increasing concentrations of NPs or free soluble CPX. The peg lids were then inserted into the microplates 
containing the inocula (Figure 4.1). Microplates were incubated at 37ºC for 24 h. The peg lids with biofilm 
were rinsed twice with PBS (by placing the lid in a microplate containing 200 μL of PBS in each well) to 
remove loosely adherent planktonic cells, and cells forming biofilms were recovered by centrifugation. Serial 
dilutions of recovered cells were plated in LB or TSB agar plates and colony-forming units were counted. 
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To evaluate the effect of NPs functionalized with DNase I against already established biofilms, the same 
procedure explained above was followed, apart that the bacteria inoculum was cultivated in absence of NPs. 
After this step, the peg lids with biofilm were then transferred to 96-well assay plates (tissue culture-treated 
polystyrene; Costar 3595) containing 200 μl of Mueller-Hinton broth (BD Biosciences) supplemented with 
different concentrations of positively charged NPs, or free soluble CPX and DNase I as a control (to make up 
for an equivalent concentration of CPX of 0.0078, 0.0156, 0.03125, 0.0625, 0.125, 0.25, 0.5, or 1 μg mL-1
To assess the capability of NPs to eradicate established biofilms after repeated administration of the 
treatment, the biofilm assay was also repeated. Biofilms were let maturate for two days. After that, the 
culture period was extended up to 3 days, and every 24 hours the culture medium was removed and refreshed 
with medium supplemented with a dose of NP-CPX formulation. Every day, samples were analyzed as 
explained above, to quantify the number of biofilm forming cells. 
). 
These plates were incubated at 37°C for another 12 h. Subsequently, the peg lids were rinsed twice with 
0.9% saline, and cells forming biofilms were recovered by centrifugation. Serial dilutions of recovered cells 
were plated in LB or TSB agar plates and colony-forming units were counted.  
 
Figure 4.1: Scheme of the experimental set up for biofilm formation on the peg lid. 
 
 
4.2.8 NPs cytotoxicity 
Macrophage cells (murine cell line J774, ATCC) were seeded into 96-well tissue culture plates (6x104 per 
well) in culture medium without antibiotics, supplemented with different concentration of nanoparticles, or 
left untreated. Cell viability was assessed by using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) colorimetric assay (Sigma-Aldrich, Spain). After, 24 and 48 hours of exposure to the 
different compounds, culture supernatants were removed and 10% of MTT in complete medium was added 
to each well and incubated for 3 hours at 37ºC. Then, water-insoluble formazan salt was dissolved by adding 
acidic isopropanol. Absorbance was measured at 550 nm (Infinite M200 Microplate Reader, Tecan).  
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4.2.9 Statistical Analysis 
Values are expressed as mean ± Standard Error of the Mean (SEM) or median of three to five replicates (n=3 
to 5). Statistical analyses were performed using GraphPad Prism 4.00 (GraphPad Software, San Diego, CA, 
USA) software package. Single comparisons were performed by unpaired Mann-Whitney test. Correlation 
analyses were performed using non-parametric correlation Spearman test. A value of p<0.05 was considered 
as statistically significant. 
 
 
 
4.3 Results 
 
4.3.1 Preparation of nanoparticles  and drug  encapsulation  
NPs with spherical shape (as shown in Figure 4.2) were fabricated using a modification of the 
nanoprecipitation method, and their physical characteristics are listed in Table 4.1. The NPs final yield was 
96.3 ± 1.7% of the total polymer mass at the beginning of the fabrication protocol. The average diameter 
ranged between 200 and 300 nm, with a narrow, monodisperse, size distribution (PDI values between 0.085 
and 0.122). The Z-potential of the NPs varied accordingly to the type of surface coating applied. When PVA 
was the only additive in the coagulation bath, negatively charged NPs were obtained (approx. -13 mV), 
whereas addition of PL generated positively charged particles (+30 mV). Functionalization with DNase, had 
no significant effect on the overall surface charge. For all NPs formulation, CPX encapsulation efficiency 
was low, and the average drug content in the carriers varied between 1.7 (for PLGA-PL-DNase-CPX) and 
2.6 µg mg-1 
 
of NPs (for PLGA-CPX). DNase I grafted on PL coated NPs retained its DNase activity, as 
quantified by gel electrophoresis, with 1 mg of functionalized NPs being able to degrade 26.2 µg of DNA in 
1 hour (Figure 4.3). 
4.3.2 In vitro release of ciprofloxacin 
Negatively and positively charged (both PL and PL-DNase coating) NPs presented a burst release in the first 
hour, upon suspension in PBS, when between 40 and 50% of the total CPX load is released (Figure 4.2). 
After this period, the drug release is slower, and negatively charged NPs end up depleting their drug amount 
within 12 hours. Positively charged NPs showed a steady release of the remaining antibiotic, and after 12 
hours PL and PL-DNase coated NPs delivered respectively about 60 and 80% of the loaded ciprofloxacin.  
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Figure 4.2: CPX release profile and SEM micrographs of (A, B) uncoated, (C, D) PL-coated and (E, F) 
PL-DNase I functionalized NPs. 
 
 
0
20
40
60
80
100
0 400 800 1200 1600
C
um
ul
at
iv
e 
re
le
as
e 
[%
]
Times [minutes]
PLGA
0
20
40
60
80
100
0 400 800 1200 1600
C
um
ul
at
iv
e 
re
le
as
e 
[%
]
Times [minutes]
PLGA-PL-DNase
0
20
40
60
80
100
0 400 800 1200 1600
C
um
ul
at
iv
e 
re
le
as
e 
[%
]
Times [minutes]
PLGA-PL
A
C
E F
D
B
114 
 
 
Figure 4.3: Degradation of a DNA plasmid by DNAse and PLGA-PL-DNase NPs. 
 
4.3.3 Minimum inhibitory concentrations (MICs) 
The MICs of different ciprofloxacin formulations (alone and encapsulated) are given in Table 4.2. 
Negatively charged PLGA-CPX worked better against P. aeruginosa, when compared to free-soluble CPX. 
The MIC was 0.39 µg mL-1 for soluble CPX, 0.0625 µg mL-1 for PLGA-CPX, 0.5 µg mL-1 for PLGA-PL-
CPX and 0.5 µg mL-1 for PLGA-PL-CPX-DNase (equivalent total dose of CPX). Considering the drug 
release kinetics, at the end of the MIC assay (12 h), only a portion of encapsulated  drug has been effectively 
released in the bacteria culture media. The effective MICs for the NPs, as corrected considering the release 
profiles are 0.0625 µg mL-1 for PLGA-CPX, 0.29 µg mL-1 for PLGA-PL-CPX, and 0.35 µg mL-1
 
 PLGA-PL-
CPX-DNase I. NPs with no drug encapsulated showed no antimicrobial effect.  
Table 4.2: Minimal inhibitory concentrations of soluble and encapsulated ciprofloxacin. 
 
 MIC (ciprofloxacin- µg mL-1) 
P. aeruginosa PAO1 
ATCC 4122 CPX PLGA-CPX 
PLGA-PL-
CPX 
PLGA-PL-
CPX-DNase I 
CPX total equivalent 
dose 0.39 0.0625 0.50 0.50 
CPX release at 12h 0.39 0.0625 0.29 0.35 
 
 
4.3.4 Antibiofilm activity of CPX loaded NP 
All formulations, including free-soluble CPX resulted effective to reduce biofilm formation, starting from the 
lower drug concentration (0.0078 µg mL-1) (a reduction between 80 and 90% of the cell content in the 
biofilm, compared to the untreated control), and complete prevention of biofilm formation was achieved with 
higher concentrations of drug and NPs (between 0.125 and 0.5 µg mL-1
 
) (Figure 4.4). 
1. Control
2. PLGA  NPs and DNase
3. PLGA-PL-DNase
2 31
Plasmid →
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Figure 4.4: Degree of biofilm formation for different NPs formulations. 
 
Treatment with DNase and CPX was found to be effective against already formed biofilms (Figure 4.5). The 
samples with no DNase, PLGA-CPX and PLGA-PL-CPX NPs, were less effective on biofilms, being able to 
reduce bacterial cells respectively by 10 to 50 and 30 to 55%, in a concentration-dependent fashion. The 
combination of DNase and CPX lead to a decrease between 85 and 95% (comparable for free soluble 
molecules, and PLGA-PL-DNAse NPs without CPX, but mixed with PLGA-PL-CPX NPs). PLGA-PL-CPX-
DNase I NPs that carry both the antibiotic and the enzyme showed the best results, reducing bacterial cells 
by 95% at the lower concentration and by more than 99% at the highest. 
 
 
Figure 4.5: Effect of DNase and DNase-functionalized NPs on already established biofilms. 
 
Multiple administrations of NPs (one dose/day, up to three days) were also tested against established 
biofilms (Figure 4.6). PLGA-CPX were effective starting from 0.03125 µg mL-1 of equivalent concentration 
of encapsulated CP. At the highest concentration and at the end of the three days treatment a 90% reduction 
of the bacterial cells was observed. PLGA-PL-CPX worked better against P. aeruginosa biofilms, 
eliminating between about 80 and 96% (for the lowest and the highest drug concentration respectively) of the 
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bacterial cells at the end of the 3 day treatment. NPs with DNase I gave the best results, eliminating by the 
third day from 90 to 99.9% of the bacteria forming the biofilm. 
 
 
 
Figure 4.6: NPs 3-days treatment on established biofilms. (A) PLGA-CPX, (B) PLGA-PL-CPX, and 
(C) PLGA-PL-CPX-DNase I. 
 
 
4.3.5 Cytotoxicity 
Cytotoxicity was evaluated for PLGA-CPX, PLGA-PL-CPX and PLGA-PL-CPX-DNase I nanoparticles 
(Figure 4.7). No relevant cytotoxic effect was observed, although some NPs formulations showed a slight 
reduction in macrophages metabolic activity. Compared to macrophages cultured with no NPs, metabolic 
levels measured in presence of NPs after 24 hours were slightly lower (between 70% for PLGA-PL-CPX-
DNase and 85% for PLGA-PL-CPX). At 48 hours, in all the experimental groups an increment in the 
metabolic activity could be observed, possibly indicating cell proliferation. Furthermore, samples 
conditioned with NPs showed a significant improvement in metabolic activity, which became more similar to 
that of the NPs-free controls (between 76% for PLGA-PL-CPX-DNase and 90% for PLGA-CPX and PLGA-
PL-CPX). 
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Figure 4.7: Cytoxicity assessment of CPX loaded (A) PLGA, (B) PLGA-PL and (C) PLGA-PL-DNase I 
NPs (MTT assay). 
 
 
4.4 Discussion 
In this work, PLGA NPs encapsulating the antibiotic ciprofloxacin have been prepared using a green solvent-
based method. The size of the obtained particles falls in the typical range to diffuse in the mucus pores in 
chronically infected lungs (between 200 and 500 nm) [23]. Untreated, polylysine, and polylysine-DNase I 
coated NPs were produced, characterized and tested in vitro for their capability to treat established biofilm of 
P. aeruginosa. 
The polymeric nanoparticles were fabricated using a modification of the nanoprecipitation method, starting 
from a PLGA-ethyl lactate semi-diluted solution. As the polymeric solution drops enter the water medium, 
they are quickly broken by eddies generated surface tension gradient between the solvent and the non-
solvent, and nanoparticles are immediately formed by solvent displacement and interfacial deposition of the 
PLGA [24]. Typically, NPs with monodisperse size distribution can be obtained with such method, as it is 
confirmed by the DLS measurements. As a downside, it is best suitable to encapsulate hydrophobic 
compounds (with very high efficiencies [25]), since hydrophilic molecules are easily dispersed into the water 
phase during the particle formation, and even though approaches to improve the encapsulation of hydrophilic 
drugs have been studied, they lead to limited improvement of encapsulation efficiencies [26]. This is 
confirmed by our results, showing a quite low CPX loading, despite of working at neutral pH, where CPX 
displays its minimum solubility in water [27], and are consistent with what has already been reported in 
literature in relation to encapsulation of fluoroquinone antibiotics [28]. Addition of hydrophilic moieties to 
the NPs formulations, such as lechitin or pluronic, has also been suggested to improve efficiency [13], but 
preliminary tests performed in our case did not improve the amount of encapsulated drug (data not shown). 
A consequence of low loading of hydrophilic molecules is their tendency to accumulate at the NPs surface. 
As a consequence, this mode of entrapment usually leads to a burst release of the drug in the first hours, due 
to the compound being washed off the particle [29], as also seen in the CPX release profiles described in this 
study (Figure 4.2). A fast burst release, followed by a sustained release is preferred, in the case of antibiotics 
in biofilms, since this can help preventing the insurgence of antibiotic tolerance of the surviving biofilm [28, 
A B C
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30]. However, PLGA-CPX NPs quickly depleted their antibiotic load, unlike PL-and PL-DNase I coated 
NPs. In the two positively charged NP types, the polycationic PL may have helped to stabilized the NPs and 
interact ionically with the antibiotic, reducing its rate of removal from the NPs [31]. These differences in the 
release kinetics may have an implication in the determination of the MICs for encapsulated CPX against 
P.Aeruginosa.  Encapsulated antibiotic tend to have a higher efficacy against planktonic cells compared to 
free drug, especially negatively charged PLGA-CPX NPs, although no appreciable difference is shown 
regarding the capability of preventing biofilm formation. NPs advantage consists in treating established 
biofilms, such as those in persistent lung infections [32,33,34], where properly designed NPs can penetrate 
the biofilm porous matrix and provide high local concentrations of antibiotics in the proximity of bacterial 
cells. Ideally, NPs should be able to diffuse homogenously through the target biofilm, and their ability to 
penetrate the biofilm matrix depends on their size and surface chemistry. Forier et al., have demonstrated on 
model polystirene NPs systems that both positively and negatively charged NPs bind into biofilms, and 
suffer an equal reduction in diffusion velocity [35]. Positively charged NPs were found to be bound to wire-
like components, possibly biofilm polymers and eDNA, while negatively charged NPs, were bound in the 
proximity of bacterial cells, probably due to hydrophobic interactions. Although some researchers have 
proposed non-fouling, PEG-coated particles in streategies to enhance carriers mobility [36], NPs 
functionalized with mucolytic agents hold the promise to improve the distribution of antibiotics into 
biofilms, while increasing biofilm eradication. In the work developed in this thesis, combination of CPX and 
DNase I on PLGA NPs was shown to be an effective strategy to target established P. areuginosa biofilms. 
While PLGA-CPX and PLGA-PL-CPX NPs alone showed a good extent of biofilm eradication, antibacterial 
activity of CPX was greatly improved in presence of DNase I (Figures 4.5 and 4.6). Free-soluble and CPX 
and DNase I showed comparable activity to PLGA-PL-CPX NPs combined with PLGA-PL-DNase I with no 
drug encapsulated NPs. This is due to an improved mobility of NPs, as the enzyme is actively degrading the 
eDNA of the biofilm matrix, as also indicated by Messiaen et al., who have found 10-times improved 
diffusional rates of charged polymeric NPs in biofilm, in presence of DNase [37]. Moreover, greater results 
were obtained when NPs bearing both CPX and DNase I at the same time were used (PLGA-PL-CPX-DNase 
I), even at lowest CPX concentrations and with a single application, suggesting that drug delivery-ECM 
degrading NPs may penetrate better into the bacterial colony, and better harness its integrity. This result is 
even more important when considering a longer treatment of the infection, as repeated administration of this 
NPs formulation up to 3 day, bacteria reduction was steadily improved with no sign of tolerace arising. 
Moreove, at the higher concentrations, PLGA-PL-CPX-DNase I NPs were even able to eradicate the 
established biofilm. Cytoxicity of the NPs at the used doses was very low, and although slightly higher for 
PLGA-PL-CPX-DNase I, for all NPs formulation, macrophage cells had their metabolic activity increased 
during the second day of culture, indicating they were proliferating, which is an indicator of cells health [38]. 
This data, together with other reassuring results regarding PLGA NPs cytocompatibility [39, 40], supports 
the feasibility of the proposed drug delivery approach. 
  
119 
 
4.5 Conclusions and future perspectives 
In this work, CPX-loaded PLGA NPs were successfully prepared using a method involving no harmful 
chemicals. These NPs have adequate size for antibiotic drug delivery to biofilms located in the airways, and 
also display a profitable drug release profile for this specific application. However, CPX loading was quite 
low, and further refinement of the fabrication parameters would be required to improve encapsulation 
efficiency. The proposed NPs could be employed as a platform for chemical modification and to test the 
efficacy of functionalization with active DNase I. Coating the NPs with polylysine enriched the carriers with 
chemically reactive groups, enabling a simple way to functionalize them. Enzyme-linked NPs, able to 
degrade P. aeruginosa biofilm ECM, were successful at improving antibacterial potential of the encapsulated 
drug and to achieve biofilm eradication. These results allow obtain novel, antibiofilm-active drug delivery 
devices and to apply the proposed approach to more type of carriers and antimicrobial compounds 
combination, to treat persistent bacterial infections. 
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Chapter 5 
 
Cell delivery from functionalized polylactic acid microcarriers tuning 
MSCs migratory behavior in response to chemokine stimulation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In this chapter, microcarriers produced following the fabrication method described in chapter 3 are 
characterized as cell carriers for mesenchymal stromal cell therapy. The surface of the 
microcarreries is modified with different approaches to introduce bioactive coatings, and the effect 
of these coatings over cell homing, adhesion, proliferation, expression of CXCR4 -a receptor 
involved in chemokine-dependent migratory pathways-  and cell migration in response to SDF-1α 
stimulation are studied.  
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5.1 Introduction 
One of the most challenging limitations in cell therapy is poor cell survival upon transplantation, since more 
than 90% of the therapeutic cell population dies in the first days after intravenous or direct injection [1]. 
Moreover, the limited amount of surviving cells suffers of poor tissue localization, because biological fluids 
can easily disperse them from the desired site [2]. This massive cell death can occur for mechanical damage 
during the injection, but also for the environmental stress imposed by the target tissue, since injected cells are 
usually required to attach, home and survive in injuried tissues, that can be ischemic, highly inflamed and 
even necrotic [3]. The use of biomaterial carriers can dramatically increase anchorage-dependent cells 
viability and engraftment in host tissues, by providing mechanical support, homing and pro-survival cues. As 
reviewed in Chapter 2, several injectable biomaterials, such as in situ-forming hydrogels [4] or microcarriers 
[5] have been proposed to deliver differentiated and progenitor cells, including Mesenchymal Stromal Cells 
(MSCs) [6]. However, cell survival and engraftment alone may not be sufficient for clinical applications, 
since cells are often required to migrate and localize at specific sites throughout the target tissues, in order to 
express their therapeutic activity.  
The use of MSCs for cell therapies has received a lot of attention due to the ability of these cells to 
differentiate towards several phenotypes, exert immunomodulatory activity and secrete paracrine factors [7]. 
Furthermore, MSCs can migrate towards damaged tissues in a specific manner, and thus can act as vehicles 
to deliver therapeutic agents to organs whose surgical treatment is not always possible. For example, MSCs 
transplanted to treat myocardial infarction, can localize to the ischemic heart, and improve its function via 
bystander effects [8]. Moreover, MSCs have been used to target tumoral cells in aggressive gliomas. It has 
been shown that, in the brain, MSCs are recruited to the forming tumor vascular network, and then spread 
into the main tumor mass. At the same time, they can also track satellite glioma cells in process of invasion, 
and associate with them with great accuracy [9]. To exploit this capability, MSCs have been engineered to 
deliver tumor-killing agents, able to effectively reduce glioma mass in an animal model [10].  
This MSCs specific migration occurs in response to chemokines expressed by the pathological tissue. 
Among these signals, a major role is played by Stromal cell-Derived Factor 1α (SDF-1α, or CXCL12), which 
is a potent chemotactic agent for MSCs, and is also secreted by ischemic and tumoral tissues [8, 11]. 
Additionally, the recognition of SDF-1α by its receptor, CXCR4, triggers a cascade of pro-survival and 
homing responses [12], and MSCs (as well as immature osteoblasts) continuously secrete SDF-1α, 
presumably to keep themselves in their niche [13]. CXCR4 and SFD-1α are fundamental in physiological 
tissues, and their knock outs are lethal, resulting in severe bone marrow failure and abnormal development of 
the heart and brain [14, 15]. In this context, the SDF-1α/CXCR4 axis became a promising target for 
regenerative medicine approaches aiming cardiac, nervous and osteochondral tissue repair [16]. A variety of 
studies have been conducted to fabricate SDF-1α controlled delivery devices able to induce progenitor cells 
recruiting for tissue engineering [17, 18], as well to improve CXCR4 expression in MSCs, in order to 
increase viability, migration and regenerative potential, e.g.  for cardiac cell therapy [19] and angiogenesis 
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[13]. Along with these strategies, biomaterials are still deemed necessary for cell delivery. Therefore, it is 
important to design biomaterial carriers not only to retain seeded cells, but also to act as reservoirs from 
which cells can migrate, possibly in a temporally-controlled manner. Even though the study of cell-materials 
interactions is a fundamental aspect of tissue engineering, it is still unclear how to tune biomaterials 
properties to control cell responsiveness to cytokines stimulation. Furthermore, there is no report about how 
common biomaterials engineering strategies, such as surface modification, can influence key cell migratory 
pathways. A deeper understanding of such relationship would provide fundamental hints to improve cell 
delivery devices design.  
The aim of this work is to characterize polylactic acid microcarriers as vehicles for cell homing and delivery, 
and to evaluate their effect on MSCs migratory potential. Polylactic acid Microcarriers (MCs) design was 
studied to discern how to target SDF-1a/CXCR4 axis via surface functionalization strategies, and thus exert a 
control over cell release. Herein, the effect of several MCs functionalization approaches on MSCs viability, 
release and migration in relation to SDF-1α/CXCR4 axis were studied in vitro. Collagen and RGD peptide-
modified MCs were compared to evaluate coatings having different nature -long extracellular matrix (ECM) 
protein vs. short functional sequence-. The biomolecules were introduced either via covalent grafting or 
simple physisoprtion, in order to assess also the role of the stability of the coating on cell delivery potential. 
 
 
5.2 Materials & Methods 
5.2.1 Materials 
Poly(lactic acid) (Purasorb PLDL 7038, inherent viscosity midpoint 3.8 dL / g-1, Mw ≈ 850 000 Da) was 
purchased from Purac. (-)-Ethyl L-lactate (purity > 99.0%) was obtained from Fluka and used without further 
purification. Glass microcarriers beads, poly(vinyl alcohol) (PVA, 30–70 kDa, 88% hydrolyzed) and all the 
other reagents were from Sigma-Aldrich, unless specified otherwise. 
 
5.2.2 MCs fabrication 
PLA MCs were prepared following a previously described in Chapter 3. Briefly, a 3.5 % w/v PLA solution 
in Ethyl Lactate was dispensed at 10 mL h-1
 
, and the formed droplets were collected into a coagulation bath, 
composed by 0.3% w/v PVA in 70 vol% ethanol. MCs were rinsed with deionized water, frozen in liquid 
nitrogen and lyophilized for 48 h. MCs were visualized with Scanning Electron Microscopy (SEM, Quanta 
Q200, FEI company) and their size, polydispersity and surface area were measured via electrical sensing 
zone technique (Coulter Counter Multisizer IIe, Beckman Coulter). 
5.2.3 MCs functionalization 
Surface modification of the MCs was carried out using a three step procedure [27]. First, MCs were 
immersed into a 50 mM NaOH solution for 10 minutes to induce hydrolysis of the PLA backbone and thus 
126 
 
enrich the MCs surface with carboxyl groups. After that, exposed COOH terminals were activated with a 
ethyl(dimethylaminopropyl) carbodiimide / N-hydroxysuccinimide  100 mM / 200 mM (EDC/NHS) solution 
in 70 vol% ethanol for 2 hours. Finally, biomolecules coatings were covalently attached to the MCs surface 
through amide bonds between the activated carboxyles and the amino groups from the target protein or 
peptide. For this purpose, human recombinant Collagen type I (FibroGen Inc., USA) or custom-made 
GGGGGGRGDS peptides (RGD, GenScript Inc., USA) were dissolved in PBS at a concentration of 100 µg 
mL-1 and incubated with the MCs for 24 hours. Functionalization via physisorption was carried out by 
simply immersing untreated PLA MCs into a 100 µg mL-1
Bicinchoninic acid assay (BCA assay, Thermo Scientific) allowed for the quantification of the grafted 
protein, following the protocol described by the manufacturer. The different experimental groups are 
summarized in Table 5.1. 
 solution of the desired biomolecule for 24 hours.  
 
Table 5.1: MCs modified with the different functionalization strategies analyzed in this study. 
Sample Biomolecule Type of coating 
PLA none none 
CC collagen covalent 
CP collagen physisorbed 
RC RGD peptide covalent 
RP RGD peptide physisorbed 
 
 
5.2.4 Isolation of mesenchymal stromal cells 
Mesenchymal Stromal Cells (MSCs) where isolated from long bones of 2-4 weeks old Lewis rats according 
to a previously decribed protocol [28]. Briefly, rats were anesthetized using 5% isoflurane and the sacrifice 
was performed through CO2 saturated atmosphere. Bone-marrow was obtained by flushing control medium 
(M199 supplemented with 20% Fetal Bovine Serum –FBS-, 1% Pyr, 1% Pen/Strep, 1% L-glu and 22 µg mL-
1 heparin) through the bone. The cell fraction was resuspended in control medium and plated in Petri dishes 
for 24 h. The adherent cell population was cultured in Advanced DMEM supplemented with 15% FBS, 1% 
Pen/Strep and 1% L-glu until reaching sub-confluence, and expanded into a T75 NunclonTM flask until 
passage 2. The acquired population of cells was highly enriched in Stro-1+, CD105+, CD44+, CD34-and 
CD45-
 
 MSCs. For all the experiments described in this study, cells between passage 4 and 6 were used. All 
the protocols concerning the animal care were previously approved by Committee on the Ethics and Animal 
Experiments of the Scientific Park of Barcelona (Permit number: 0006S/13393/2011). Cell expansion and 
experiments were carried out culturing MSCs in proliferation medium, consisting of Advanced DMEM, 
provided with 15% FBS, 1% Pen/Strep and 1% L-glu. 
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5.2.5 Cell culture assays 
Biological assays were carried out to describe the effect of surface modifications on cell adhesion, 
proliferation and migratory potential in response to specific chemoattractant stimulation.  
 
5.2.5.1 MSCs adhesion assay 
3 mg of the different MCs, previously disinfected by immersion in a 70 vol% EtOH solution, were placed 
into a well of an anti-adhering 24-well plate (Costar® Ultra Low-Attachment Cluster Plate, Corning Inc, 
USA) and let equilibrate for 2 hours in serum-free medium. 9 x 104 cells suspended in serum-free medium 
were seeded under static conditions in each well and placed in an incubator at 37 °C, 95 % relative humidity 
and 5 % CO2 partial pressure. Tissue Culture Polystyrene (TCPS) was used as control. In the first hour, 
every ten minutes the plate was gently shaken in order to facilitate an even distribution of the cells on the 
MCs. After 4 hours, the medium was removed and the MCs were washed with PBS to remove unattached 
cells.  Number of adhered and metabolically active cells was quantified using the alamarBlue® (Life 
Technologies) assay (n=4), following the instructions of the manufacturer. Briefly, the samples were 
incubated for 2h with adhesion medium provided with 10% v/v alamarBlue®. After this period, the 
reduction of resazurin to the fluorescent compound resorufin, due to cell metabolic activity, was analyzed 
(λex = 560 nm, λem
The degree of cell adhesion on the MCs was studied by means of immunofluorescence (n = 3). 4 hours after 
seeding, cell-laden MCs were collected, washed with PBS, fixed with paraformaldehyde (PFA) and 
permeabilized with Triton X-100. MC-MSCs complexes were incubated in a 3% w/v bovine serum albumin 
(BSA) in PBS-Gly as a blocking solution for 30 minutes. Nuclei were stained with 4',6-diamidino-2-
phenylindole (DAPI),  Actin cytoskeleton with phalloidin-rhodamine (Life Technologies). Vinculin was 
stained using a mouse anti-rat vinculin primary antibody (Life Technilogies) and with a goat anti-mouse 
secondary antibody conjugated to AlexaFluor 488 dye (Life Technologies). Images were taken with a 
confocal laser scanning microscope (Leica TCS SP5, Leica Microsystems). 
 = 590 nm).  
 
5.2.5.2 MSCs proliferation assay 
MCs preparation and seeding were performed as described for the adhesion assays; except that PLA 
untreated MCs were equilibrated in proliferation medium (supplemented with serum). For all the samples (n 
= 4), cell seeding was also performed suspending cells in proliferation medium. MSCs proliferation on the 
MCs was estimated using the alamarBlue® assay after 1, 3, 5, 7 and 14 days of static culture. Medium was 
replaced every 2 days. Cell quantification was carried out using a standard curve, referring to known 
amounts of cells seeded on TCPS. Immunofluorescence was used to qualitatively describe cell colonization 
of the MCs surface during the assay. MCs samples taken at day 1, 7 and 14 of culture were stained with 
DAPI and phalloidin-ActiStain 488 (Cytoskeleton Inc.). 
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5.2.6 CXCR4 expression analysis 
5.2.6.1 Immunofluorescence 
CXCR4 expression by MSCs was revealed by immunofluorescence in cell cultured on 2D surfaces (TCPS) 
and in 3D on MCs, both untreated and functionalized.  MSCs were cultured in proliferation medium for 24 
hours and then fixed with PFA and permeabilized with Triton X-100. BSA was used as a blocking agent. 
Rabbit anti-rat CXCR4 (Abcam) was used as a primary antibody, while the secondary antibody was a goat 
anti-rabbit conjugated with AlexaFluor 488 (Life Technologies). 
 
5.2.6.2 Flow cytometry 
MSCs pool expressing CXCR4 was determined with flow cytometry. Cells were cultured for 24 hours or 4 
days on the MCs (untreated PLA, functionalized and glass beads) and on 2D surfaces (TCPS, PLA films and 
collagen-coated PLA films) and then dissociated with 0.25 % trypsin-EDTA for 3 minutes at 37 °C. MSCs 
were also cultured for 24h on CC MCs and then retrieved and subcultured on 2D TCPS for 3 additional days. 
MSCs where collected and washed with a flow cytometry buffer (PBS, 1% bovine serum albumin and 1 mM 
EDTA). Staining of surface CXCR4 was performed using rabbit anti-rat CXCR4 as a primary antibody at 4 
°C in the dark for 30 minutes. The secondary antibody, a goat anti-rabbit conjugated with AlexaFluor 488, 
was applied for additional 30 minutes at 4 °C in the dark. Background staining was assessed by incubation of 
cells with rabbit isotypematched immunoglobulins (isotype controls). Flow cytometric analysis of MSCs was 
performed with a Gallios flow cytometer (Beckman Coulter). Signals from subcellular debris were 
eliminated during data acquisition by gating. The Summit v4.3 software package was used to process the 
data. Moreover, MCs without cells were filtered with a 90 µm sieve and analyzed. These MCs underwent the 
immunostaining procedure detailed above and were analyzed with the flow cytometer, in order to exclude 
false-positive signals.  
  
5.2.7 Migratory response of MSC to SDF-1α 
MSCs capability to migrate from the MCs upon chemotactic stimulation was assessed using a modified 
Boyden chamber assay (Figure 5.1). 3x104 cells were seeded on 1 mg of microcarriers and let adhere for 12 
hours. Cell-loaded MCs were moved to a 24-well Millicell®, hanging cell culture insert (Millipore) with a 
porous membrane (pore size 8 µm), already placed in a 24-well culture plate.  In order to simulate a tissue-
like 3D environment, the MCs were embedded in 100 µL of Matrigel (Growth Factor Reduced, phenol-red 
free, BD Biosciences) solution 1:1 in culture medium, and put in the incubator at 37 °C for 30 minutes to 
allow for Matrigel gelification. The lower well of the Boyden chamber was loaded with low-serum medium 
(LS) consisting of ADMEM with 0.5% FBS, L-glutamine and 1% penicillin-streptomicin, supplemented or 
not with 50 ng mL-1 of either Stromal cell-Derived Factor 1α (SDF-1α, rat recombinant, Peprotech) or 
Vascular Endothelial Growth Factor (VEGF, rat recombinant, Peprotech). MSCs were allowed to migrate for 
12 hours. After this time, the cells were fixed with PFA, the content of the upper side of the insert (Matrigel, 
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cells and MCs) was accurately removed using a cotton swab, and the cells nuclei stained with DAPI. The 
number of cells that migrated through the membrane was counted from 5 randomly chosen fields using a 
fluorescence inverted microscope with a 10x magnification objective. The number of cells that crossed the 
membrane was normalized against the actual number of adhered cells on the MCs at the beginning of the 
assay, determined with an alamarBlue assay. Cell migration was expressed through a Migration Index, 
defined as the ratio between the normalized numbers of migrated cells for a given sample and for the 
untreated PLA MCs under basal condition (low serum medium without chemoattractants). The experiment 
was performed also with cells seeded directly on the insert membrane and embedded in Matrigel. 
Furthermore, in order to evaluate MSCs capability to migrate towards gradients of SDF-1α, a standard 
boyden chamber assay was performed, using increasing concentrations of this chemokine and VEGF as a 
positive control.  
 
Figure 5.1: Schematic representation of the modified Boyden chamber assay. 
 
5.2.8 Statistical analysis 
Each experiment was performed in three to five replicates (n=3 to 5). Data are presented as mean and 
standard deviation of the replicates. Statistical significance was assessed performing Student’s t-test using 
Origin 8.0 Software (OriginLab, USA). 
 
 
5.3 Results 
5.3.1 MCs characterization and surface coating 
PLA MCs with an average diameter of 67.68 ± 21.80 µm were prepared, with a measured specific surface 
area of 2.31 ± 0.28 cm2 mg-1. The density of collagen coating on the MCs surfaces was quantified as 2.57 ± 
0.17 and 0.71 ± 0.04  µg cm-2
 
 for covalent and physisorption functionalization approaches, respectively.  
5.3.2 Cell response in terms of adhesion and proliferation 
All MCs types, independently of their surface treatment, allowed cell attachment (Figure 5.2). Untreated 
PLA and physisorbed RGD samples showed the lowest number of adhering cells after 4 hours in serum-free 
medium, with about 60% of adhered cells, compared to the control. Collagen coatings, both covalent and 
physisorbed gave the best result, with more than 90% of adhering cells. These MCs also promoted the 
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highest degree of adhesion and spreading (Figure 5.3). Particularly, CC MCs were the only carriers to show 
positive vinculin staining, a marker for the formation of focal adhesion points. Cells on RC MCs (>80% cells 
adhered) appeared to be non-spread but with already developed filopodia stretching on the particles surface, 
indicating an early phase of attachment. MSCs seeded on RP and PLA MCs were rounded and poorly 
attached to the surface.  
 
Figure 5.2: Quantification of adhering cells after 4 hours. Results are expressed as percentage of 
adhering MSCs on a TCPS control surface. Lines show statistically significant differences (p<0.05). 
 
 
Figure 5.3: Immunofluorescence of MSCs adhesión on different MCs after 4 hours. Arrows indicate 
the formation of focal adhesion points.  
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In longer cell culture assays with complete medium (supplemented with FBS), MSCs proliferation could be 
observed (Figure 5.4). All MCs formulations allowed cell homing and cell number increased steadily until 
reaching confluence after 5 days of culture. Afterwards, cell population started to decrease for all non-
covalently coated samples. Instead, CC and RC MCs were able to maintain their cell pool constant. 
Furthermore, CC MCs showed a significantly higher MSCs number than RC samples. Cell proliferation was 
also observed by immunofluorescence staining (Figure 5.5). In all samples, MSCs started colonizing 
individual or small groups of MCs. As the static culture time increased, MSCs started connecting 
neighboring particles and formed larger MC-MSCs complexes. At day 14, all MCs in the culture wells were 
clustered in a macroaggregate, and no qualitative difference could be appreciated between the experimental 
groups. 
 
Figure 5.4: Proliferation of MSC on MCs. Stars indicates statistically significant differences (p<0.05). 
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Figure 5.5: Immunofluorescence of proliferating MSC on PLA and CC MCs.  
5.3.3 Evaluation of migratory potential in response to SDF-1α 
5.3.3.1 CXCR4 expression 
MSCs cultured on 2D TCPS were positive for CXCR4 staining, and this expression was preserved in cells 
homing to 3D MCs (Figure 5.6). The receptor was found in the cytoplasm, both at the perinuclear space, and 
in the cell periphery, in presence of, but not co-localized with, developed actin fibers. The distribution of the 
receptor in 3D MC culture was comparable to that observed for 2D TCPS. No difference could be 
appreciated between the MCs experimental groups, regardless of their surface coatings. 
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Figure 5.6: CXCR4 expression and localization in MSCs cultured on 2D TCPS surfaces and in 3D, on 
two representative experimental groups of MCs.  
 
Flow cytometry (Figure 5.7) confirmed CXCR4 intracellular expression, with 97.18 ± 1.83% of the whole 
MSCs population showing positive staining (Figure 5.8). However, only a small pool of cells (less than 4%), 
expressed the receptor at the cell membrane, where it can be functional for SDF-1α sensing. Similar results 
were found for 2D culture on different materials, namely PLA films coated or not with collagen. 3D cell 
culture on MCs, instead, promoted functional expression of CXCR4 as a surface receptor, as showed in 
Figures 5.9, and 5.10. Among MSCs seeded on MCs, the population of positively stained cells for CXCR4 at 
the cell membrane increased significantly, compared to 2D culture. Most notably, collagen coated MCs (both 
covalent and physisorbed), induced a 5-fold increment (up to 25-30% of the overall cell population). About 
15% of the cells cultured on PLA, RC and RP samples expressed CXCR4 at the membrane. This effect on 
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CXCR4 expression is reversible and dependent on the culture condition, as shown in Figure 5.11. The cell 
pool expressing the receptor at the surface quickly returned at values lower than 4%, when MSCs were 
retrieved from collagen coated MCs, and subsequently plated on TCPS.  
 
 
 
Figure 5.7: Example of surface CXCR4 expression flow cytometry results for (a) isotype control (b) 
cells cultured on CC MCs. 
 
 
 
   
Figure 5.8: Intracellular expression of CXCR4 in MSCs (cultured on TCPS and isotype control are 
shown). 
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Figure 5.9: Surface CXCR4 expression for MSCs cultured on different substrates. 
 
 
Figure 5.10: Pool of MSCs expressing CXCR4 at the cell membrane as obtained analyzing flow 
cytometry data. Lines indicate statistically significant differences (p<0.05). 
 
 
Figure 5.11: Adaptive beahvior of MSCs expression of CXCR4 to the culture condition. 
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5.3.3.2 Migratory response of MSC to SDF-1α 
MSCs were able to migrate towards gradients of SDF-1α in a concentration dependent manner, reaching 
migration index values between 3 and 4 at the highest chemoattactant concentration. MSCs responded to 
SDF and VEGF gradients also when encapsulated in Matrigel, although showing a migration index of 3, a 
slightly lower value compared to when seeded directly on the membrane of the boyden chamber insert (Fig. 
5.12).  
 
Figure 5.12: Standard (A) and Matrigel-modified (B) Boyden chamber assay with SDF-1α gradients. 
 
MSCs cultured on MCs were able to migrate from the carriers in response to SDF and VEGF gradients 
(Figure 5.13). For all the experimental groups, in presence of the Matrigel, the migration index of MSCs 
increased 2-fold after chemokines stimulation, compared to the basal condition (low serum medium). Cells 
homing on PLA MCs and physisorptive coatings showed a migration index between 2 and 2.5, whereas the 
index was halved on surfaces modified with stable, covalent coatings –both collagen and RGD-. 
Furthermore, the number of migrating cells was comparable for the two covalent coatings, on one side and 
for the untreated and physically modified MCs on the other. 
 
 
Figure 5.13: Migration index for cells cultured on MCs, normalized against the value for PLA 
untreated MCs (A), and increment of migratory index respect to basal conditions after chemokines 
stimulation (B). MSCs-MCs complexes were encapsulated in Matrigel. Lines highlight the statistically 
significant differences between samples (p<0.05). 
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5.4 Discussion 
The development of injectable delivery devices is required for cell therapy, in order to improve the otherwise 
poor survival of adherent-dependent cells upon transplantation. A common strategy to enhance cell 
attachment and viability is surface modification of biomaterials with bioactive molecules. However, the 
interplay between materials surface properties, functionalization, cell migration and release is still not 
understood. This is especially important, as in the body, injected cells are influenced by several chemokines, 
that are crucial to recruit therapeutic cells and trigger tissue repair.  
In this study, PLA MCs were designed to promote MSCs i) survival and proliferation, and ii) controlled 
release. The combination of physical and chemical factors provided by the carrier morphology and 
functionalized surfaces, was used to act on SDF-1α/CXCR4 axis, a key target in chemotactic and 
regenerative processes. 
Since PLA lacks of chemical groups to trigger specific cell response, PLA MCs were modified with two 
molecules: collagen, or a short peptide, bearing the cell-adhesive sequence RGD.  
Collagen is a large ECM protein rich in: i) functional groups that allow for chemical reactions (i.e. 
crosslinking), ii) cell-adhesive motifs, and iii) domains able to bind growth factors and other signaling 
molecules [29]. On the other hand, the short RGD peptide is a simplified construct, bearing a single, but 
specific signal to promote cell adhesion [30]. Such molecules were introduced on PLA surfaces either via 
covalent or physisorbed mode of coupling. Unlike physisorption, covalent grafting induced higher collagen 
densities, since it forms a stable and durable coating, more resistant to being degraded, displaced or masked 
by competitor proteins found in biological fluids. Additionally, covalently bound macromolecules can 
present multiple grafting points to the surface, that limit the degree the coating can be stretched by cells, 
therefore affecting mechanosensing and cell behavior [27, 31]. Thus, these coatings provide the MCs with 
different physic-chemical properties that induce a broad spectrum of responses on MSCs, in terms of 
adhesion, proliferation, migration and targeting CXCR4/SDF-1α axis, as summarized in Table 2.  
 
Table 5.2: Effect of the functionalized MCs on MSC behavior. Plus and minuses indicate improvement 
and reduction, respectively. 
 Adhesion Proliferation CXCR4 expression Migration 
PLA - - + ++ 
CC +++ +++ ++ - 
CP ++ - ++ ++ 
RC + +++ + - 
RP - - + ++ 
 
All the biomolecules introduced on PLA carriers are well-known promoters of cell adhesion and 
proliferation, which are indicators of cell health. However, physisorption of RGD short peptides appeared to 
be an unsuitable procedure to improve MSCs response to PLA, and thus to produce optimal MCs for cell 
delivery. In fact, for all the analyzed parameters (adhesion, proliferation, migratory potential), RP samples 
showed no significant difference with untreated MCs. This is most likely because physical interactions 
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between the short peptide and the surface are too weak to allow an efficient engraftment, and such surfaces 
may not be enriched with enough RGD domains that can influence cell adhesion. On the other hand, 
functionalization with collagen showed the best results, both in terms of number of attached cells and degree 
of spreading after 4 hours, indicating a rapid adhesion process. This is especially remarkable for CC MCs on 
which MSCs expressed clusters of vinculin, an indicator of focal adhesion complexes [32]. RC modification 
was suitable to enhance cell adhesion on PLA, although less efficiently than collagen-coated surfaces, both 
qualitatively and quantitatively.  
MSCs proliferated on all the MCs, and for all samples confluence was reached between day 5 and 7 of 
culture. After this point only cell populations cultured on covalently coated surfaces maintained their pool, 
whereas all the other samples experienced a decrease in cell number, possibly due to detachment of cells 
aggregates. This result suggests that stable coatings, particularly collagen ones, might be suitable for long-
term cell culture and expansion, which is necessary to achieve relevant amounts of MSCs for clinical 
applications. Furthermore, covalently modified MCs are able to preserve the pool of therapeutic cells for a 
longer period of time, thus presenting an advantage as cell delivery vehicles. The formation of large cell-
MCs aggregates observed in this static culture assay can be avoided using a dynamic culture system, such as 
a spinner flask bioreactor [33]. Cell proliferation on individual or small groups of carriers is preferable, as it 
would make easier to administrate the therapy with direct injections. Implications of this culture technology 
in different aspects of regenerative medicine, as well as the injectability/extrudability of MCs suspensions 
are discussed Chapter 6.  
Besides sustaining cell attachment and proliferation, the different functionalized surfaces had an impact on 
cell migratory capability. [12]. MSCs have been shown to migrate towards gradients of SDF-1α, which 
activates its cognate receptor on the cell membrane, CXCR4. This pathway plays a major role in MSCs 
recruitment, homing and specific localization in damaged, tumoral and ischemic tissues [12]. Although such 
migratory behavior was observed both in vitro and in vivo [34], harvested MSCs that are expanded with 
conventional techniques in T-flasks are known to quickly lose the functional expression of CXCR4 at the 
cell membrane [35].  Our results for MSCs cultured on 2D TCPS confirm this tendency: almost the totality 
of the cell population expressed the receptor intracellularly, but only a small pool (3-5%) retained surface 
CXCR4. To explain this, in previous studies it was postulated that MSCs undergo a certain degree of 
differentiation during in vitro expansion [36]. However, the stimuli provided by 3D culture on MCs 
determined a sensible increment of surface CXCR4 positive cells. This change in the receptor expression is 
reversible, as MSCs can resume expressing CXCR4 only intracellularly if retrieved from the MCs and plated 
again on TCPS. Therefore, such behavior appears to be due to an adaptation of MSCs to the culture 
condition, rather than a differentiation or ageing process. A comparable result was observed by Potapova et 
al., when culturing MSCs as spheroids, and may be attributed to cytoskeleton reorganization or improved 
cell-cell communication in MSCs aggregates in spheroids and MCs [13].  
In the search for improved recruitment and engraftment into damaged tissues, enhancing functional CXCR4 
expression of in vitro cultured MSCs is a promising target for cell therapy. For instance, Wiehe et al. 
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successfully transfected MSCs expanded on standard TCPS to highly overexpress surface CXCR4 (> 90% of 
the cells) [19]. Culture and subsequent transplantation of MSC-laden MCs can be a powerful method to 
perform MSCs expansion with improved CXCR4 expression and localization, without the need of genetic 
modification. The modulation of such expression can be controlled by MCs design. In fact, CXCR4 
expression also greatly depends on an accurate choice of the chemistry of the biomaterial substrate, varying 
widely between untreated particles, collagen coating or even glass-coated polystyrene MCs. The mechanism 
behind this effect is not clear yet, although it has been suggested that CXCR4 can be a part of complexes 
assembled at the point of focal adhesions [13]. Furthermore, SDF-1α was found to activate focal adhesion 
kinase in hematopoietic cells and to induce cytoskeleton rearrengements [37]. Thus, it can be hypothesized 
that MSCs tuning of CXCR4 expression and localization may be related to integrin-mediated pathways 
dependent on the material chemistry, MSCs cytoskeletal reorganization on 3D, spherical MCs, and possibly 
improved cell-cell contacts, typical in MCs culture [38]. 
The only parameter affecting cell delivery potential after SDF-1α stimulation was the mode of coating 
attachment. Given a mode of functionalization, comparable migration indexes were found for both RGD and 
collagen coatings, even though with the latter MSCs had improved CXCR4 surface expression. CXCR4 
overexpression, although beneficial for in vivo homing [39], was found ineffective to enhance the already 
high MSCs tendency to migrate in vitro [19]. Covalent functionalizations reduced cell migration from MCs, 
whereas physisorbed coatings and untreated PLA MCs were associated with higher migration indexes. Cell 
migration had been previously related to the method of coupling of ECM ligands, in studies involving 2D 
biomaterials surfaces. HUVECs cultured on covalent fibronectin coatings grew as monolayers and were 
unable to properly migrate, whereas they were able to migrate and associate into capillaries if seeded on 
coatings weakly bound to the biomaterial [40]. This behavior was related to ECM sensing and reorganization 
mediated by specific integrins [40, 41]. A similar mechanism might play a role in tuning MSCs adhesion and 
migration from MCs. Mechanosensing of stiffer covalent coatings, which influences stem cells 
differentiation [31], could also guide cells fate in terms of migration, inducing retention on MCs surface, 
rather than release. MCs functionalization affected the non-specific basal migration of the MSCs, in absence 
of SDF-1α and VEGF gradients, rather than their response to chemoattractants. In fact, for all the samples, 
including MSCs cultured without MCs, the efficacy of chemokines stimulation was comparable, and induced 
a 2-fold migration index increment, compared to the basal condition. Switching between physisorptive and 
covalent functionalization methods could be used to exert a control over cell delivery. On one hand, covalent 
coatings should be preferred when retention of MSCs on the biomaterial carrier is needed (i.e. several tissue 
engineering strategies), but also when it is necessary to prevent unspecific cell dispersion, towards tissues 
that are not secreting SDF-1α. On the other hand, MCs with physisorbed coatings could be beneficial when 
quick release of higher amounts of cells is desired. 
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5.5 Conclusions 
PLA MCs are promising devices for cell therapy. MCs modified covalently with collagen enhance MSCs 
adhesion and proliferation, thus offering a suitable environment for cell survival, homing and expansion. 
Surface functionalization allows acting on MSCs migratory behavior in response to chemokines, and directly 
affects SDF1-α/CXCR4 axis. In fact, MCs culture, combined with the mode of binding and the nature of the 
coating, permits to tune CXCR4 expression during in vitro cell expansion. Higher CXCR4 functional 
localization on collagen-modified surfaces, regardless of the mode of coating, suggests such modification 
can be profitable to use MCs to improve cell grafting after transplantation. Simplified constructs such as 
RGD short peptides, although successful in promoting cell attachment, cannot trigger the mechanical or 
chemical pathways that improve the expression of the receptor. Physisorptive and covalent modifications 
respectively maintain and reduce the basal level of MSCs migration from the MCs, while not affecting the 
efficacy of SDF-1α at mobilizing cells. This knowledge can be useful to apply MCs to exploit or limit 
untriggered cell release, and balance SDF-1α mediated MSCs recruitment towards specific target tissues. 
Furthermore, these are key findings to aid the design of new biomaterials devices for efficient and 
controllable cell delivery. 
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CHAPTER 6 
 
Cell-laden microcarriers as building elements for tissue constructs via 
3D bioprinting 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In this chapter, polylactic acid microcarriers developed according to the method described in 
Chapter 3 are used as components to generate 3D living tissue constructs, by means of a 
bioprinting technology. The microcarriers are colonized by MSCs and characterized for their 
ability to support osteogenic differentiation. Cell-laden microcarriers are mixed with a gelatin-
methacrylamide/gellan gum hydrogel to form a composite bioink. The suitabiltiy of this mixture for 
bioprinting is characterized, together with its effect on hydrogel mechanical properties, cell 
viability and bone formation in vitro, and eventually constructs are biofabricated, via an additive 
manufacturing process. With such technique, osteochondral models, consisting of bone and a 
cartilage-mimicking layers, printed using the composite bioink and the gelatin-based hydrogel 
alone, are produced to show the potential of the proposed approach. 
 
This work was developed in collaboration with the Department of Orthopaedics of the University 
Medical Center Utrecht (UMC Utrecht, The Netherlands). Part of the experimental work was 
performed during a research stay at UMC Utrecht, under the supervision of Dr. Jos Malda. 
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6.1 Introduction 
Tissue engineering can yield three-dimensional (3D) tissue-like constructs that can serve as experimental 
platforms for biological studies and drug screening [1], and as implants for clinical application. 
Recapitulating the complexity of living tissues, with regards to the variations in cell types, matrix 
components and organization, remains however a major challenge. Bioprinting is an innovative technology 
that allows for the generation of organized 3D tissue constructs via a layer-by-layer deposition process of 
cells and biomaterials [2, 3]. In this way, hydrogel matrices with embedded viable cells have already been 
produced, such as functional vascular-like networks with enhanced transfer of nutrients [4, 5]. In this 
fashion, bioprinting can potentially address the zonal organization of cartilage and osteochondrondral 
constructs [6-8].   
The building materials in biofabrication are generally cell-laden hydrogels - also known as bioinks. Bioinks 
are critical components in biofabrication, as they should possess the right rheological parameters required for 
the printing process and, simultaneously, offer an optimal environment for cell survival, proliferation, 
migration and biosynthetic activity [9, 10]. Among them, thermo- and photoresponsive gelatin 
methacrylamide (GelMA) has been proven as a versatile and promising platform for cartilage tissue 
engineering [11]. At the same time, by blending GelMA with viscosity enhancers, such as hyaluronic acid 
[12] or gellan gum [6, 13], it displays improved properties for printing of geometrically complex structures.  
There are several challenges in the fabrication of hydrogel-based tissue constructs. For example, hydrogels 
provide a highly hydrophilic microenvironment in which suspended cells are constrained to a round shape, 
regardless their native morphology [14]. Therefore, inclusion of cues to guide cell fate would be desired. 
Second, printing of large, clinically-relevant grafts requires the encapsulation of high amounts of cells, which 
are difficult to obtain from biopsies [15]. For this reason, time-consuming 2D expansion steps are required, 
which reduces the therapeutic potential of the cultured cells by affecting their phenotype (e.g. 
dedifferentiation, loss of pluripotency) [16]. Moreover, hydrogels are too soft for application in load-bearing 
locations in the body [8]. Consequently, strategies to enhance biological and mechanical properties of 
bioinks, and the high numbers of regenerative cells which will have to be incorporated or attracted once 
implanted in the host in order to obtain functional tissue constructs.  
A potential solution would be to produce composite printable materials by suspending particles with 
bioactive potential into the hydrogel matrix. Among particulate materials, microcarriers (MCs) are especially 
interesting, due to their versatility and wide array of applications. Injectable MCs designed to promote 
attachment, homing and survival of adherent-dependent cells [17, 18], and suitable for cell expansion in 
stirred bioreactors, allow for the generation of high cell amounts and cell-MCs complexes. These aggregates 
are rich in cell contacts and extracellular matrix (ECM), that resemble the in vivo microenvironment, 
resulting in improved biological activity of cells [19]. Fo instance, many cell types cultured on MCs, 
including chondrocytes [20], osteoblasts [20], keratinocytes [21] and tenocytes [22] have been found to 
better retain their phenotype and display greater potential to regenerate the tissue of their competence 
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compared to 2D culture. Mesenchymal Stromal Cells (MSCs) from different sources (i.e. bone marrow, 
adipose tissue, placenta-derived) can be cultured on MCs to either preserve their pluripotency or to improve 
their differentiation [17, 23]. Moreover, MCs can be loaded with bioactive molecules as a cue to guide the 
differentiation of cells [24, 25]. Cultured MCs can be easily embedded in hydrogel matrices, and their 
encapsulation increases the mechanical strength of the gel, and offers a high cell-anchoring and spreading 
surface [26, 27, 28]. In addition, osteoblastic cells have been shown to induce superior formation in a 
synthetic hydrogel when incorporated as complexes with MCs compared to suspended cells. This indicates 
that MC-loaded hydrogels are promising composite materials for bone regeneration [14]. Thus, MCs are 
potential candidates to perform cell expansion, improve hydrogels mechanical properties and introduce cues 
to guide cell behavior. 
The aim of this work is to generate living tissues constructs of clinically relevant sizes, by combining 
bioprinting and MC culture technologies. GelMA-based hydrogels were used as bioinks, and the effect of the 
incorporation of custom designed polylactic acid MCs was evaluated for the mechanical and printing 
properties. In addition, morphology and osteogenic potential of cells in MC-laden bioinks was assessed. 
Several methods were explored to obtain MC-enriched bioinks, including culture of MSCs on MCs in a 
spinner flask bioreactor, prior to biofabrication. To provide a proof of application of such an approach, 
biphasic scaffolds consisting of an osteogenic layer with MC-laden bioink, and a cartilage region composed 
by MC-free bioink were fabricated.  
 
 
6.2 Materials and Methods 
6.2.1 Materials 
Polylactic acid (PLA, Purasorb PLDL 7038, IV midpoint 3.8 dL g-1, Mw ≈ 850000 Da) was purchased from 
Purac (The Netherlands). (–)-Ethyl-L-lactate (purity = 99.0%) and polyvinyl alcohol (PVA, 30–70 kDa, 88% 
hydrolyzed) were obtained from Sigma-Aldrich (Spain). PLA MCs were fabricated with the method 
described in Chapter 4. MCs with a mean diameter of 120 µm, and a surface area of 2 cm2 mg-1 were used. 
GelMA was synthesized from gelatin derived from porcine skin (Sigma-Aldrich) as described elsewhere [8]. 
GelMA hydrogels were obtained by dissolving GelMA (10% w/v) in deionized water supplemented with 
5.4% w/v D-mannose (Sigma-Aldrich) and 0.1% w/v of Irgacure 2959 (Ciba, BASF, Germany) under 
magnetic stirring for 20 minutes at 90°C. In order to optimize GelMA as a bioink for 3D printing, 1% w/v 
gellan gum (Gelzantm
 
 CM, Sigma-Aldrich) was added. Cells and cell-laden MCs were mixed in the GelMA 
solutions. The other reagents where purchased from Sigma-Aldrich, unless specified otherwise. 
6.2.2 Microcarrier surface modification 
PLA MCs were functionalized with human recombinant collagen type I (FibroGen, USA), in order to 
improve cell response to the material, according to the protocol described in Chapter 5 [29]. Briefly, MC 
147 
 
surface was enriched in carboxyl group by controlled hydrolysis in 50 mM NaOH for 10 minutes. The 
generated groups were activated with ethyl(dimethylaminopropyl) carbodiimide (Acros Organics, Belgium) 
and N-hydroxysuccinimide. This allowed for the covalent binding between the free amines of the collagen 
and the activated COOH, after soaking the samples in a collagen type I solution (100 µg mL-1
 
, 24 hours). All 
reactions byproducts were water soluble and eliminated by washing the samples in Phosphate Buffered 
Saline (PBS). 
6.2.3 Cells and culture conditions 
MSCs were isolated from the long bones of 2-4 weeks old Lewis rats according to a previously published 
protocol and as already described in Chapter 5 [30]. The protocols concerning the animal care were 
previously approved by Committee on the Ethics and Animal Experiments of the Scientific Park of 
Barcelona (Permit number: 0006S/13393/2011). Cell expansion and experiments were carried out by 
culturing MSCs in proliferation medium, consisting of Advanced DMEM, supplemented with 10% FBS, 1% 
Pen/Strep and 1% L-glu. 
 
6.2.4 Microcarrier culture 
MCs were prepared for cell culture by soaking them in 70% v/v ethanol, repeated washing with PBS under 
sterile conditions, and incubation in serum-free tissue culture medium. MSCs were cultured on PLA MCs 
both under static and dynamic conditions. For static culture, 3 mg of MCs were placed into an ultra-low 
attachment multiwell plate (Costar, Corning Inc., USA). The MSC suspension was seeded directly onto the 
particles, at a density between 1·105 – 3·105 cells/well. For dynamic culture, a 250 mL spinner flask device 
was used (BellCo, USA). The bioreactor was filled with 100 mL of culture medium and 2 g L-1 of MCs. The 
inoculum consisted of 2·105 cells mL-1. An intermittent stirring regime was maintained for the first 6 hours of 
culture (30 rpm for 1 minute every 30 minutes). After this seeding period, the suspension was stirred 
continuously at 30-35 rpm. 2 mL samples were taken from the MCs suspension to estimate the number of 
cells in culture. The MC-MSCs complexes were lysed with M-PER solution (Thermo Scientific, Spain). The 
cell amount was calculated from a standard curve, by measuring lactate dehydrogenase (LDH) activity in the 
supernatant using the Cytotoxicity Detection KitPLUS
 
 (Roche, Switzerland). 
6.2.5 Cell viability in MC-laden bioinks 
30 mg mL-1 of MCs where either preseeded with MSCs and then suspended into GelMA-Gellan Gum 
solutions, or directly co-suspended with the cells into the hydrogels. The mixtures were then manually 
dispensed through a 20G conical needle (inner diameter = 0.61 mm, Nordson EFD, USA) into a multiwell 
plate and exposed to UV irradiation (intensity of 4 mWcm-2, λ = 365 nm for 15 minutes) to induce an 
irreversible crosslinking of the hydrogel. At day 1 and 3 of culture, MSC viability was evaluated from 
microscopy images using a LIVE/DEAD Assay (calcein AM/ethidium homodimer, Life Sciences, USA). 5 
random fields for each sample (n=3) were used to count living cells. A control group was prepared by 
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dispensing MSC-laden MCs suspended in PBS and not exposed to UV light. To evaluate cell localization on 
MCs and into the hydrogel, samples were cultured for 4 hours, fixed in buffered paraformaldehyde, 
permeabilized with 0.5% v/v Triton X-100 and stained with phalloidin-FITC (Life Sciences, USA) and 4',6-
diamidino-2-phenylindole (DAPI).  
 
6.2.6 Mechanical properties of MC-laden bioink 
The effect of MC concentration on the compressive modulus of GelMA-Gellan Gum hydrogels was assessed 
in an unconfined uniaxial compression test, using a dynamic mechanical analyzer (TA 2980 DMA, TA 
Instruments, USA). UV-crosslinked hydrogels samples measuring 4x4x2 mm, containing increasing amounts 
of MCs (0, 30, 40 and 50 mg/mL) were subjected to a force ramp of 1 N/min up to 4 N and the related stress-
strain curve was obtained. The slope of the curve in the elastic region was used as a representative value for 
the compression modulus. 5 replicates for each sample were tested. The assay was performed at room 
temperature.   
 
6.2.7 Osteogenic differentiation 
The role of MCs in the differentiation of MSCs towards the osteogenic lineage was investigated. First, MC 
culture was compared to standard culture on 2D polystyrene surfaces. After that, the differentiation 
capability of the cells encapsulated in GelMA based hydrogels was evaluated. To this end, 30 µL of hydrogel 
mixture was placed into a poly(dimethyl siloxane) mold and UV-crosslinked. A preliminary test evaluating 
the effect of different MCs concentrations on osteogenic differentiation was also performed. Since no 
consistent differences were found, we kept the concentration of MCs at 30 mg/mL for the differentiation 
assay.  The volume of the gels samples used (30 uL), the cells densities and MCs amount where chosen so 
that all the experimental group had approx. the same number of cells. The experimental groups are 
summarized in Table 6.1. 
 
Table 6.2: Experimental groups analyzed in the osteogenic differentiation assay. 
 
Experimental  
group 
Description MSCs 
density 
TCPS Culture on 2D tissue culture polystyrene surfaces 105 cm-2 
MCs Static culture on MCs 105 cm
GelMA 
-2 
Cells encapsulated in GelMA 8·106 mL
GelMA-GG 
-1 
Cells encapsulated in GelMA-Gellan Gum 8·106 mL
GelMA-GG 
MC-MSCs 
-1 
Preseeding on 30 mg mL-1 8·10 MCs overnight and encapsulation in 
GelMA-Gellan Gum hydrogels 
6 mL
GelMA-GG 
-1 
MCs and MSCs 
30 mg mL-1 8·10MCs and the cell suspension are mixed together in 
GelMA-Gellan Gum hydrogels, with no preseeding 
6 mL-1 
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All samples were cultured for 21 days either in medium with or without supplemented osteogenic factors 
(10-8 M dexamethasone, 50 µg mL-1
 
 ascorbic acid, 10 mM β-glycerol phosphate). Differentiation was studied 
by quantifying alkaline phosphatase (ALP) activity at day 7, 14 and 21 of culture; osteocalcin (OCN) 
secretion at day 14 and 21, and by alizarin red staining on cryostat sections at day 21 to assess the deposition 
of mineralized matrix. For ALP analysis, samples were washed with sterile PBS and the hydrogels were 
grinded using a pestle. Protein extracts were obtained inducing cell lysis with M-PER solution, followed by 
centrifugation for 15 minutes at 2500 rpm, to remove debris from cells, gels and MCs. ALP activity was 
measured using Sensolyte® pNPP Alkaline Phosphatase Assay Kit (AnaSpec, Inc., USA). OCN 
quantification was performed from cell culture supernatant using an Enzyme-Linked ImmunoSorbent Assay 
kit (Demeditec Diagnostic GmbH, Germany), following the instructions of the manufacturer. OCN and ALP 
data were normalized against total cell number, as evaluated measuring LDH activity. 
6.2.8 Bioprinting of MC-laden GelMA 
Models of the constructs were obtained using Computer Aided Design (CAD) software (Rhinoceros, 
McNeel, Seattle, WA, USA). The CAD files were loaded in Computer Aided Manufacturing (CAM) 
software (PrimCAM, Einsiedeln, Switzerland), and printed with the Bioscaffolder system (SYS+ENG, 
Salzgitter-Bad, Germany), which has been described previously [11]. GelMA-GG hydrogels loaded with 
MCs, tested for printability, and used as a bioink. While 50 mg mL-1 was the highest printable MC 
suspension, a concentration of 40 mg mL-1 MCs was chosen to maximize the amount of MCs and loaded 
cells, while simultaneously maintain a safety margin to prevent nozzle clogging by formation of MC-MSCs 
complexes during the pre-culture period. The optimal settings for printing were found to be an extrusion 
velocity of 2.40 (adimensional number) and a printing speed of 475 mm/min, at room temperature. The 
dispensing tip was a 20G conical nozzle. Distance between the hydrogel strands was set at 2.25 mm in the 
CAM model, while layer-to-layer spacing was set to 0.4 mm. Printed constructs were then UV cured for 5 
minutes (λ = 320–500 nm, intensity of 6 mWcm2 at 365 nm, Superlite S-UV 2001AV lamp, Lumatec, 
Germany), and the immediately captured with an Olympus DP70 camera connected to a stereomicroscope. 
MC-MSCs complexes were introduced into the GelMA-GG hydrogels in order to assess the effect on cell 
viability and printability. MSCs were either pre-cultured on MCs under static conditions (12h) or in a spinner 
flask bioreactor for 5 days. For these assays, cylindrical, single-layered constructs were produced (diameter 
16 mm, height 2.5 mm), using the settings described previously. To test cell viability, the constructs were 
cultured for 1 and 3 days in proliferation medium and then were analyzed with a LIVE/DEAD assay. Cell 
distribution in the printed constructs was observed with a fluorescence microscope (Olympus BX51, 
Olympus, USA), after staining cells for actin. In the samples, a total of 10·106 cells mL-1 was encapsulated, 
with or without 40 mg mL-1 
 
of MCs. 
6.2.9 Fabrication of bilayered osteochondral models 
Cylindrical, bilayered constructs with anatomically relevant size (diameter 16 mm, height 5 + 5 mm) were 
fabricated, composed of two different bioinks. GelMA-GG encapsulating 40 mg mL-1 MCs was used to 
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represent the bone compartment, while the cartilage layer was printed using the GelMA-GG without MCs. 
The optimal conditions to print the hydrogel without MCs were found to be an extrusion velocity of 3.80, a 
printing speed of 600 mm/min, and 34°C temperature. 
 
6.2.10 Statistical analysis 
Each experiment was performed in three or five replicates (n=3 or 5). Data are presented as mean and 
standard deviation of the replicates. Statistical significance was assessed performing Student’s t-test using 
Origin 8.0 Software (OriginLab, USA). 
 
 
 
6.3 Results 
6.3.1 Cell viability in MC-laden bioinks  
Non-viscous suspensions of MSC-loaded microcarriers in PBS (30 mg mL-1
 
) where successfully dispensed 
without clogging of the syringe needle. After dispensing, 80% of the cells were viable 1 day and more than 
90% after 3 days (Figures 6.1A, 6.1B and 6.1E). MCs, cells and MC-MCS complexes suspended in GelMA-
GG were homogeneously distributed in the gel matrix and showed good cell viability (Figures 6.1C-G). Pre-
seeded particles suspended in the gels had the lowest number of viable cells (60%) after 1 day of culture, 
which recovered to 90% after 3 days, indicating a high proliferation rate. Interestingly, MSCs that were 
separately mixed with MCs into GelMA-GG hydrogels, without a pre-seeding step, were found attached to 
the MCs surface. After 4h, in presence of GelMA, MSCs were found in an early stage of adhesion onto MCs, 
whereas they already expressed organized actin fibers if seeded directly on the MCs (Figures 6.2A and 
6.2B). 
 
 
Figure 6.1: (A) Viability of MSCs after dispensing; (B,E) Non-encapsulated cells cultured on MCs; (C,F) 
gels loaded with pre-cultured MC-MSC complexes and (D,G) with cells and MCs separately. Scale bar 
represents 50 µm.  
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Figure 6.2: (A) Morphology of MSCs 4 hours after mixing with cell-free microcarriers in GelMA-GG 
(dashed circle indicates a MC) and (B) seeded directly on the MCs in absence of the gel. Scale bar is 40 
µm. Cytoskeleton stained in green, nuclei in blue. 
 
 
6.3.2 Mechanical properties of MC-laden GelMA 
The incorporation of MCs into the GelMA-GG hydrogels resulted in an increment of the compressive 
modulus (Figure 6.3). The stiff PLA MCs reinforced the softer hydrogel matrix, and the compression 
modulus increased along with the MC concentration. For the highest concentration tested, stiffness was 2-
fold higher than for MC-free gels. 
 
Figure 6.3: Compression modulus of GelMA-GG with different concentrations of MCs. The four 
samples show significantly different moduli (p<0.05). 
 
6.3.3 Osteogenic differentiation of MSCs 
Cell number was monitored along the culture time (7, 14 and 21 days) using the LDH assay, and cell 
amounts were comparable between all the experimental groups, ranging between 2·105  and 2.5·105 
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bone markers was observed during culture for all samples, suggesting the absence of spontaneous 
differentiation. In presence of osteogenic medium, ALP activity increased over time and was considerably 
higher for 2D monolayer cultures compared to 3D MC culture (Figure 6.4A). However, MC-MSC 
complexes displayed enhanced OCN secretion, while histological analysis of both samples revealed the 
deposition of mineralized matrix, thus suggesting a consistent MSCs differentiation. MC culture also showed 
areas of alizarin red positive staining (Figure 6.5), in case standard proliferation medium was used.  
During long-term culture of hydrogel samples under osteogenic conditions, GelMA and GelMA-GG samples 
induced higher levels of active ALP, when compared to the gels with incorporated MCs (either pre-seeded 
with cells or not). On the other hand, encapsulated MC-MSC complexes secreted more OCN compared to 
the other experimental groups, indicating cell differentiation and a production of mature components of bone 
matrix. In all experimental samples cultured in osteogenic medium, MSCs deposited calcified matrix. 
However, both in GelMA and GelMA-GG samples, the mineralized ECM appeared as discrete and small 
alizarin red stained areas, more likely in the proximity of the cells suspended into the gel matrix (Figure 6.6). 
Instead, GelMA-GG MC-MSCs samples displayed a diffuse staining surrounding the MCs. 
 
 
 
Figure 6.4: (A) ALP and (B) OCN produced by MSCs in 2D culture (TCPS) and MCs. Quantification 
of (C) ALP and (D) OCN from GelMA-based hydrogels with or without MCs. The symbols group 
together samples that display statistically significant differences between them (p<0.05). 
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Figure 6.5: Alizarin red staining of monolayer cell cultures on TCPS and static MC culture after 21 
days. Scale bar is 200 µm. 
 
 
 
 
Figure 6.6: Alizarin red staining on hydrogel samples after 21 days of culture in osteogenic medium. 
Scale bar is 200 µm. 
 
 
 
6.3.5   Bioprinting of MC-MSC constructs 
MC-MSC laden bioinks were printable, meaning that they formed strands upon extrusion able to retain their 
shape. Cell laden constructs were fabricated with a strand diameter of 715 ± 86 and pore width of 1006 ± 121 
µm. MSCs and MC-MSC complexes displayed a high viability after the automated printing process, both 
following static seeding and dynamic MC culture (Figure 6.7). MC-MSCs were cultured in a spinner flask, 
and excessive aggregation of the MCs was prevented. Viability values at day 1 and 3 after printing and 
photocrosslinking were comparable to those observed when MC-MSCs were dispensed manually. For all 
tested modalities, constructs were fabricated with homogeneous distribution of cells and MCs through the gel 
matrix, comparable geometry to the cell-free constructs (overall dimensions, strands orientation, struts and 
pore sizes), and a good fidelity to the original CAD design (Figure 6.8).  
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Figure 6.7: Viability of MSCs encapsulated in GelMA-GG hydrogels after printing. 
 
 
 
 
 
 
Figure 6.8: Immunofluorescence staining for actin cytoskeleton (green) on bioprinted GelMA-GG 
hydrogels with encapsulated cells and MCs. (A) MSCs were precultured on MCs either in a spinner 
flask bioreactor for 5 days; (B), under static conditions for 12 h or (C) directly mixed together in the 
hydrogel solution without preculture. Lower panels and inserts show higher magnification of the 
constructs. Scale bar is 500 µm.  
 
MSCs only MC-MSCs
Static 12h
MC-MSCs
Spinner Flask
0
10
20
30
40
50
60
70
80
90
100
Li
ve
 ce
lls
 [%
]
 Day 1
 Day 3
155 
 
6.3.6 Printing of osteochondral models 
Using the MC-based biofabrication approach, it was feasible to fabricate bilayered osteochondral graft 
models of clinically relevant size. The cartilage region was printed with GelMA-GG and the bone region was 
represented by GelMA-GG with encapsulated MCs. MC-laden gels flowed smoothly through the dispensing 
nozzle and strands retained their rounded shape better than the gel-only bioink, possibly due to the increased 
rigidity of the composite material. As a result, the constructs showed a strand diameter of 682 ± 74 µm (with 
an average pore width of about 1226 ± 83 µm) for the MC-laden gel and 755 ± 92 µm for the gel-only ink 
(with an average pore width of 1020 ± 80 µm).The two compartments were well aligned and no delamination 
was observed during the manipulation of the construct. There was a consistent axial porosity that can be 
observed in figure 6.9A and 6.9B. The MC-laden region showed a homogenous distribution of the PLA 
particles throughout the structure and appeared optically opaque (opposed to the translucent hydrogel-only 
section, figures 6.9A and 6.9C). As quite common with hydrogel printing, no significant lateral porosity was 
introduced into the construct, as the bioinks tend to lean on the underlying layer (Figure 6.9D).  
 
 
 
Figure 6.9: Bilayered GelMA-GG cylindrical osteochondral graft model (16 mm diameter, 1 cm 
height). (A) MC-laden layer top view, (B) GelMA-GG layer top view, (C) perspective, (D) cross-
section. Scale bars are (A, B) 400 µm and (C, D) 4 mm. 
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6.4 Discussion 
In this study, living 3D structures containing MC-MSCs complexes were fabricated using bioprinting 
technology. MCs were found to be suitable substrates to for cell adhesion and osteogenic differentiation and 
acted as reinforcing material to the hydrogel. Furthermore, high cells concentrations could be obtained by 
pre-culturing MSCs on MCs.    
GelMA-GG was chosen as a bioink for bioprinting. Due to its shear-thinning behavior, it can be easily 
extruded into filaments, which then maintain their shape once deposited on the printing substrate, thus 
allowing the generation of 3D printed structures with good shape fidelity [6, 13]. Finally, the obtained 
scaffolds can be irreversibly crosslinked after mild UV-exposure. We found this procedure had little impact 
on cell viability, which is in line with previous research [31-33]. It should be noted that human MSCs may 
show different survival rates compared to rat MSCs in response to mechanical stresses and UV radiation, 
although previous work reported reassuring results regarding MSCs differentiation (hence survival) after 
UV-encapsulation in collagenous hydrogels [34]. 
Another issue regarding the current crosslinking set-up, is that constructs were UV cured after the printing 
process, may limit the size of the constructs, since UV may not penetrate deeply into larger grafts. However, 
this can be solved by inducing photocrosslinking during the printing process. Such technology has been 
recently described by Cui et al., and could be adapted to our system by a hardware modification [35]. 
In this work, cells and MCs were either suspended as precultured MC-MSCs complexes or mixed separately 
into the hydrogel. The first approach is preferable, since such aggregates have been shown to promote cell 
viability, biomolecules synthesis and differentiation [26], due to the establishment of cell-cell contacts and 
actin cytoskeleton reorganization [36]. However, since large aggregates can easily clog the injection nozzle, 
expansion periods under static culture should be limited. As an interesting alternative, MCs and MSCs can 
be separately mixed, without preculture steps. The current work showed that such suspensions can easily be 
dispensed, and once suspended in the bioink, cells were able to migrate through the hydrogel matrix to 
adhere, spread and proliferate on the MC surface. Although it could be possible to use this approach to tune 
MSCs adhesion and response, the amount of cells that could be loaded into the gel would be limited by 
standard 2D proliferation protocols. Therefore, 3D-expansion methods are required. To retain a printable 
bioink, cells should be expanded on individual MCs or small aggregates, a condition that can be achieved in 
a stirring bioreactor, as also shown in this study.  
Composite bioinks were thus created, in which MCs, made of a mechanically stiff polymer, were dispersed 
in the softer hydrogel matrix. It is known that hydrogel stiffness can be improved increasing the polymer 
concentration or the crosslinking degree (UV exposure, temperature) [12]. A high crosslink density however 
is less desirable, as it can hamper the migration of encapsulated cells and their ability to homogeneously 
colonize the hydrogel with newly synthesized extracellular matrix [37]. Instead, incorporation of MCs does 
not alter the nature of the hydrogel network, and construct stiffness was shown to increase along with the 
concentration of MCs. However, it should be considered that stress at failure may be reduced, although this 
was not evident in our mechanical assay. MC reinforcement of hydrogels does not lead to compressive 
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moduli similar to hard tissues. When hydrogel-based constructs are implanted in load-bearing locations, 
external fixation will be required to reduce weight on the implant. Another strategy that can be implemented 
to improve the mechanical properties of hydrogel constructs, is co-printing of a supportive thermoplastic 
polymer network [12, 38]. Still, in all regenerative approaches, the final mechanical properties should be 
provided by the neo-tissue that is secreted by the embedded cells [39].  
To further enhance the hydrogel compression modulus and match the stiffness of hard tissues, it may be 
feasible to encapsulate particles made of different materials (e.g. calcium phosphates) [40], provided that 
they do not sediment over the time scale of the printing process and their size allows the extrusion of the 
bioink. However, an advantage of MCs encapsulation is to use them as devices to efficiently expand MSCs 
and then print MC-MSCs aggregates with improved biological behavior and bone forming potential [23]. For 
this reason, MCs with a highly porous core made from low density materials and suitable for spinner flask 
culture were chosen.  
The potential to improve the osteogenic differentiation of MSCs by encapsulating them with MCs into 
GelMA hydrogels was studied in vitro. All the samples cultured with differentiation medium displayed 
calcified matrix deposition, and MSC commitment towards osteogenic lineage, thus supporting the 
suitability to use GelMA-based gels for bone bioprinting. Alizarin red staining, which appeared as discrete 
spots surrounding cells without MCs, intensely marked diffused areas around MC-MSCs complexes. This 
indicates strongly mineralized regions, probably due to the fact that local cell density is higher on cell-
colonized MCs, a factor affecting cell behavior and differentiation [23]. At a molecular level, MC-laden 
samples showed markedly reduced ALP activity compared to their respective controls. This was 
accompanied by a higher secretion of OCN, which is a late marker for maturation of osteoblasts, and key 
component of bone extracellular matrix [41]. MC-MSCs gels gave the best results regarding the secretion of 
OCN, and at the same time induced matrix calcification, suggesting that they are able to form a mature bone-
like tissue. This discrepancy of ALP levels in vitro and bone-forming capacity of MSCs was recently 
described by Goh et al. who compared the bone forming potential of human fetal MSCs cultured as 
monolayers with Cytodex 3 MCs. Despite a 45-fold reduction in ALP activity on MCs, MSCs cultured on 
MCs and MC-MSCs complexes induced better and more consistent bone formation in vitro and in vivo (in a 
rodent model), indicating that MC culture can improve the potential of MSCs in bone tissue engineering 
[42]. 
Eventually, it is worthwhile to underline that the addition of gellan gum to the bioink formulation did not 
have a relevant effect on osteogenic differentiation of MSCs. Gellan gum, may thus be safely mixed with 
GelMA for printing of bone tissue in order to increase the solution viscosity and improve the printability of 
the bioink [13]. The results of the differentiation assay also suggest that it is not advisable to use solely 
MSCs in GelMA-based hydrogels for the cartilage region, since they can easily differentiate towards 
osteoblastic lineage. For this reason, it would be preferable to use chondrocytes, which have shown capable 
of chondrogenic differentiation in GelMA in vitro and in vivo [11, 38]. MSCs can play an important role in 
maintaining chondrocyte phenotype in co-cultures [43-45], although the mechanism underlying this crosstalk 
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is not fully understood, and cases of downregulation of chondrocytes differentiation have also been reported 
[46]. However, co-cultures of MSCs and chondrocytes in hydrogel systems have been reported, suggesting 
the beneficial effect of the combination of such cell types in generating bone and cartilage tissues. For 
instance, Mo et al. demonstrated that MSCs and chondrocytes interacted in an alginate matrix, possibly due 
to trophic factors secretion, determining an enhancement of GAGs secretion by chondrocytes and an 
initiation of osteogenesis of MSCs, which induced osteocalcin production [47]. These effects were found to 
be dependent on the MSC/chondrocyte ratio [47].  
Proven that MC-laden GelMA-GG can be a matrix for bone tissue engineering, the material was used as a 
bioink to construct model of an osteochondral graft. Recently, calcium phosphate particles (size 100-212 
µm) have been introduced at low concentrations (up to 15 mg mL-1
In tissue constructs fabricated from all MC-bioinks (short-term static culture, dynamic culture, and without 
preseeding), the complexes or the free cells and particles were homogeneously distributed in the printed graft 
with shape fidelity comparable to that of the cell-free constructs, thus proving the printability of MC-MSCs 
complexes. Under these conditions, zonal constructs composed of MC-laden and MC-free layers of gels with 
clinically relevant size were obtained. The size of the strand was not significantly affected by the presence of 
the MCs, thus allowing a good stacking and alignment of the two compartments, which generated a 
) into alginate bioinks to promote bone 
regeneration [48]. Poldervaart et al. also printed gelatin microparticles for controlled release of Bone 
Morphogenic Protein-2. Both cases showed promising results in terms of in vivo osteoinduction, however 
low amounts of particles where encapsulated [49]. We found that the addition of high concentrations of MCs 
to GelMA-GG hydrogels did not reduce the printability of the ink, nor did it affect the size of the extruded 
strands and the porosity. Living constructs were obtained by adding MC-MSCs to the bioink mixture, either 
after a short period of static culture (12h) or longer culture (5 days) in a spinner flask bioreactor. Both 
approaches generated viable MC-MSCs complexes, but the latter has a clear advantage, as dynamic culture 
allows cell proliferation while preventing formation of large, difficult to extrude, aggregates. Furthermore, 
spinner flask culture has the great potential to combine 3D printing with a well-established cell expansion 
technology. To date, bioprinting of cell aggregates was prevalently performed by producing tissue spheroids 
and using them as bioink components [50]. Despite of the interesting biological performance, spheroid 
generation methods are still time consuming and not suitable for mass production, thus limiting the size of 
printable tissues [50]. Conversely, microcarrier culture is a simple, industrially scalable technology to 
achieve large cell numbers, with precise control over cell culture conditions [51]. MSCs aggregates have 
been demonstrated to improve cell proliferation, survival and multilineage differentiation, especially when 
the endogenous ECM produced in the aggregates is preserved [52]. Such matrix preservation is a 
characteristic of MC-MSCs complexes [19] which are profitable to induce cell differentiation and build 
tissue engineered constructs [53]. Additionally, to further exploit the advantage of 3D cell-cell connections, 
MCs with an open porous structure could be used, so that cells can colonize the inside of the carrier and 
display a 3D organization in it [16]. MC culture opens promising possibilities when combined with 
bioprinting technologies.  
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consistent and well-aligned axial porosity all through the construct. The high viability of MSCs, and the 
results of the multimaterial printing process demonstrates the feasibility of a combined MC culture-
bioprinting strategy to generate large, living constructs, with potential applications in osteochondral tissue 
engineering and as 3D tissue models. 
 
 
6.5 Conclusions and future perspectives 
MC-laden GelMA-based bioink was shown to be a promising composite material for bioprinting. PLA MCs 
acted as a mechanical reinforcement to the soft GelMA matrix, without compromising the printability of 
GelMA bioinks. Additionally, encapsulation of MC-MSCs complexes - with improved cell adhesion and 
cell-cell contacts – supported bone matrix deposition, and hence is of great interest for the engineering of 
bone tissue. Finally, MC-MSC-rich living construct where obtained using bioprinting combined with 
microcarrier dynamic expansion. These are key findings to build advanced constructs for bone and cartilage 
tissue engineering. Furthermore, the printability of bioinks with high MC concentrations opens possibilities 
for the fabrication of biomedical screening models. Drug-encapsulating MCs could be used, adding an 
additional level of complexity in the bioprinting of living tissues. Co-delivery of cells and growth factors 
with control over the spatial and temporal distributions would be possible, and constitutes another promising 
trend that can be explored in the area of biofabrication. 
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7.1 Conclusions 
This Thesis is an extensive study on the development of novel nano- and microcarriers, and demonstrates the 
versatility and high potential of such carriers.  Below are summarized the main conclusions of the work 
reported in the experimental chapters (Chapters 3-6). 
 
7.1.1 Chapter 3 – MCs fabrication 
• A novel method to process PLA and fabricate MCs was developed and characterized. 
• This method involves the use of chemicals that are non-harmful, green and biodegradable, thus 
improving the biocompatibility of the device and fabrication procedure. Furthermore, the method 
can be potentially scaled up and poses no significant harm to the environment and the workers 
involved in the MCs fabrication. 
• MCs size can be controlled by adjusting experimental parameters such as polymeric solution 
viscosity, and aero- and hydrodynamic parameters such flow velocity of the polymer phase and the 
nitrogen phase. 
• Additionally, the method can be adapted to generate MCs made of different materials, modifying the 
choice of solvent and coagulation bath. 
• The MCs production and solidification technique is suitable to encapsulate bioactive compound of 
both hydrophobic and hydrophilic nature, by loading them either into the coagulation bath or into the 
polymeric phase.  
• The PLA-EtLac system can be of potential interest for green fabrication routes to generate devices 
for other types of applications (scaffolds and films for tissue engineering, membranes for separation 
technology and films for packing purposes). 
 
7.1.2 Chapter 4 – Antimicrobial NPs 
• The green approach to particles fabrication presented in Chapter 3 was adapted to fabricate NPs 
made of PLGA. The EtLac-polymer system was used in a nanoprecipitation-based processing 
method to successfully generate monodisperse NPs. CPX, an antibiotic, was encapsulated in the 
particles. 
• These spherical NPs have size ranging between 200 and 300 nm, suitable for drug delivery to 
bacterial biofilms established into the airways. 
• PLGA NPs could be prepared unmodified, thus bearing a negative surface charge or in presence of 
PL, to endow them with a positively charged coating. 
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• Positively charged NPs could also be functionalized with DNase I, and the enzyme coated on the 
NPs surface retained its capability to degrade DNA. 
• The drug loading into the NPs is low, although this is comparable with other studies reported in the 
literature, as the nanoprecipitation method is most effective for encapsulating hydrophobic 
compounds, rather than hydrophilic. 
• The CPX release profile, with a high burst in the first hours and a slower release until complete 
depletion of the loaded drug is compatible with the application of antibiotic delivery to biofilms, and, 
as suggested in the literature, can be suitable to reduce insurgence of resistant bacterial strains. 
• All the NPs formulation loaded with CPX (unmodified, PL coated and PL-DNase I coated) were 
active against planktonic P. aeruginosa, a biofilm-forming bacteria involved in infections related to 
cystic fibrosis, and the encapsulated antibiotic retained its antimicrobial potential. The NPs were also 
able to prevent biofilm formation by planktonic bacterial cells. 
• NPs functionalized with DNase I were the most effective at eradicating established biofilm 
infections. With this approach, both the bacterial cell and the matrix they produce are targeted in the 
treatment of persistent bacterial infections,. 
• Degradation of the bacterial ECM composing the biofilm with enzyme-functionalized NPs appears 
as a promising strategy to improve controlled drug delivery into biofilms. Combination of 
functionalized NPs and antibiotic release can thus help to treat persistent bacterial infections. 
 
7.1.3 Chapter 5 – Cell delivery and migration from MCs 
• PLA MCs fabricated according to the method proposed in Chapter 3 were successfully 
functionalized with RGD short peptides and collagen type I, either via coavalent bonding or 
physisorption. These MCs were demonstrated to be suitable carriers for MSCs homing and 
proliferation. 
• The highest values for cell adhesion and proliferation were found on MCs covalently functionalized 
with collagen that thus offered a suitable environment for cell survival, homing and expansion. 
• Surface functionalization does not only modulate cell adhesion and proliferation, but also allows 
acting on MSCs migratory behavior in response to chemokines, and directly affects SDF1-α/CXCR4 
axis.  
• These effects are dependent on surface functionalization, both in terms of nature of the coating 
(bio)molecule and mode of surface modification (physisorption vs. covalent), together with cues 
given by cell culture on MCs 3D spherical devices. 
• Culture on 3D MCs, in comparison to 2D surfaces and modification of material chemistry by 
collagen coatings, induced higher CXCR4 expression in MSCs. This is especially important as 
MSCs tend to lose functional CXCR4 expression when expanded in vitro, and thus MCs can be an 
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advantageous substrate for cell proliferation, cell delivery and to improve cell grafting after 
transplantation. 
• Simplified molecules such as RGD peptides can promote cell adhesion and proliferation, but do not 
trigger the biological pathways that improve CXCR4 expression. 
• Covalent modification reduce the basal level of MSCs migration in absence of chemokine 
stimulation, and may therefore be used to prevent cell non-triggered release from the MCs and to 
limit cell migration. On the other hand, physisorbed coatings permit higher cell migration from the 
carrier. These findings can help to choose properly biomaterial devices that can balance SDF-1α 
mediated MSCs recruitment towards specific target tissues. Furthermore, they highlight the 
importance of considering the effect of biomaterial carrier properties on cell migration, in order to 
design devices for efficient and controllable cell delivery. 
 
7.1.4 Chapter 6 – Cell-laden MCs bioprinting 
• PLA MCs prepared with the method described in Chapter 3 can be used as injectable cell carriers, 
and the injection of MSCs-laden MCs causes no negative impact on cell viability.  
• Cell-laden MCs can be suspended in a hydrogel to be injected. In this study, MCs loaded in a 
GelMA-GG solution could be suspended and injected. Furthermore, the mixture showed good 
extrudability properties, meaning that it was injectable and formed strands upon extrusion.  
• MSCs-laden MCs encapsulated in GelMA-GG can be used as a composite bioink for bioprinting, via 
layer by layer deposition of spatially-organized MC-hydrogel strands. 
• PLA MCs acted as a mechanical reinforcement to the soft GelMA-GG matrix, without 
compromising the printability of GelMA-based bioinks. 
• MSCs formed complexes on MCs that supported osteogenic differentiation and bone matrix 
deposition. 
• MC-laden bioinks can be suitable as components to generate complex bone and cartilage tissue 
engineering constructs by means of bioprinting. As a proof-of-concept of such an approach, an 
osteochondral graft model was printed using a MC-laden bioink to fabricate the bone compartment 
and a GelMA-GG only bioink to build the cartilage region. 
• MCs can be used to expand under dynamic conditions MSCs and then to print cell-rich living 
constructs with potential applications in tissue engineering, as well as in vitro 3D tissue models, 
disease models and platforms for drug screening. 
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7.2 Future perspectives   
The work developed in this Thesis shows the versatility of MCs and NPs that can be applied for drug 
delivery, cell therapy, tissue engineering and in vitro 3D tissue modeling applications, among many 
possibilities. As several important implications of the use of particulate carriers in such applications have 
been investigated and deepened (i.e. impact of fabrication processes on materials properties, surface 
modification and functionalization, interaction with biological milieu, cell-materials interface and its 
influence on cell behavior, generation of advanced biomaterial devices with cutting-edge technologies), the 
work presented herein opens a wide array of possibility for future research. At the same time the topics 
developed in this Thesis could also be faced with alternative approaches and further aspects of particulate 
carriers development and applications could be explored. In this section, a non-exhaustive list of possible 
future development of the work presented in this Thesis is provided. 
The fabrication procedure exposed in Chapter 3, on one hand can be adapted to generate MCs made of 
different type of materials, according to the type of desired application. On the other hand, considering PLA-
based polymers, in terms of MCs fabrication and design, there are several interesting aspect that may be 
researched. As already mentioned in the previous chapters, solid spheres MCs can be loaded with drugs (in 
the inside), while carrying seeded cells on their surface, allowing for a compartmental separation of the drug 
and the cells component. This strategy, as already shown in the literature [1, 2], can be used, for instance, to 
guide cell behavior via controlled release of growth factors. There is a huge spectrum of the possible drug-
cell pairing, and the proper choice of these components, of course, depends on the type of target tissue to 
regenerate/disease to treat (i.e. bone morphogenic proteins and MSCs/osteoblasts for bone tissue 
engineering). MCs with open porosity are also widely studied as substrate for cell expansion and as cell 
carriers [3]. It could be of interest to study the introduction of porogens during the MC fabrication step, in 
order to modulate pore size, shape and interconnectivity. Open porosity allows for higher surface available 
for cell proliferation and also for improved formation of 3D cell-cell communication and aggregate in the 
inside of the MC [4]. This would permit to study the effect of this greater extend of 3D cell-cell organization 
on parameters such as stem cells differentiation, ECM deposition, biomarkers expression, secretion of 
paracrine factors. Both drug- and cell-loaded solid sphere MCs and open porous MCs would provide 
appealing approaches for MCs bioprinting of living tissues, as suggested in Chapter 6.  
Regarding the work presented in Chapter 4, the proposed NPs system, it would be interesting to test DNase I 
functionalized NPs in vivo in animal models of persistent infections due to established P. areuginosa 
biofilms. This would be an especially important step, due to the fact that currently only a very limited 
number of in vivo studies concerning antibacterial nano/microscale delivery systems are reported in the 
literature [5]. 
Moreover, in vivo studies would also be a natural development of the research described in Chapters 5. An 
interesting investigation would be that of MSC-MCs complexes injection in vivo, with or without chemokine 
stimulation, followed by live tracking of MSCs localization and number (for instance using cells modified to 
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express luciferase). Finally, the next step for the study described in chapter 6 would be that of evaluating the 
tissue deposition from long term co-cultures of MSC-laden MCs and chondrocytes, encapsulated in different 
compartment of a hydrogel system, in order to recapitulate the bone-cartilage transition in osteochondral 
tissues. Bioprinted, bilayered and cell- and MC encapsulating osteochondral grafts could be evaluated for in 
vitro tissue formation in a dynamic culture system (i.e. bioreactor providing mechanical compression 
stimulation) and in vivo tissue regeneration after implantation of the graft.    
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